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Muscarinic acetylcholine receptors (MRs), a family of five G protein-coupled
receptors (GPCRs), play an essential role in the regulation of mammalian physiology. In
the brain, MR-mediated neurotransmission is required for the control of movement and
motivated behavior by the basal ganglia, and MR dysfunction may contribute to
schizophrenia, Alzheimerʼs disease, and motor disorders. Functional studies of the
muscarinic receptors have been hampered by a lack of selective pharmacology, poor
receptor immunoreactivity and a wide, overlapping pattern of expression. MRs are
characterized by the presence of a large third intracellular loop domain (i3), the
sequence of which is divergent between MR subtypes. The i3 is known to determine
signaling and trafficking characteristics of GPCRs by binding to defined subsets of
regulatory and effector proteins. In an effort to discover novel, subtype-specific
muscarinic receptor regulatory mechanisms, we performed yeast two-hybrid proteinprotein interaction screens with the five MR i3 regions. An interaction between M5 and
the Arf GAP protein AGAP1 was detected, and was observed to be specific to the M5
subtype. This interaction was confirmed in vitro, and was shown to mediate the binding
of the AP-3 adaptor complex to the M5 i3. Immunocytochemical and live cell imaging of
primary rat hippocampal neurons revealed co-localization of M5 and AGAP1- or AP-3positive vesicles after treatment with a muscarinic agonist. Activity-induced receptor

trafficking studies demonstrated that interaction with AGAP1 and activity of AP-3 were
required for the endocytic recycling of M5 in neurons, the lack of which resulted in downregulation of cell surface receptor density. M5 has been shown to be expressed in the
dopaminergic neurons of the ventral midbrain and to function in the presynaptic
modulation of dopamine release in the striatum. Results from dopamine release studies
suggest that the abrogation of AGAP1-mediated recycling decreases the magnitude of
presynaptic M5-mediated release potentiation. Our study demonstrates a novel, neuronspecific trafficking function for AGAP1 and AP-3, and suggests the presence of a
previously unknown receptor recycling pathway that may underlie mechanisms of
sustained sensitivity of GPCRs.
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INTRODUCTION

1.1 Acetylcholine and cholinergic neurotransmission
Acetylcholine, the first molecule identified as a chemical neurotransmitter,
plays an essential role in the physiology of animals. In the peripheral nervous
system (PNS), acetylcholine (ACh) mediates the execution of voluntary
movements via its release from motor neuron axon terminals at the
neuromuscular junction. Also in the PNS, ACh functions as the post-ganglionic
neurotransmitter of the parasympathetic nervous system, innervating heart,
smooth muscle and glandular tissue, and serving to stimulate functions such as
bronchial constriction, heart rate decrease, salivation, digestive peristalsis and
blood vessel dilation. ACh further serves as the pre-ganglionic neurotransmitter
for both the parasympathetic and sympathetic divisions of the PNS. In the
central nervous system (CNS), ACh plays a neuromodulatory role in nearly every
region of the brain. ACh neurotransmission is implicated in such processes as
arousal, reward, learning, and memory. In addition, ACh is known to exhibit
hormone-like activity, with autocrine and/or paracrine functions described in such
non-innervated tissues as skin, lymphocytes, and the endothelium, as well as in
cancer cells (Wessler et al., 2003; Wess et al., 2007; Cheng et al., 2008). The
ubiquity of ACh is further demonstrated by its identification as a phylogenetically
ancient molecule; ACh and its synthetic enzyme choline acetyltransferase (ChAT)
have been detected in protozoa, algae, and even bacteria, and ACh is seen to
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modulate such fundamental cellular processes as proliferation, migration, and
morphology (Wessler et al., 1999).
In the CNS, cholinergic projection and interneurons provide widespread,
diffuse innervation of nearly every brain region. Cholinergic afferents project
from areas of the basal forebrain and brainstem; these neurons are further
subdivided into eight nuclei based on location and targets (Ch1-Ch8), with
anatomy generally conserved across mammalian species (Mesulam, 2004). The
basal forebrain nuclei provide the majority of cholinergic projection neuron
innervation in the CNS. Cholinergic neurons in the medial septal nucleus (Ch1)
and the vertical nucleus of the diagonal band (Ch2) innervate the hippocampus,
Ch3 neurons of the horizontal limb of the diagonal band project to the olfactory
bulb, while cholinergic afferents originating in the nucleus basalis of Meynert
(Ch4) project widely to the cerebral cortex, with particularly dense innervation of
the sensory and limbic cortices in humans. In the brain stem, cholinergic
projection neurons in the pedunculopontine (Ch5) and laterodorsal tegmental
(Ch6) nuclei project to the thalamus and regions of the basal ganglia, while Ch7
and Ch8 neurons of the medial habenula and parabigeminal nucleus project to
midbrain regions. In contrast to this system of cholinergic projection neurons, the
striatum receives little input from cholinergic afferents, but is characterized by
extensive intrinsic innervation by giant aspiny cholinergic interneurons. As
judged by staining for cholinergic markers (ChAT and the extracellular ACh
degradative enzyme acetylcholine esterase (AChE)), the striatum is in fact the

2

brain region most heavily innervated by the cholinergic system (Zhou et al.,
2002a).
The cellular effects of ACh are mediated by two classes of receptors:
nicotinic (nAchR) and muscarinic (mAchR; MR), so named for their sensitivity to
the tobacco alkaloid nicotine and the mushroom toxin muscarine, respectively.
Nicotinic acetylcholine receptors are a family of homo- and hetero-pentameric
ligand-gated cation channels. In muscles, nAchRs are expressed postsynaptically at the neuromuscular junction, and their activation by ACh results in
contraction. nAchRs mediate fast excitatory neurotransmission in PNS ganglia,
while in the CNS, nAchRs serve a neuromodulatory function, most notably in the
terminals of basal ganglia dopaminergic neurons (Dajas-Bailador and Wonnacott,
2004; Zhang and Sulzer, 2004). Muscarinic acetylcholine receptors, on the other
hand, are metabotropic receptors belonging to the G protein coupled receptor
superfamily; activation of MRs by ACh stimulates production of intracellular
second messenger molecules, which in turn mediate cellular effects. MRs, of
which five subtypes are known to exist in mammals, are expressed in a complex,
overlapping pattern in both the CNS and periphery; in fact, nearly every cell type
is known to express multiple MR subtypes (Wess et al., 2007). Adding to this
complexity is the fact that MRs couple to multiple signaling pathways, leading to
both convergent and divergent second messenger pathway activation in AChstimulated cells (Nathanson, 2000). In the following sections, we will discuss the
structure, second messenger coupling, distribution, and regulatory characteristics
of the muscarinic receptors in the context of this functional complexity.

3

1.2 G protein-coupled receptors: general characteristics
G protein-coupled receptors (GPCRs) are a structurally conserved gene
superfamily, constituting the largest and most functionally diverse group of
proteins in mammals and representing over 30% of identified drug targets to date
(Oldham and Hamm, 2008). GPCRs are multiple-pass integral membrane
proteins consisting of seven transmembrane α-helices, an extracellular Nterminus, a cytoplasmic C-terminal tail and three each of both extracellular and
cytoplasmic loop regions positioned between the transmembrane helices. The
GPCR superfamily is generally divided into five main subgroups based on
phylogeny: class A (rhodopsin-like), class B (secretin receptor-like) class C
(metabotropic glutamate receptor-like), adhesion receptor-like and Frizzled family
receptors (Fredriksson et al., 2003; Foord et al., 2005). The rhodopsin-like group
contains by far the greatest number of member GPCRs, including the muscarinic
acetylcholine receptors. Among members of this group, structural and sequence
motifs are highly conserved, implying shared mechanisms of function
(Rosenbaum et al., 2009). GPCRs are activated by a variety of extracellular
stimuli, including light (rhodopsin), volatile odorants and pheromones (olfactory
and vomeronasal receptors, respectively) as well as small molecule, peptide,
protein, ion and lipid ligands.
The classical mechanism by which GPCRs transduce extracellular signals
to the cell interior relies on activation of heterotrimeric G proteins. In the resting
state, GDP-bound Gα (a small GTPase protein) forms a complex with Gβ and Gγ
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subunits. Upon activation, the GPCR is able to function as a GDP exchange
factor (GEF) for the heterotrimeric G protein, catalyzing the exchange of GDP for
GTP by the Gα subunit and leading to dissociation of activated Gα and the Gβγ
dimer, thus allowing activation of effector proteins by Gα-GTP. A recently
described crystal structure of the light-sensitive GPCR opsin in a pseudo-active
state suggests that activation-induced conformational changes in the GPCR
allow direct binding to Gα (Scheerer et al., 2008). Signaling is terminated upon
hydrolysis of GTP to GDP by Gα, and subsequent re-assembly with the inhibitory
Gβγ dimer into the inactive heterotrimeric complex. As the intrinsic GTPase
activity of Gα is low, termination of signaling is accelerated by the presence of
RGS (regulator of G-protein signaling) proteins, which function as GTPase
activating proteins (GAPs) for Gα (Hepler, 1999). In addition, GPCRs typically
undergo a stereotyped series of desensitization events subsequent to activation,
including phosphorylation by GPCR kinases, binding of β-arrestin, and
uncoupling of receptors from G-proteins; we describe this process in detail in
section 1.3 of this chapter.
In contrast to the nearly 800 identified GPCRs in the human genome, far
fewer G protein subtypes exist. Functional categorization of Gα subunits reveals
four classes of G-protein heterotrimers: Gi/o, Gs, Gq, and G12 (Simon et al.,
1991). Gαi/o and Gαs are negatively and positively coupled, respectively, to the
production of cyclic AMP (cAMP) by adenylate cyclase. The second messenger
cAMP, in turn, activates protein kinase A (PKA), which is able to act upon a wide
variety of downstream targets, including enzymes, ion channels (Ca2+ and K+),
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transcriptional regulators, and the signal integration protein DARPP-32 in the
medium spiny neurons of the striatum (Greengard, 2001). Activated Gαq
stimulates the phospholipase C beta (PLC-β)-mediated cleavage of
phosphatidylinositol-4,5-bisphosphate (PIP2), thereby generating the second
messengers diacylglycerol (DAG) and inositol triphosphate (IP3). Diffusible IP3
stimulates intracellular Ca2+ release by the gating of channels located in the
endoplasmic reticulum, while membrane-bound DAG, along with Ca2+, activates
protein kinase C (PKC). Ca2+ and PKC, in turn, act upon a number of
downstream targets, including ion channels and the mitogen-activated protein
(MAP) kinases. Gα12 class proteins appear to signal mainly through Rho GEF to
affect cellular morphology and motility by downstream modulation of actin
cytoskeleton dynamics (Worzfeld et al., 2008). Coupling specificity between G
proteins and GPCRs is thought to arise from binding domains present on the
cytoplasmic face of the receptors (Kostenis et al., 1997; Kostenis et al., 1999;
Oldham and Hamm, 2008). Factors complicating this model of GPCR signal
transduction include 1) GPCRs may couple to multiple G protein subtypes
(Maudsley et al., 2007); 2) GPCRs also stimulate non-Gα mediated signaling,
such as the modulation of voltage-gated calcium channels by Gβγ and activation
of the MAP kinase pathway by β-arrestin (McDonald et al., 2000; Dolphin, 2003);
and 3) GPCRs may exist as functional heterodimers (Satake and Sakai, 2008).
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1.3 The muscarinic acetylcholine receptor family
The muscarinic acetylcholine receptors are a family of five rhodopsin-type
(group A) GPCRs in mammals (Bonner et al., 1987). The family can be further
subdivided into two groups based on G protein coupling: muscarinic receptors 1
(M1), 3 (M3) and 5 (M5) signal predominantly through Gq, while MRs 2 (M2) and
4 (M4) couple to Gi. The MR family is distinguished structurally by the presence
of large third intracellular loop (i3) regions which are conserved in sequence
across species but highly divergent between subtypes, save for juxtamembrane
regions likely involved in G protein recognition and / or binding (figure 1.1)
(Wess et al., 1995; Wess et al., 1997). In contrast, the extracellular and
transmembrane regions of the MRs, including the presumed ligand binding
domain, show strong sequence similarity across subtypes (figure 1.1). As a
consequence of this similarity, the pharmacological specificity of cholinergic
agonists and antagonists with respect to receptor subtype is poor; in addition,
divergent regions of MRs appear to offer low antigenicity, precluding the
successful development of subtype-specific antibodies (Wess et al., 2003;
Jositsch et al., 2009). Combined with the widespread, overlapping distribution
pattern of MRs, these technical limitations have greatly hampered functional
studies of individual muscarinic receptors in vivo. The investigation of MR
function in a subtype-selective manner has instead relied upon the use of single
or double MR knockout mice (Wess et al., 2007). Below, we summarize the
current knowledge of MR subtype function in the CNS and periphery based on
knockout loss-of-function and MR binding site studies combined with tissue-
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i1

i2

CT

i3

Figure 1.1 Muscarinic acetylcholine receptor topology and sequence
alignment. Top: Snake plot of rat M4 illustrating extracellular, transmembrane,
and cytoplasmic domains (from www.GPCR.org). i1,i2, i3: first, second and third
intracellular loops, respectively; CT, C-terminal tail. Bottom: Alignment of five rat
muscarinic receptor amino acid sequences, with i1, i2, i3, and CT regions
highlighted. Residues are colored according to shared physical properties.
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specific and global gene expression data (Oki et al., 2005; Regard et al., 2008;
Ito et al., 2009).

1.3.1 M1
The M1 receptor is the most highly expressed muscarinic receptor
subtype in the CNS, constituting the majority of MR radioligand binding sites and
the entirety of ACh-stimulated Gq activation in the cortex and hippocampus
(Porter et al., 2002; Oki et al., 2005). Activation of post-synaptic M1 receptors is
generally excitatory, and appears to exert this neuromodulatory effect through a
number of distinct mechanisms. First, activation of M1 (and other Gq-coupled
receptors including M3 and M5) leads to membrane depolarization by inhibition
of the voltage-dependent, outwardly-rectifying M-current (IM). IM is mediated by
KCNQ2/3 K+ channels, which require PIP2 for activation; stimulation of PLC-β by
M1 / Gαq hydrolyzes PIP2 and deactivates this hyperpolarizing current (Zhang et
al., 2003). Second, M1 activation can inhibit the activity of a number of voltage
gated Ca2+ channels through a slow-acting mechanism involving diffusible
second messengers such as PIP2 and/or PKC activation (Liu et al., 2006; PerezBurgos et al., 2008). M1 receptors mediate the neuromodulatory effects of ACh
in cortical pyramidal neurons (Gulledge et al., 2009) and post-synaptic M1
receptors in CA3 neurons are required for induction of hippocampal gammaoscillations (Fisahn et al., 2002). Additionally, M1 is the sole MR responsible for
ACh-induced MAP kinase activation in the hippocampus, a process implicated in
the mechanism of long-term plasticity (Berkeley et al., 2001). Outside of the
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CNS, M1 receptor expression is low, although deficits in PNS functions such as
salivation and blood pressure homeostasis were observed in M1 knockout mice
(Bymaster et al., 2003). Behaviorally, M1-/- mice are moderately hyperactive,
display subtle learning and memory deficits, and are insensitive to the seizureinducing muscarinic agonist pilocarpine (Hamilton et al., 1997; Miyakawa et al.,
2001; Bymaster et al., 2003).

1.3.2 M2
M2 receptors are the predominant MR expressed in heart myocytes,
where they mediate the rate-slowing and atrial contraction strength-decreasing
effects of ACh release by parasympathetic afferents. The cardiac effects of M2
are mainly transduced by Gβγ-stimulated opening of GIRK K+ channels, leading
to membrane hyperpolarization. M2 receptors are also expressed in smooth
muscles, where they serve to potentiate the M3-mediated contractile effects of
ACh via a cAMP-related mechanism (Stengel et al., 2000). M2 is widely
expressed in the CNS, and appears to function as the primary autoreceptor for
ACh at cholinergic neuron terminals outside of the striatum (Zhang et al., 2002a).
The autoinhibitory effects of M2 are largely mediated by fast-acting Gβγ bindinginduced inhibition of N- and P/Q- type Ca2+ channels (Shapiro et al., 2001). M2
also serves as an inhibitory autoreceptor and modulatory receptor at postganglionic parasympathetic and sympathetic nerve terminals, respectively (Zhou
et al., 2002b; Trendelenburg et al., 2003). The M2 -/- mouse exhibits reduced
sensitivity to the analgesia-inducing muscarinic agonist oxotremorine, altered
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neuronal plasticity in the hippocampus, and deficits in memory and behavioral
flexibility (Gomeza et al., 1999a; Tzavara et al., 2003; Seeger et al., 2004).

1.3.3 M3
M3 receptors are expressed in nearly all smooth muscle and glandular
tissues, and are the primary MRs mediating the effects of ACh released by the
parasympathetic PNS on blood vessels, the eye, the gastrointestinal,
reproductive and urinary tracts, and in exocrine glands (Bymaster et al., 2003).
In addition, M3 plays a key role in the regulation of glucose homeostasis by
mediating the IP3-dependent potentiation of glucose-stimulated insulin release
by pancreatic islet β cells (Gautam et al., 2006). M3 receptors are expressed
widely in the CNS, but appear to play a minor role in the regulation of neuronal
excitability, although hypothalamic dysfunction has been noted in the M3 -/mouse (Yamada et al., 2001b; Gautam et al., 2009). Aside from exhibiting
peripheral abnormalities associated with PNS dysfunction (and the glucose
homeostasis phenotype described above in a β cell conditional knockout model),
M3-/- mice exhibit feeding deficits, reduced serum leptin levels, and are
abnormally small and lean (Yamada et al., 2001b; Gautam et al., 2009).

1.3.4 M4
M4 receptors are expressed at low levels outside of the CNS, where they
play a minor, M2-like functional role in peripheral tissues and may be important
for the motility of keratinocytes during wound healing (Zhou et al., 2002b;
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Bymaster et al., 2003; Trendelenburg et al., 2003; Chernyavsky et al., 2004). In
the brain, M4 is a low-abundance autoinhibitory receptor at cortex and
hippocampal cholinergic terminals, likely functioning similarly to M2 via a Ca2+
channel mechanism (Zhang et al., 2002a). However, M4 is expressed at high
levels in the striatum, where it functions both pre- and post-synaptically
(discussed in further detail in section 1.2.8) (Zhang et al., 2002b; Oki et al.,
2005). M4 -/- mice exhibit modest M2-like deficits in muscarinic agonist-induced
analgesia, but are markedly hyperlocomotive and hypersensitive to the effects of
D1 dopamine receptor agonists (Gomeza et al., 1999b; Gomeza et al., 2001).

1.3.5 M5
The M5 receptor is the least abundant muscarinic receptor expressed in
mammals. M5 comprises less than 2% of the total MR population in the brain
and is functionally undetectable in peripheral tissues, though low levels of M5
mRNA have been reported in skin and in some cancer cell lines (Kohn et al.,
1996; Oki et al., 2005; Ito et al., 2009). However, M5 is the only muscarinic
receptor for which expression is detected in the midbrain dopaminergic neurons
of the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA)
(Weiner et al., 1990; Wess et al., 2007). Both somatodendritic and pre-synaptic
M5 receptors mediate the ability of ACh to potentiate dopamine release from SNc
and VTA neurons (Yamada et al., 2001a; Forster et al., 2002). In addition, M5 is
the sole MR responsible for the dilatory action of ACh on cerebral arteries and
arterioles, a function mediated by the M3 receptor elsewhere in the body
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(Yamada et al., 2001a). The M5 -/- mouse exhibits mild cognitive defects,
decreased sensitivity to amphetamine and morphine, reduced cocaine selfadministration, and altered sensorimotor gating (Basile et al., 2002; Wang et al.,
2004; Thomsen et al., 2005; Araya et al., 2006).

1.3.6 Muscarinic receptor distribution and function in the striatum
The basal ganglia (BG), a group of subcortical nuclei composed of the
substantia nigra, pallidum, subthalamic nucleus, and striatum, play a critical role
in the processing and integration of neuronally encoded information to produce
motivated behaviors. The striatum is the major input nucleus of the BG,
consisting mainly (90-95%) of GABAergic medium spiny neurons (MSNs)
projecting to the BG output nuclei. The striatum can be divided functionally and
anatomically along a dorsolateral to medioventral axis: dorsolateral areas,
receiving glutamatergic afferents from sensorimotor cortex and dopaminergic
input from the SNc, function mainly in the execution of movement and in spatial
and procedural memory, while the medioventral striatum (including the nucleus
accumbens) receives glutamatergic afferents mainly from limbic areas (including
the hippocampus and amygdala) and dopaminergic input from the VTA, and
plays a central role in motivation, reward, and the pathophysiology of drug
addiction (Voorn et al., 2004). Striatal anatomy can be further subdivided on the
basis of MSN efferent pathways, illustrated in figure 1.2: “direct” striatonigral
MSNs directly innervate the BG output nuclei (the substantia nigra pars reticulata
(SNr) and globus pallidus internal capsule (GPi)), while “indirect” striatopallidal
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MSNs project to an intervening inhibitory nucleus (the globus pallidus external
capsule, or GPe) and ultimately innervate the SNr/GPi indirectly via the
subthalamic nucleus (STN). Importantly, direct pathway MSNs express
excitatory D1 dopamine receptors, while indirect MSNs express inhibitory D2
receptors. This segregated expression pattern allows dopamine to potentiate the
MSNsʼ disinhibition-mediated activation of thalamocortical output pathways
(figure 1.2). The balance of non-MSN neurons in the striatum is composed of
GABAergic and cholinergic interneurons. The giant aspiny cholinergic
interneurons, comprising 2% of the total neuronal population of the striatum, are
tonically active and provide both volumetric and synaptic innervation of MSNs
through highly arborized axons (Pisani et al., 2007). The interaction between
cholinergic and dopaminergic activity in the striatum plays a major role in the
regulation of MSN activity and plasticity, and in turn is required for proper
coordination of motivated locomotor activity (Pisani et al., 2007).
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Figure 1.2 (following page), Cholinergic innervation and muscarinic
receptor expression in the basal ganglia. Red, green, yellow and blue
represent GABAergic, glutamatergic, cholinergic, and dopaminergic neurons
and terminals, respectively. Small squares and circles represent dopamine
and muscarinic receptors, respectively, with subtype noted by number. Green
receptors are excitatory, while red receptors are inhibitory. Circles indicate
neuron somatodendritic compartments, and axon terminals are indicated by
triangles; non-synaptic terminals indicate volumetric ACh release (striatum) or
diffuse innervation (thalamostriatal and thalamocoritical pathways, and
cholinergic innervation of the cortex). GPe, globus pallidus external capsule;
STN, subthalamic nucleus, SNr, substantia nigra pars reticulata, GPi, globus
pallidus internal capsule, SNc, substantia nigra pars compacta, VTA, ventral
tegmental area; MSN, medium spiny neuron.
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Muscarinic receptors are expressed in a complex, overlapping pattern in
the striatum, and play a central role in the mediation of AChʼs effects upon BG
function (figure 1.2). Giant aspiny interneurons receive input from SNc and VTA
dopaminergic neurons and co-express the D2 and D5 dopamine receptor
subtypes. Activation of D2 receptors inhibit, while activation of D5 receptors
stimulate, the firing rate and ACh release of aspiny interneurons; however, the in
vivo coordination of these actions on individual cholinergic neurons is unknown
(Yan et al., 1997; Yan and Surmeier, 1997). Medium spiny neurons express
dendritic M1 and M4 muscarinic receptors, with anatomical and functional
evidence suggesting preferential expression of M4 receptors on direct pathway
MSNs (Santiago and Potter, 2001). MSN M1 activation is generally excitatory,
although M1-stimulated Ca2+ / PKC activity can inhibit voltage-gated calcium
channels (Calabresi et al., 2000). Post-synaptic M4 activation is seen to inhibit
GABA release by medium spiny projection neurons. However, M4 also plays a
key, striatum-specific autoinhibitory role at cholinergic interneuron terminals,
functioning to reduce the ACh input to M1- and M4- expressing MSNs (Zhang et
al., 2002a). M2 and M3 are present at low levels in the striatum, with
neurotransmitter release-modulating functions reported for these receptors at
corticostriatal glutamatergic and GABAergic interneuron terminals, respectively
(Zhang et al., 2002b). In addition, cholinergic neurons themselves likely express
somatodendritic M1 and M4 muscarinic receptors, with volumetrically released
ACh providing input (Pisani et al., 2007).
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Further complicating the system of muscarinic receptor function in the
striatum is the fact that ACh can also exert influence on the release of dopamine
by nigrostriatal and mesolimbic neurons (figure 1.2). Studies of evoked
dopamine release in MR knockout mice have shown that M4 and M5 receptors
mediate the ability of ACh to potentiate evoked DA release in the striatum; M4
likely exerts an indirect, trans-synaptic effect via receptors expressed on MSNs
or cholinergic interneuron terminals, while ACh activation of dopaminergic
terminal-localized M5 receptors is able to modulate dopamine release directly.
M3 receptor activation was seen to indirectly inhibit evoked dopamine release,
while a dopamine-modulatory role for M1 and M2 receptors was not observed
(Zhang et al., 2002b). In addition, muscarinic receptor M5, the only MR
detectably expressed in midbrain dopaminergic neurons, was seen to mediate
the ability of ACh released from brainstem afferents to stimulate prolonged
dopamine release from mesolimbic neuron terminals (Forster et al., 2002). Thus,
while the overall effect of ACh on MSNs is to oppose the stimulatory action of
dopamine on the disinhibition of thalamic output nuclei, the possibility of singleneuron co-expression of excitatory and inhibitory MRs, the opposing effects of
pre- and post-synaptically localized M4, and the complex nature of AChregulated DA release leaves great uncertainty as to the precise roles of MR
subtypes on striatal function. Adding a final layer of complexity is the role of
muscarinic receptors in the regulation of DARPP-32 in MSNs; although not
directly examined, activation of the Gq-coupled M1 and Gi-coupled M4 receptors
may lead to inhibition of PKA activity and altered intracellular Ca2+ levels, thus
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modulating DARPP-32ʼs protein phosphatase-1 mediated effects on downstream
receptor or transcriptional effectors (Svenningsson et al., 2004). The exact role
of muscarinic receptor in the function of the striatum and BG is thus incompletely
understood, and underscores the the need for development of cell-specific and
MR subtype-selective experimental tools.

1.3.7 Muscarinic receptors and CNS disease / dysfunction
Muscarinic receptor dysfunction has been implicated in a number of
diseases of the CNS. In Alzheimerʼs disease (AD), selective death of basal
forebrain neurons leads to reduced cholinergic innervation of the hippocampus
and cortex (Auld et al., 2002). Although the M1-/- mouse exhibited only modest
cognitive dysfunction, transgenic AD-model mice treated with an M1-preferring
agonist showed both improvements in cognitive function and reductions in
β-amyloid and Tau pathologies in the cortex and hippocampus (Caccamo et al.,
2006) and systemic administration of the non-selective muscarinic receptor
antagonists scopolamine or atropine results in profound learning and memory
inhibition in rodents and humans (Fibiger et al., 1991). In addition, M2 -/- mice
show substantial learning and memory deficits, and decreased short- and longterm potentiation in hippocampal synapses (Tzavara et al., 2003; Seeger et al.,
2004).
Although the pathophysiology of schizophrenia is most closely associated
with dysfunction in mesolimbic neurotransmission, extra-dopaminergic symptom
characteristics and the well-described interaction between the cholinergic and
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dopaminergic systems suggest that ACh function may be clinically significant.
The following observations argue for a role of muscarinic receptors in
schizophrenia: 1) Post-mortem and in vivo imaging studies have identified
decreased MR binding site density in the cortex, hippocampus and striatum of
schizophrenic patients; 2) High doses of muscarinic antagonists lead to
psychosis-like states, and N-desmethylclozapine, a metabolite of the widely used
atypical antipsychotic clozapine, shows strong subtype-selective partial agonism
towards M1 (Sur et al., 2003); 3) genetic linkage studies have implicated the M5encoding Chrm5 gene as a schizophrenia susceptibility locus; and 5) M5 -/- mice
show alterations in schizophrenia-related sensorimotor gating behaviors (Wang
et al., 2004; Thomsen et al., 2007). Knockout mouse and genetic linkage studies
have also implicated muscarinic receptors in the etiology of pain, drug addiction,
type 2 diabetes, and PNS-related disorders (Wess et al., 2007).
Despite the potential of muscarinic receptors as drug targets for the
treatment of CNS diseases, the utility of such compounds has been limited by the
undesirable parasympathetic-related side-effect profile of MR agonists and
antagonists. The successful development of subtype-specific muscarinic drugs
has been greatly hampered by the high conservation among MRs of the ACh
(orthosteric) binding site. Thus, although targeting of predominantly neuronallyexpressed MRs (M1, M4, and M5) could significantly reduce PNS-related offtarget effects, only non-selective muscarinic agonists and antagonists, as well as
cholinergic transmission-enhancing AChE inhibitors, are currently in clinical use.
Aside from their obvious utility in research applications and in the treatment of
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diseases directly related to muscarinic receptor dysfunction, such subtypespecific MR drugs could also show efficacy in the treatment of Parkinsonʼs
disease, for which non-selective muscarinic antagonists were the first accepted
treatment and are currently used to alleviate dystonia symptoms. Parkinsonʼs
disease is a movement disorder characterized by the death of SNc nigrostriatal
dopaminergic neurons, leading to relative hyperactivity of the striatal cholinergic
system. M4-targeted drugs could alleviate hypercholinergia either by antagonism
of post-synaptic M4 receptors distributed preferentially on direct pathway MSNs,
or by stimulating interneuron M4 autoreceptors and decreasing striatal ACh tone.
Additionally, development of M5-specific agonists could prove useful in the
treatment of age-related cognitive impairment by increasing cerebral blood flow.

1.4 Regulation of muscarinic receptor function
The regulation of GPCR signaling efficacy in time and space is central to
the ability of a cell to both respond and adapt to outside stimuli. The steady-state
density of cell surface receptor molecules, and the degree to which termination of
ligand-induced GPCR signaling events is followed by receptor resensitization,
are crucial in determining the effects of sustained stimulation on cellular
physiology (Hanyaloglu and von Zastrow, 2008). In neurons, such sensitivitytuning mechanisms are important for plasticity events underlying learning and
memory (Wang et al., 2005; Wang et al., 2009a). Despite the large number of
GPCRs expressed in mammals, the basic mechanisms regulating nascent
receptor delivery, plasma membrane sorting in polarized cells, steady-state cell
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surface density, desensitization, resensitization and down-regulation of GPCRs
are generally conserved. Nonetheless, important receptor-, tissue-, and
subcellular compartment-specific regulatory details exist. A common theme
binding these GPCR-modulating mechanisms is the importance of protein-protein
interactions between receptors and trafficking, anchoring, or signal-regulating
molecules. As with functional studies of muscarinic receptors, however, the lack
of subtype-specific antibodies and ligands has left us with a limited
understanding of the mechanisms governing the regulation of muscarinic
receptors in vivo. Below, we discuss the regulation of MRs in the context of more
thoroughly characterized GPCR systems.

1.4.1 Cell-surface delivery of newly synthesized MRs
GPCRs newly translated in the endoplasmic reticulum are delivered to the
plasma membrane via the Golgi complex largely through the unregulated
secretory pathway (figure 1.3) (Achour et al., 2008). Although the regulation of
nascent GPCR expression is far less understood than the endocytic trafficking of
mature cell surface receptors, a number of protein-protein binding events
influencing plasma membrane delivery have been identified. For example,
interaction between the third intracellular loops of serotonin receptors 5-HT1B
and 5-HT4 and the annexin II light chain protein p11 increases the cell surface
expression of these receptors in a functionally significant manner (Svenningsson
et al., 2006; Warner-Schmidt et al., 2009). Similar chaperone-like interactions
negatively or positively influencing surface expression of GPCRs have been
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Figure 1.3 Summary of canonical GPCR trafficking pathways. Upper left,
clathrin-dependent endocytosis of an activated GPCR. After endocytic vesicle
uncoating, internalized receptors are delivered to the early endosome and are
sorted to the degradative pathway via the rab7-positive late endosome (bottom
left) or to the recycling pathway via a fast, rab4/rab35-dependent pathway
(middle left) or through a slow pathway via the rab11-positive endocytic recycling
compartment (ERC; middle right). Newly synthesized GPCR molecules are
delivered to the plasma membrane from the trans-golgi network (TGN) via the
unregulated secretory pathway (right) or through a regulated TGN-to-endosome
pathway (middle right).
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described for the dopamine D1 receptor (DRiP78), the angiotensin AT2 receptor
(ATBP50), and the thromboxane A2 receptor (RACK1) (Bermak et al., 2001;
Wruck et al., 2005; Parent et al., 2008). Heterooligomerization of GPCRs can
also influence plasma membrane delivery: cell surface expression of the
GABABR1 receptor is dependent upon co-expression, and physical interaction
with, the GABABR2 receptor (Margeta-Mitrovic et al., 2000). Finally, regulated
delivery of D1 dopamine and δ-opioid receptors to the cell surface from
intracellular pools has been described, and may represent a mechanism of
receptor sensitization (Achour et al., 2008).
A secondary, TGN-to-endosome mediated pathway of GPCR trafficking
may also play a role in the regulated expression of newly synthesized receptors.
Subcellular transport of GPCRs and other integral membrane protein cargo is
mediated by a complex system of intracellular membrane trafficking, the details
of which are still being elucidated. The basic mechanism of intracellular receptor
trafficking is as follows: Adaptor proteins, heterotetrameric complexes of which
four are known to be expressed in mammals (AP-1 through AP-4), are recruited
to specific intracellular membrane compartments, in many cases by interaction
with GTP-bound Arf (ADP ribosylation factor) proteins. There, the adaptor
proteins are able to simultaneously bind to both cytoplasmic receptor domains
containing specific amino acid motifs and membrane coat proteins, the most
common of which is clathrin. Cargo-containing, coated membrane buds are
“pinched-off” from host membranes through the action of accessory proteins such
as dynamin, endophillin and amphiphysin. Endosomal vesicles are then
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transported to specific locations via interaction with motor proteins and the
cellular cytoskeleton, and cargo proteins delivered to target membranes by coat
disassembly and vesicle fusion. The identity and functional characteristics of
transport vesicles are regulated by membrane phospholipid content, and by the
presence of specific Rab family proteins; these membrane-associated small
GTPases recruit other functional and scaffolding proteins to specific vesicular
compartments. Rabs switch between GTP-bound “on” and GDP-bound “off”
states, the cycling of which is regulated by the presence of specific GEF and
GAP proteins. TGN-to-endosome mediated transport of nascent GPCRs to the
cell surface likely proceeds via an AP-1 and clathrin-dependent process, whereby
the AP-1 complex recruits targeted receptors by binding to signal sequences
present in intracellular regions (Nakatsu and Ohno, 2003). Such a process may
underlie the motif-dependent delivery of the V2R vasopressin and α2B
adrenergic receptors to the cell surface, and in the targeting of GPCRs to apical
or basolateral domains in polarized cells (Dong and Wu, 2006).
Little is known regarding mechanisms regulating the cell surface delivery
of newly translated muscarinic receptors. It has been shown, however, that in
the polarized Madin-Darby canine kidney cell line, M2 is targeted to the apical
plasma membrane domain, while M3 is targeted basolaterally via a dominant
sorting signal present in the third intracellular loop (Nadler et al., 2001).
Additionally, a phenylalanine-rich motif in the M2 receptor C-terminal tail was
shown to bind the ER-associated protein DRiP78, leading to intracellular receptor
sequestration in an exogenous expression system (Bermak et al., 2001).
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1.4.2 Stabilization of MRs in the plasma membrane
The cell surface localization and two-dimensional diffusion characteristics
of GPCRs are regulated by interaction with scaffolding proteins, among other
mechanisms. Such regulation is particularly important in neurons, where
localization of GPCRs to synaptic compartments and stabilization of receptors at
the cell surface play a critical role in synaptic plasticity. The scaffolding protein
PSD-95 is the best characterized of these molecules; it is localized almost
exclusively at the post-synaptic density, and serves to organize and stabilize
synaptic proteins, most notably AMPA and NMDA glutamate receptors (Kim and
Sheng, 2004). PSD-95 can bind directly to the β1 adrenergic receptor via a Cterminal tail PDZ-binding domain, and indirectly to metabotropic glutamate
receptors mGluR1 and mGluR5 via the scaffolding adaptor protein Homer; both
of these interactions were shown to stabilize the receptors at the cell surface
(Xiao et al., 1998; Hu et al., 2000). A second example of a scaffolding protein /
GPCR interaction is the binding of the dopamine D2 and α2 adrenergic receptors
via their i3 loops to spinophilin, an actin- and protein phosphatase-1-binding
protein. This interaction was shown to stabilize receptors in the basolateral
membrane domain of polarized cells, and to regulate GPCR-stimulated Ca2+
signaling by the concurrent binding of RGS2 (Brady et al., 2003; Wang et al.,
2005). To date, however, no specific interactions between scaffolding proteins
and muscarinic receptors have been identified.
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1.4.3 Agonist-induced desensitization and internalization
After activation, nearly all GPCRs undergo a similar series of molecular
events that serve to desensitize the receptor to further stimulation. In ligand
gated receptors, the process was first identified in, and is best characterized for
the β2 adrenergic receptor (β2AR) (Lohse et al., 1990; Gainetdinov et al., 2004;
Hanyaloglu and von Zastrow, 2008). Upon ligand binding and G protein
heterotrimer dissociation, GPCRs undergo a conformational change leading to
phosphorylation on serine and threonine residues present on the C-terminal tail
and i3 loop by G protein-coupled receptor kinases (GRKs). This phosphorylation
induces binding of β-arrestin to cytoplasmic regions of the receptor, and serves
to uncouple the GPCR from its cognate G protein complex by steric hindrance,
leading to rapid desensitization of signaling. The GPCR-bound β-arrestin
molecule also functions to bind adaptor protein AP-2 complex subunits, thus
recruiting the desensitized receptor to PIP2, clathrin and AP-2 enriched structures
known as clathrin-coated pits. Upon further binding of AP-2 subunits to tyrosinecontaining motifs on the GPCR C-terminal tail, recruitment of clathrin by AP-2 to
the nascent vesicle, and membrane scission by a dynamin-dependent
mechanism, the receptor-β-arrestin complex is internalized into a clathrin-coated
vesicle (figure 1.3). Variations to this generalized mechanism exist, however, and
likely depend on the differential receptor-regulatory protein interactions based on
the presence or absence of specific protein-protein binding motifs on GPCR
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cytoplasmic regions. Examples include constitutively internalized receptors,
clathrin-, β-arrestin and/or dynamin-independent receptor internalization,
dileucine motif-dependent internalization, and non-GRK mediated receptor
phosphorylation (Pals-Rylaarsdam et al., 1997; Budd et al., 2000; Marchese et
al., 2008). In addition, 1) heterologous (ligand binding-independent) GPCR
phosphorylation activity can influence receptor / G protein coupling, and 2) the
degree to which receptors undergo activity-induced phosphorylation may
regulate the strength of β-arrestin binding, leading to differential downstream
resensitization characteristics (Daaka et al., 1997; Marchese et al., 2008).
With the exception of M5, the phosphorylation and agonist-induced
internalization characteristics of the muscarinic acetylcholine receptors have
been investigated in heterologous expression systems. Muscarinic receptors M1
through M4 are phosphorylated by GRK2 in an agonist-dependent manner,
exhibit desensitization of G protein signaling after prolonged stimulation, and
undergo agonist-induced internalization and sequestration, events that require
the presence of the i3 loop region (van Koppen and Kaiser, 2003). However, the
mechanistic details of these events differ between subtypes. Whereas M1, M3
and M4 internalize via a β-arrestin- and clathrin-dependent mechanism, M2
receptor internalization is β-arrestin-, dynamin- and clathrin-independent,
although overexpression of β-arrestin or β-arrestin-2 was able to increase the
rate of M2 endocytosis (Pals-Rylaarsdam et al., 1997). In cardiac myocytes,
internalization of endogenous M2 receptors was seen to be caveolin-dependent;
however, M2 expressed exogenously in HEK-293 cells was not observed to
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internalize through caveolae (Pals-Rylaarsdam et al., 1997; Dessy et al., 2000).
Additional subtype specificity exists on the level of receptor phosphorylation. For
example, the kinase CK1α plays a major role in the agonist-induced
phosphorylation of exogenously expressed M3. This phosphorylation event
appears to attenuate Gq, but not MAP kinase pathway coupling, and does not
stimulate receptor internalization (Budd et al., 2000; Luo et al., 2008). Agonistinduced phosphorylation of M3 by CK2 and GRK6 has also been observed;
however, involvement of these kinases was apparently expression system and
cell type-dependent (Willets et al., 2003; Torrecilla et al., 2007). A recent study
has also demonstrated constitutive, non-agonist stimulated and i3 loopindependent internalization of M3 receptors expressed in HeLa cells (Scarselli
and Donaldson, 2009). Finally, the i3 loops of M1, M3 and M5 were shown to
bind selectively to the G protein signaling attenuator RGS2. In M1, this receptor
binding activity was required for the antagonism of agonist-stimulated PLCβ
activity, suggesting that protein-protein binding mediated recruitment of RGS
molecules to MRs may serve as a general mechanism of signaling
desensitization (Bernstein et al., 2004). Taken together, current evidence points
to the regulation of muscarinic receptor desensitization and internalization by
heterogenous, cell- and subtype-specific mechanisms, the details of which
remain unclear.
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1.4.4 Endocytic recycling
Resensitization of agonist-internalized GPCRs begins with dissociation of
β-arrestin, receptor dephosphorylation, and delivery of receptors to the Rab5-and
phosphatidylinostiol-3-phosphate- positive early endosome. From this structure,
signaling-competent receptors can be recycled to the cell surface through two
general pathways (figure 1.3). In the fast recycling route, Rab4 / Rab35
endosomes return receptors to the plasma membrane directly from early
endosomes. In the slow endocytic recycling route, which is more highly
regulated and the most common pathway for GPCR recycling, receptors are first
delivered to the typically perinuclear, Rab11-positive tubulovesicular endocytic
recycling compartment (ERC) before returning to the plasma membrane via
recycling endosomes (Grant and Donaldson, 2009). The ERC is likely composed
of membrane and cargo proteins derived from matured membrane tubules
extending from the early endosome; therefore, ERC-mediated receptor recycling
is to some extent iterative / constitutive (Maxfield and McGraw, 2004). However,
sorting signal-mediated protein interactions do play a role in the targeting of
GPCRs for recycling, although the exact nature of these signals and interacting
proteins remain poorly characterized. Recycling of the β1 and β2 adrenergic, the
lutropin LH, and the κ-opioid receptors was seen to depend on interaction of
distinct C-terminal tail motifs with PDZ domain-containing proteins (including
PSD-95, NHERF-1, and GIPC) (Cao et al., 1999). In addition, a recycling motif
present in the dopamine D1 C-terminal tail was shown sufficient to re-route a
second receptor from the degradative to recycling pathways when fused to its C-
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terminus (Vargas and Von Zastrow, 2004). In neurons, the endocytic recycling
system is specialized; for example, rab11-positive recycling endosomes are
present in dendrites and axons, and their translocation to dendritic spines plays a
critical role in the mechanism of long-term potentiation (Park et al., 2004; Park et
al., 2006; Wang et al., 2008). The neuronal endocytic recycling system serves a
key function in the maintenance of axon / somatodendritic polarity by the targeted
sorting of endocytosed plasma membrane proteins.
The endocytic recycling of muscarinic receptors has not been extensively
studied. Agonist-internalized M1, M3 and M4 receptors expressed exogenously
in HEK-293 cells were observed to undergo efficient endocytic recycling and
signaling resensitization (Vogler et al., 1998; Krudewig et al., 2000). The
endocytic recycling of M4 receptors was shown to depend on a 21-amino acid
region in the i3 loop; fusion of this motif to a recycling-negative muscarinic
receptor conferred upon it recycling activity (Krudewig et al., 2000; Hashimoto et
al., 2008b). In addition, endocytic recycling of endogenous, predominantly M3like muscarinic receptors in SH-SY5Y neuroblastoma cells was observed
(Szekeres et al., 1998a); however, desensitization and resensitization of M3
receptors expressed exogenously in CHO cells was seen to proceed
independently of receptor internalization and recycling (Tobin et al., 1992). Thus,
similar to desensitization, endocytic recycling of muscarinic receptors appears to
be subtype- and cell-specific but is poorly characterized in endogenous systems.
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1.4.5 Lysosomal targeting and down-regulation
Upon agonist-induced endocytosis, GPCRs may be targeted for
proteolytic degradation in lysosomes as opposed to cell surface recycling-based
resensitization (figure 1.3). Degradative pathway targeting results in a decrease
of overall receptor protein levels and forms a major component of the GPCR
down-regulation response, a process distinct from that of rapid receptor
desensitization and central to cellular adaptations to chronic stimulation,
including those observed in the drug-addicted brain. The sorting of lysosomallytargeted GPCRs to Rab7-positive late endosomes occurs mainly at the early
endosome level and is dependent on a number of relatively well-characterized
protein-protein interactions between trafficking molecules and targeting motifs
present in GPCR cytoplasmic regions. Many GPCRs contain lysosomal sorting
signals in their C-terminal tails conforming to tyrosine-based YXXΦ (with Φ
representing bulky hydrophobic residues) or dileucine-based [D/E]XXXL[L/I]
motifs (Bonifacino and Traub, 2003). These signals confer lysosomal targeting
by binding to adaptor protein complexes, and are critical to the constitutive
degradation of endocytosed GPCRs. Similarly, the binding of GPCR-associated
sorting proteins (GASPs) with C-terminal tail sequences is required for lysosomal
targeting of endocytosed δ-opioid receptors, as well as a variety of other GPCRs
(Whistler et al., 2002; Heydorn et al., 2004). Finally, covalent addition of ubiquitin
to cytoplasmic lysine residues of GPCRs can serve as a degradative signal,
functioning to direct sorting to lysosomes via the late endosome / multivesicular
body through interaction with ESCRT complex proteins (Marchese et al., 2008).
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In β2 adrenergic receptor-expressing cells treated chronically with agonist,
receptor ubiquitination leads to diversion of endocytosed β2AR from the recycling
to the lysosomal pathway, resulting in proteolytic down-regulation of the receptor
(Shenoy et al., 2001).
YXXΦ and DXXXLL lysosomal targeting sequence-like motifs are present
in the C-terminal tails of muscarinic receptors M2/M4 and M1, respectively. In
addition, GASP-1 and GASP-2, members of a 10-protein family sharing a GPCR
interaction domain, were observed to bind M1 and M2 C-terminal tails in vitro
(Simonin et al., 2004) However, among the M1-M4 receptor subtypes, only M2
has been shown to undergo degradative down-regulation (Krudewig et al., 2000).
Mutation of the M2 C-terminal tail tyrosine residue was seen to reduce receptor
down-regulation but did not effect agonist-induced endocytic sequestration
(Goldman and Nathanson, 1994). Down-regulation of muscarinic receptor
binding sites was observed in cultured chick retina and rat cerebellar granule
neurons after chronic agonist stimulation (Siman and Klein, 1983; Xu and
Chuang, 1987). Finally, cocaine self-administration was shown to down-regulate
muscarinic receptor binding sites in the mouse striatum; however, the magnitude
this down-regulation was paradoxically increased in GASP-1-/- mice (Boeuf et al.,
2009). As is the case with other aspects of muscarinic receptor regulation, the
study of MR down regulation in a cell- and receptor-specific manner remains
complicated by overlapping subtype expression patterns and a lack of
appropriate experimental tools.
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1.5 Summary and study rationale
Muscarinic receptors influence the function of nearly every cell in the
mammalian body. As metabotropic G protein-coupled receptors that transduce
the effects of extracellular acetylcholine, MRs mediate such varied physiological
responses as cell growth and motility, glandular secretion, smooth muscle
contraction, neuronal excitability, synaptic plasticity, and dopamine release. The
five muscarinic receptors share with other GPCRs common signaling and
regulatory pathways; therefore, the general characteristics governing activity of
the MR family are well known. However, an understanding of MR subtypespecific functional mechanisms remains elusive. Muscarinic receptors are highly
similar in sequence throughout much of their structure, including that of the
orthosteric ligand binding domain; as a result, few truly subtype-selective small
molecule agonists and antagonists have been identified. In addition, the MRs
have proven particularly resistant to the development of subtype-selective
antibodies useful for the identification and analysis of receptors expressed in
vivo. In combination with the fact that nearly every cell type expresses at least
two distinct MRs, this lack of subtype-selective tools has greatly limited our ability
to precisely study muscarinic receptor signaling and regulation. The
physiological effects of ACh are clearly not homogenous with respect to tissue
and cell type; thus, our knowledge of this ubiquitous and fundamental
neurotransmitter system remains incomplete.

33

The structure of muscarinic receptors is notable for the presence of a
large third intracellular (i3) loop region whose sequence, in contrast to that of the
remaining structural domains, is highly divergent between subtypes. In other
GPCRs, the i3 loop region has been shown to mediate the binding of signaling,
regulatory and trafficking proteins. These protein-protein interactions are largely
responsible for determining the effector coupling, distribution, and re- or desensitization characteristics of a given GPCR. Although many of these protein
binding events are determined by the presence of conserved amino acid motifs
on the receptor i3 loop regions, the precise nature of most protein-GPCR
interactions are unknown. Given the strongly divergent nature of the muscarinic
receptor i3 loops, we reasoned that subtype-specific receptor-protein interactions
may exist, and that knowledge of such interactions could shed light upon
signaling and/or regulatory mechanisms heretofore unknown as a result of the
paucity of MR experimental tools. In addition, identification of muscarinic
receptor-interacting proteins could provide novel intracellular targets for the
subtype- or tissue-specific modulation of MRs in vivo. In an effort to discover
such MR-interacting proteins, we performed a series of unbiased yeast twohybrid protein-protein interaction screens using as “baits” the five MR i3 loop
regions. A protein identified in the M5 i3 loop screen, AGAP1, was subsequently
shown to be a bona fide, subtype-selective M5 receptor interacting protein. We
further demonstrated that interaction with AGAP1 was required for the endocytic
recycling of M5, and that this trafficking proceeded through a novel, tissuespecific mechanism. Physiological experiments suggest that interaction with
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AGAP1 is required for the normal function of the M5 muscarinic receptor in the
regulation of striatal dopamine release.
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2

IDENTIFICATION OF NOVEL MUSCARINIC RECEPTOR

BINDING PROTEINS BY YEAST TWO-HYBRID SCREEN

2.1 Summary
Muscarinic acetylcholine receptors are GPCRs characterized by the
presence of large, unstructured third intracellular loops that are divergent in
sequence between receptor subtypes. Binding of proteins to intracellular regions
of GPCRs is required for normal signaling, desensitization, and trafficking
functions. In an effort to uncover proteins regulating muscarinic receptor function
in a subtype-specific manner, we performed yeast two-hybrid screens employing
as “baits” the third intracellular loop regions of the five muscarinic receptors.
Using a diploid mating strategy, we achieved full coverage of the rat and human
brain cDNA “prey” libraries used in the screens. Based on confirmation of
positive interactions by prey plasmid retransformation and by identification and
analysis of positive clone cDNA sequences, we selected three putative
muscarinic receptor- interacting candidate proteins for further study.

2.2 Introduction
The yeast two-hybrid (Y2H) system allows for detection of protein-protein
interactions by transcriptional activation of reporter genes (Fields and Song,
1989; Chien et al., 1991). The genesis of the Y2H system was based on the
following observations: First, the DNA binding and transcriptional activator
functions of eukaryotic transcriptional regulatory proteins were shown to be
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separable and functionally compartmentalized (Hope and Struhl, 1986; Keegan
et al., 1986). Second, it was shown that fusion of DNA-binding repressors with
transcriptional activator proteins (Gal4) or fragments thereof could allow
activation of transcription downstream of the bound repressor sequence (Brent
and Ptashne, 1985; Ma and Ptashne, 1988). Finally, it was observed that native
transcriptional activators need not directly bind DNA; for example, the herpes
simplex VP16 protein activates transcription by binding to DNA-bound host
proteins (Triezenberg et al., 1988), and c-Fos activates transcription as part of
the AP-1 complex by binding to c-Jun (Curran and Franza, 1988).
In the first demonstrated example of the Y2H assay, a fusion of the Gal4p
DNA binding domain (BD; Gal41-147) and the protein kinase SNF1 was coexpressed in the yeast Saccharomyces cerevisiae with the Gal4p transcription
activation domain (AD; Gal4768-881) in fusion with SNF4, a known binding partner
of SNF1 (Fields and Song, 1989). The yeast strain used included a lacZ
transgene under control of a Gal4 binding sequence (UASG) and carried
mutations for the Gal4 AD and BD plasmid markers HIS3 and LEU2 (Fields and
Song, 1989). Whereas co-expression of the Gal4-AD and Gal4-BD was unable
to activate transcription from UASG, binding of the fused proteins SNF1:Gal4-BD
and SNF4:Gal4-AD in the yeast nucleus was able to reconstitute GAL4 activity,
allowing colorimetric detection of the lacZ protein product β-galactosidase.
Subsequently, the Y2H system was shown to be able to reconstitute a known
homo-dimeric interaction by using a SIR4:GAL4-BD fusion protein to screen a
GAL4-AD-yeast genomic DNA library (Chien et al., 1991).
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A number of important improvements to the Y2H system have since been
developed. The modern Y2H screen was introduced with the addition of an
auxotrophic reporter gene under Gal4 transcriptional control, GAL1-HIS3, to the
lacZ reporter described above. This system allowed for the successful screening
of a GAL4-AD-human lymphocyte cDNA library for clones interacting with a
GAL4-BD-”bait” fusion protein by positive growth selection and colorimetric
confirmation (Durfee et al., 1993). Next, Y2H “interaction trap” screening
systems employing a bacterial LexA-based DNA BD and reporter genes under
transcriptional control of the lexA operator (LexA-OP) were developed (Gyuris et
al., 1993; Vojtek et al., 1993; Zervos et al., 1993). Such screening systems are
compatible with bait libraries fused with yeast GAL4, viral VP16, and bacterial
B42 ADs (Ruden et al., 1991; Vojtek et al., 1993; Dagher and Filhol-Cochet,
1997). Advantages of the LexA system include lack of endogenous DNA binding
sites and protein binding partners for the bacterial DNA-BD, avoidance of the
toxic effects of GAL4 overexpression, and ease of titering reporter gene
sensitivity by varying copy number of the upstream LexA-OP sequences (Gyuris
et al., 1993; Toby and Golemis, 2001). In addition, the development of Y2H
screens in diploid yeast after mating of bait and prey strains provided a simplified
method for the exhaustive coverage of library complexity (Bendixen et al., 1994;
Fromont-Racine et al., 1997).
The strength of the Y2H system is illustrated clearly by the number of
studies employing the technique for the identification and characterization of
novel protein-protein interactions. Y2H screens have yielded important findings
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pertaining to signaling cascades. For example, the small GTPase H-Ras was
shown to interact directly with its kinase effectors c-Raf and A-Raf (Vojtek et al.,
1993); the G1 and S phase protein phosphatase Cdi1 was discovered to interact
with the cyclin-dependent kinase Cdk2 (Gyuris et al., 1993). Y2H screen results
have led to insight into the regulation of cytoskeletal dynamics; the rho GEF Lfc
was identified as a binding partner of the actin- and protein phosphatase 1binding protein spinophilin and was shown to regulate dendritic spine morphology
through this interaction (Ryan et al., 2005). Using cytosolic protein fragments as
baits, functionally significant protein-protein interactions of transmembrane
molecules have also been identified. Most notably, a Y2H screen identified the
postsynaptic density protein PSD-95 as a binding partner for the C-terminal tail of
the NMDA receptor subunit NR2 (Kornau et al., 1995). Similar screens identified
the small GTPase RhoA as a binding partner of the delayed rectifier potassium
channel Kv1.2, which was shown to play a central role in the receptor-mediated
tyrosine kinase mechanism of Kv1.2 suppression (Cachero et al., 1998) and
RGS2 as a TRPV6 Ca2+ channel interactor and functional inhibitor (Schoeber et
al., 2006). More recently, large-scale Y2H screening programs have yielded
genome-level binary protein-protein interaction maps (interactomes) for S.
cerevisiae (Yu et al., 2008) Plasmodium falciparum (LaCount et al., 2005)
Caenorhabditis elegans (Li et al., 2004) and an inter-species map between
herpesviral and human proteomes (Uetz et al., 2006).
Of particular significance to our current project are the success of Y2H
screens in the identification of novel GPCR-binding proteins. Numerous studies
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utilizing cytoplasmic fragments of GPCRs as Y2H baits have uncovered proteinprotein interactions shown subsequently to affect the signaling, localization, and
stimulation-dependent and -independent trafficking properties of the receptors.
For example, Y2H screens using GPCR c-terminal tail baits have demonstrated
the following functionally significant interactions: The α1a adrenergic receptor
and ezrin, affecting agonist-induced receptor recycling (Stanasila et al., 2006);
the prostacyclin IP receptor and PDE6δ, involved in receptor trafficking and
recycling (Wilson and Smyth, 2006); and the thromboxane A2β receptor and
RACK1, shown to be important for ER-to-plasma membrane receptor delivery
(Parent et al., 2008). Similarly, the literature contains examples of GPCR i3 loop
interactions uncovered by Y2H screens, including the binding of the protein
kinase C-zeta interacting protein (ZIP) to dopamine receptor D2, mediating
receptor down-regulation by trafficking to lysosomes (Kim et al., 2008);
up-regulation of the D3 dopamine receptor through binding to ALG-2 interacting
protein 1 (AIP1) (Zhan et al., 2008) and filamin-A (Lin et al., 2001); and promotion
of agonist-induced endocytosis of the β1 adrenergic receptor though binding to
endophilin 1/2/3 (Tang et al., 1999).
Our laboratory has successfully utilized the Y2H screen in numerous
studies identifying novel binding partners of brain-expressed GPCRs. p11, an
S100 family protein, was discovered in a Y2H screen to interact with the 5HT1b
serotonin receptor i3 loop, to regulate 5HT1b surface expression and signaling
properties, and to be required for the 5HT1B-mediated behavioral response to
antidepressant drugs in mice (Svenningsson et al., 2006). A subsequent directed
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Y2H study identified the 5HT4 serotonin receptor as a second p11 binding
partner; interaction with the i3 loop regulated receptor activity and drug
responses in a manner similar to that of 5HT1b (Warner-Schmidt et al., 2009). A
second Y2H screen using the c-terminal tail of the adenosine A2A receptor
identified an interaction with the tyrosine kinase fibroblast growth factor receptor
(FGFR); this interaction was demonstrated to underlie the synergistic effects of
FGF / adenosine co-stimulation on MAP kinase signaling, dendritic spine
morphogenesis, and synaptic plasticity (Flajolet et al., 2008). Additionally, a Y2H
screen performed with the c-terminal tail of the metabotropic glutamate receptor
mGluR5 identified binding to the neuron-specific protein norbin (neurochondrin);
this interaction was shown to potentiate mGluR5 surface expression, and to
affect mGluR5-related synaptic plasticity and behavior (Wang et al., 2009b).
The Y2H system holds a number of significant advantages over other
biochemical or genetic protein-protein interaction screening techniques with
regard to its ability to detect GPCR-interacting molecules. Most notable of the
competing methodologies, affinity purification and mass spectrometry (AP-MS)
allow for proteomic identification of individual proteins from isolated complexes
(Domon and Aebersold, 2006; Gingras et al., 2007). Affinity matrices composed
of glutathione-S-tansferase (GST) fusions of cytosolic GPCR fragments
immobilized on glutathione resins have been used to purify and identify serotonin
5HT2C C-terminal tail- and muscarinic M4 i3 loop- binding proteins by MALDITOF MS (Becamel et al., 2002; McClatchy et al., 2002). In addition,
immunoprecipitation of native metabotropic glutamate mGluR5 receptors from rat
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brain was used to identify co-purified proteins by liquid chromatography-tandem
mass spectrometry (Farr et al., 2004). Compared to the Y2H system, however,
AF-MS is inherently less sensitive to both low-affinity and low-abundance protein
interactions; the Y2H system is sensitive to interactions with Kd constants as high
as 10-7, and, as it is a genetic screen, is unaffected by physiological target protein
abundance (Phizicky et al., 2003). Affinity purification by GST-fusion protein is
limited to recombinant proteins well-expressed in Escherichia coli, and is prone
to high non-specific binding (Maurice et al., 2008; Daulat et al., 2009). In
addition, immunoprecipitation strategies are hampered by the need to solubilize
receptors under detergent conditions that may disrupt GPCR-protein interactions,
and the fact that few high-affinity GPCR antibodies exist (the latter point
especially true for the muscarinic receptors) (Daulat et al., 2009). Other wellcharacterized protein-protein interaction methods, such as phage-display and
protein microarrays, have not as of yet been utilized in a whole-genome / wholeproteome screen for GPCR-interacting proteins (Smith, 1985; Stephen and Lane,
1992; Heydorn et al., 2004; Fam et al., 2005).
An important consideration in the design of a Y2H screen for GPCRinteracting proteins is the fact that full-length receptors are inappropriate as baits.
As alluded to above, soluble cytoplasmic regions, either C-terminal tails or
intracellular transmembrane loops, are most commonly employed as DNA-BD
fusions in Y2H studies. Useful bait fusion proteins must also be able to enter the
yeast nucleus, and must lack intrinsic transcriptional activation activity (Toby and
Golemis, 2001). As described in section 1, while rat muscarinic receptors contain
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relatively short (from 23 to 42 amino acid) C-terminal tails, their i3 cytoplasmic
loops are large (157 to 240 amino acid), lack secondary structure (Rasmussen et
al., 2007; Rosenbaum et al., 2007) and are divergent in sequence between
receptor subtypes (table 1.1). The i3 loops of muscarinic receptors have
previously been shown to be substrates for agonist dependent-phosphorylation
(Tobin and Nahorski, 1993; Budd et al., 2000; Torrecilla et al., 2007), involved in
activity-induced receptor internalization (Maeda et al., 1990), and required for
basolateral membrane sorting of MRs (Nadler et al., 2001). The i3 loop has also
been shown to be important for coupling of muscarinic receptors to signaling
pathways (Singer-Lahat et al., 1996; Wess et al., 1997; Mitchell et al., 2003) and
to mediate binding of Gαi/o and Gβγ subunits (Wess et al., 1997; Wu et al., 2000)
and regulatory proteins such as RGS2 (Bernstein et al., 2004) to MRs. Thus, in
an effort to identify novel binding proteins of the five muscarinic receptors, we
performed Y2H screens using i3 loop-DNA BD proteins as baits.
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Figure 2.1 Summary of Y2H screen strategy (following page). The use of
mating type MATa yeast strains (CG1945, L40) for expression of MRi3-DNA BD
“bait” fusions in concert with the expression of a brain cDNA library-AD fusion in
a mating type MATα strain (Y187) provided for simplified library coverage by
formation of bait / prey diploids through mating. The presence of dual
transcriptional reporters allowed for confirmation of HIS3+ clones by assay for
lacZ expression by the colorimetric X-Gal assay. Doubly-positive, sequenced
clones were verified by retransformation in the appropriate reporter strain with
positive (MRi3-pASIIΔΔ) or negative (empty pASIIΔΔ) controls and X-Gal lift
assay.
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2.3 Results
Y2H screens were performed on rat brain cDNA libraries (BD Clontech)
with rat MRi3 baits for subtypes M1, M2, M4, and M5. A human M3i3 bait
sequence was used to screen a human brain cDNA library (BD Clontech), as the
hM3 cDNA clone was previously available in the laboratory. The bait DNA BD
protein contained an intrinsic nuclear localization signal (NLS), while the prey
Gal4 AD protein was fused with the SV40 T antigen NLS (Durfee et al., 1993).
Before performing screens, we first checked for bait fusion protein toxicity by
examining yeast colony growth rates on -Trp media. All bait strains exhibited
normal growth rates (data not shown). Bait strains were then plated on -Trp-His

Table 2.1 Y2H screen characteristics. Screens were performed on rat or
human MRi3 loops in fusion with the Gal4 or LexA DNA binding domains. Total
diploid colony forming units (CFUs) indicate the number of prey clones screened.
HIS3+ / lacZ+ clones with in-frame ORF fusions were identified by sequencing.

screen type

clones screened
(total diploid CFUs)

positive
clones (His
+ / β-Gal+)

positive
clones
in-frame

rM1

Gal4

2.5x107

49

25

rM1

LexA

5.6x107

126

26

rM2

Gal4

2.7x107

7

0

rM2

LexA

4.7x107

15

10

hM3

Gal4 (human)

1.8x107

64

27

rM4

Gal4

2.0x108

234

37

rM5

Gal4

1.8x107

32

11
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media to confirm that bait protein fusions did not exhibit reporter gene
autoactivation; no colony growth was observed (data not shown).
Screens were first performed with the Gal4 system according to the
strategy outlined in figure 2.1. After mating of prey and bait strains, library
coverage was estimated by quantifying diploid colony growth on -Leu-Trp media;
in all cases, mating efficiency was sufficient for full coverage of pACT2 cDNA
library complexity (Table 2.1). Where indicated, screens were repeated in the
higher-sensitivity LexA system using MRi3 loop - LexA DNA BD fusion baits in
the L40 strain, allowing use of the pACT2-containing library strains (table 2.1).
Screen results for each MRi3 bait are described below.

2.3.1 rM1
A screen of 25 million rat brain cDNA clones with a GAL4 DNA BD-rM1i3
fusion bait yielded 49 doubly-positive yeast colonies (HIS3+, lacZ+) (table 2.1).
Twenty five of these positive colonies were identified by PCR as containing a
pACT2 library clone falling within a gene-coding open reading frame (ORF) (table
2.1). Of the seven genes represented, one was of a recognized Gal4 screen
false-positive (Asrgl1) (M. Flajolet, personal communication), and one coded for
DNA-binding zinc finger protein (Zfp61); along with Rpsp and Cenpc, these clone
plasmids were not rescued (table 2.2). Three pACT2 library clones were rescued
and amplified: one (coding for Kat5) was β-Gal negative upon retransformation
with pASII∆∆-rM1i3 in Y187 yeast, while one (coding for Ppp3r1) exhibited falsepositive activation with empty pASII∆∆ co-transformation and β-Gal lift assay
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Table 2.2
rM1i3 screen results.
Identity of HIS3+ / lacZ+ clones as
determined by PCR are listed in columns 1 and 2, with total number of clones for
each gene indicated. “+”, β -Gal+; “-”, β -Gal- after prey plasmid rescue and
retransformation in yeast strain Y187 with bait plasmid (M1) or empty vector
control (ctl). Gene names without + / - entries indicate positive clones from the
rM1i3 screens for which prey plasmid isolation was either unsuccessful or not
attempted. Green / red indicates successful / unsuccessful control experiment
result, respectively. Format applies to results listed in tables 2.3-2.6.

ID

description

#
clones

rescue
M1 ctl

(Gal4 screen)
Olfm2
Kat5
Ppp3r1
Zfp61
Rpsp
Asrgl1
Cenpc

olfactomedin 2
lysine acetyltransferase 5
calcineurin B type I
zinc finger protein 61
30S ribosomal protein S16
asparaginase like 1
centromere autoantigen C
(LexA screen)
Olfm2
olfactomedin 2
Kat5
lysine acetyltransferase 5
8 genes represented by 1-2 clones
Ywhab
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, beta
polypeptide (14-3-3β)

4
1
10
3
2
4
1

+
+

+

3
4
9
3

+
+
-

-

Sharpin

1

Sdhd
Apoe
XM_347156
xm_222273
rgd1560070
xm_216178

SHANK-associated RH domain
interactor
succinate dehydrogenase complex,
subunit D
apolipoprotein E
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1
1
1
1
1
1

-

(table 2.2). A rescued clone, representing one of four positive clones coding for a
fragment of the Olfm2 ORF, passed positive and negative retransformation lift
assays (table 2.2). Olfm2, coding for the Noelin-2 (Ofactomedin-2) protein, is a
member of the olfactomedin family of secreted glycoproteins (Barembaum et al.,
2000).
In an effort to obtain a greater number of M1i3-interacting clones, we
repeated the rM1i3 screen using an LexA-rM1i3 fusion as bait in the L40 strain.
The protein-protein interaction detection sensitivity of the LexA screen was
anticipated to be higher, as HIS3 activation in L40 is less stringent than in
CG1945, and because the bait plasmid pLEX9 contained a LexA-OP-lacZ
reporter (Vojtek et al., 1993). The rM1i3-LexA screen covered 56 million
independent library clones, of which 126 were HIS+ / lacZ+. PCR analysis
showed 26 of these positive clones to contain in-frame ORF cDNAs (table 2.1).
pACT2-library plasmid rescue failed for clones representing the genes Ywhab
and Sharpin, and was not attempted for Sdhd, Apoe, and 4 uncharacterized
genes (table 2.2). 10 pACT2 library clones were successfully rescued; of these, 8
were β-Gal negative upon retransformation with rM1i3-pLexA (table 2.2). In the
X-Gal lift assay, two clones were β-Gal+ / β-Gal- upon retransformation with
pLex9-rM1i3 and empty pLex9 vector, respectively: Olfm2, representing 3 of the
26 total positive screen colonies, and Kat5, representing 4 of the positive
colonies (table 2.2). Kat5 encodes lysine acetyltransferase 5 / TIP60, a histone
acetyltransferase shown to function in DNA damage repair, transcriptional
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control, and chromatin remodeling (Squatrito et al., 2006). Olfm2 / Noelin-2 is
described above.

2.3.2 rM2
An initial screen of 27 million independent rat brain cDNA library clones
with a Gal4 DNA BD-rM2i3 bait yielded 7 His+ / lacZ+ colonies (Table 2.1).
However, PCR analysis indicated no clones representing in-frame ORF
sequences (table 2.1). We thus repeated the screen in the less-stringent LexA
system, as described above. The LexA-rM2i3 screen covered 47 million
independent rat brain cDNA library clones, and yielded 15 His+ / lacZ+ colonies.
Of these, 10 clones represented in-frame ORF sequences, covering 3 genes
(table 2.1, 2.3). Rescue and retransformation in L40 yeast with pLex9-rM2i3
gave negative β-Gal activation results for two of the recovered clones,
representing the genes Ppp1ca and Cldn10 (table 2.3). The remaining rescued

Table 2.3, rM2i3 screen results

ID

description

#
clones

rescue
M2 ctl

(Gal4 screen)
-

0
(LexA screen)

snx20
Ppp1ca
Cldn10

sorting nexin 20
protein phosphatase 1, catalytic subunit,
alpha isoform
claudin 10
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8
1

+
-

-

1

-

-

clone, encoding a 3ʼ fragment of Snx20, represented 8 of the 10 positive / ORF
in-frame screen colonies and was β-Gal+ / β-Gal- upon retransformation with
pLex9-rM2i3 and empty pLex9 vector, respectively (table 2.3). SNX20 (sorting
nexin 20) is a member of the sorting nexin family, and was recently shown to bind
to and regulate the distribution of P-selectin glycoprotein ligand-1 (PSGL-1)
(Worby and Dixon, 2002; Schaff et al., 2008).

2.3.3 hM3
A screen of 28 million human brain cDNA clones with a GAL4 DNA BDhM3i3 fusion bait yielded 64 doubly-positive yeast colonies (HIS3+, lacZ+) (table
2.1). Twenty seven of these 64 positive clones were found by PCR analysis to
contain in-frame human ORF sequences, covering 17 unique genes (table 2.1,

Table 2.4 hM3i3 screen results

ID
Mllt3
Pou2f1
PCDHGA5
KIAA1012
Psmc1
THUMPD3
Aff4
Ranbp9

description
myeloid/lymphoid or mixed-lineage
leukemia; translocated to, 3
POU class 2 homeobox 1
protocadherin gamma subfamily A, 5
9 genes covered
proteasome (prosome, macropain) 26S
subunit, ATPase, 1
THUMP domain containing 3
AF4/FMR2 family, member 4
RAN binding protein 9
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#
clones

rescue
M3 ctl

1

+

-

3
1
1
12
3

+
+
+
-

+
+
+

2
2
2

2.4). pACT2 library plasmids covering 13 of these genes were rescued and
retransformed in Y187 yeast with pASII∆∆-hM3i3 bait constructs; of these, 9
clones failed to activate β-Gal activity in the lift assay (table 2.4). Rescued
clones containing coding sequences for Pou2f1, PCDHGA5, and KIAA1012 were
lacZ+ with both hM3i3 and control (empty vector) baits, indicating false-positive
interactions (table 2.4). One clone, containing coding sequence from the gene
Mllt3 and representing a single positive colony from the hM3i3 screen, was
β-Gal+ / β-Gal- upon retransformation with positive and negative control baits,
respectively (table 2.4). MLLT3 encodes a transcription factor implicated in the
pathology of leukemia and in the fating of human erythroid cell types (Iida et al.,
1993; Pina et al., 2008). Rescue of prey plasmids encoding an additional 4
genes (Psmc1, THUMPD3, Aff4, and Ranbp9) was not successful (table 2.4).

2.3.4 rM4
A screen of 200 million human brain cDNA clones with a GAL4 DNA BDrM4i3 fusion bait yielded 234 doubly-positive yeast colonies (HIS3+, lacZ+) (table
2.1). Thirty seven of the 234 positive clones were found by PCR to contain inframe ORF sequences, covering 11 unique genes (table 2.1, 2.5). pACT2 bait
plasmids for 6 positive clones (representing 31 of the 37 total positive colonies
from the screen) were rescued and amplified for use in the retransformation lift
assay in Y187 yeast. A rescued clone encoding Ube2i failed to show lacZ
activation when co-expressed with the Gal4 DNA BD-rM4i3 bait fusion protein
(table 2.5). Rescued pACT2 clones coding for segments of NRBP2, Pclo, and
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Ccar1 were indicated as false-positives, as co-transformation with empty
pASII∆∆ vector led to β-Gal activity (table 2.5). Rescued prey clones encoding 3ʻ
fragments of the UHRF1BP1L and Rbp3 ORFs (representing 2 and 14 of the 31
identified in-frame positive clones, respectively) were confirmed in the
retransformation lift assay as β-Gal+ with the rM4i3 bait and β-Gal- with empty
vector. UHRF1BP1L, or UHRF1 binding protein like 1 (also annotated as
KIAA0701), is uncharacterized; however, the UHRF1 protein is known to function
as an E3 ubiquitin ligase and to affect cell proliferation (Bronner et al., 2007).
Rbp3 (retinol binding protein 3; also known as Interphotoreceptor retinol-binding

Table 2.5 rM4i3 screen results. (*) Isolation of Dynlt1-encoding prey plasmid
from yeast clones was not successful; indicated results are for full-length rat
Dynlt1 coding sequence amplified by PCR from a rat brain cDNA library and
cloned into the pACT2 prey vector.

ID

description

UHRF1BP1L UHRF1 binding protein 1-like
(KIAA0701)
Rbp3
retinol binding protein 3, interstitial
NRBP2
nuclear receptor binding protein 2
Pclo
piccolo (presynaptic cytomatrix protein)
Ccar1
cell division cycle and apoptosis
regulator 1
Ube2i
ubiquitin-conjugating enzyme E2I
Dynlt1
dynein light chain Tctex-type 1
E4f1
E4F transcription factor 1
Zcchc17
zinc finger, CCHC domain containing 17
Nap1l5
nucleosome assembly protein 1-like 5
Sult4a1
sulfotransferase family 4A, member 1
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#
clones

rescue
M4 ctl

14

+

-

2
4
3
5

+
+
+
+

+
+
+

3
2*
1
1
1
1

-

+

protein / IRBP) is an extracellular glycoprotein found in the interphotoreceptor
matrix of the retina, and functions to shuttle chromophore molecules between
cells of the retinal pigment epithelium and photoreceptors (Liou et al., 1982; Jin
et al., 2009). Clones representing 4 genes (E4f1, Zcchc17, Nap1l5, and Sult4a)
were not rescued. Rescue of a clone encoding Dynlt1 failed; however, the fulllength cDNA for this gene was amplified from a rat brain cDNA library by PCR
and was cloned into the pACT2 prey plasmid for use in the retransformation lift
assay. Dynlt1 exhibited lacZ reporter activity with empty pASII∆∆ bait plasmid,
but not with the rM4i3 bait construct (table 2.5).

2.3.5 rM5
A screen of 18 million human brain cDNA clones with a GAL4 DNA BDrM5i3 fusion bait yielded 32 doubly-positive yeast colonies (HIS3+, lacZ+) (table
2.1). Eleven of these 32 positive clones were found by PCR analysis to contain
in-frame ORF sequences, representing 4 unique genes (table 2.1, 2.6). A clone
containing a 3ʻ fragment of the AGAP1 ORF (representing 4 of the 11 total

Table 2.6 rM5i3 screen results.

ID

description

AGAP1
AGAP1 / centaurin, gamma 2
Ddrgk1
DDRGK domain containing 1
RGD1566093 similar to Fusion (involved in t(12;16) in
malignant liposarcoma)
E4f1
E4F transcription factor 1
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#
clones
4
3
2
2

rescue
M5 ctl
+

-

characterized positive screen colonies) was rescued and confirmed to interact
with the Gal4 DNA BD-rM5i3 bait in the X-gal lift assay; the negative control cotransformation with empty bait vector showed no lacZ activation (table 2.6).
AGAP1 (also known as centaurin γ2 / Centg2) is a phospoinositide-dependent
Arf GAP shown to regulate endocytic trafficking (Nie et al., 2002; Nie et al.,
2003). Rescue of pACT2 plasmids from the remaining prey clones (representing
three additional genes; Ddrgk1, RGD1566093, and E4f1) was not attempted
(table 2.6).

2.4 Discussion
In this section, we have described screens performed with the yeast twohybrid system in an effort to detect proteins interacting with the five muscarinic
acetylcholine receptors. The prey / bait strain mating protocol, as opposed to cotransformation techniques, allowed us to easily generate a high number (>18
million) of diploid clones in each screen (Bendixen et al., 1994; Fromont-Racine
et al., 1997). As the oligo-dT-primed pACT2 cDNA libraries used contained
approximately 3.6 million independent clones (BD Clontech), our screens
achieved multiple-fold coverage of the approximately 1.2 million in-frame Gal4
AD-cDNA fusions potentially present. For each receptor, a number of potential
interacting clones were isolated and identified by PCR sequencing. Narrowing
this list of candidate MR-interacting proteins was necessary in order to focus our
subsequent experimental efforts.
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There are important limitations to the Y2H method that must be
considered in order to properly evaluate candidate MR-interacting clones
(Phizicky and Fields, 1995; Toby and Golemis, 2001; Lin et al., 2005; Daulat et
al., 2009). First, unlike proteomic approaches, the Y2H system is sensitive only
to binary protein-protein interactions; multi-protein complexes are not detected.
Second, in order to activate transcription of reporter genes, bait-prey interactions
occur in the yeast nucleus. Prey fusion proteins unable to translocate to the
nucleus, such as proteins containing transmembrane domains, will not be
detected in Y2H screens. Third, expression of mammalian proteins in yeast may
be inefficient or lead to toxicity and growth retardation. Although we observed no
toxic effects of either the DNA BD-MRi3 or AD-cDNA library fusions, it was
impossible to determine to what extent library clones were under-represented as
a result of poor expression or slow yeast growth. Expression of bait or prey
proteins as hybrid fusions may interfere with their native structure and/or
function. Additionally, proteins expressed in yeast may be subject to misfolding,
and may lack characteristic post-translational modifications such as
phosphorylation, glycosylation, and nitrosylation found in their native
environment. Finally, as described earlier, the Y2H system is compatible only
with soluble proteins. This necessitated the use of cytoplasmic fragments of the
MRs, rather than the full-length receptors as bait, and implied that library cDNAs
containing coding regions for protein transmembrane domains were not
represented in the screens.
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The presence of false-negative results are a result of the Y2H technical
considerations listed above. There are a number of known, physiological GPCRprotein interactions that would not be expected to be detected in our screening
system. For example, binding of G proteins to GPCRs requires both formation of
heterotrimeric complexes and interaction to second and third intracellular loop
regions present in the native receptor conformation (Bluml et al., 1994; Wess et
al., 1995) Homo- and hetero- dimerization and oligomerization of native
receptors has been described for muscarinic receptors (Zeng and Wess, 1999;
Park and Wells, 2003) as well as for GPCRs such as GABAB (Kaupmann et al.,
1998; Margeta-Mitrovic et al., 2000), β2-adrenergic and opioid receptors (Jordan
et al., 2001) and many others (Gurevich and Gurevich, 2008); these interactions
would not be indicated in the Y2H system, although detection of transmembrane
receptor association by cytoplasmic domain interactions is possible (Flajolet et
al., 2008). In addition, binding of β-arrestin to GPCRs occurs only after activation
and receptor phosphorylation by GRKs (Lohse et al., 1990; Luttrell and
Lefkowitz, 2002), post-translational modifications that are unlikely to be present
in MRi3 loops expressed in yeast. Indeed, we did not detect in our Y2H screens
a number of proteins demonstrated previously (by alternate methodologies) to
interact with MRi3s, such as RGS2, SET, and eEF1A2 (McClatchy et al., 2002;
Bernstein et al., 2004; Simon et al., 2006). Thus, the absence of clones present
in our Y2H screens was not diagnostic of absence of interaction with a given
gene product. Nevertheless, for the reasons described earlier, we considered
Y2H screens employing i3 loop regions as a desirable methodology for the
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detection of physiologically and functionally relevant MR- interactions. It should
be noted, however, that in the period since the performance of our screens, a
number of technologies have come into use that address some of the difficulties
inherent to the study of MR protein-protein interactions, such as the high-affinity
tandem affinity purification technique (TAP) for the purification of protein
complexes associated with tagged, full-length MRs (Daulat et al., 2007; Lyssand
et al., 2008).
Additional characteristics of the Y2H system are responsible for the
occurrence of false-positive clones in screens. First, prey protein fusions
exhibiting binding to the Gal4 or LexA DNA BDs could indicate interaction by
reporter gene activation despite lack of binding to the i3 loop portion of the bait
fusion protein. We therefore confirmed interacting clones by retransformation of
rescued plasmids in the presence of both bait (DNA BD-i3 loop) and negative
control (empty bait vector) plasmids. Clones displaying β-Gal activity in the
presence of DNA-BD alone were excluded from further consideration (tables
2.2-2.6). Second, the Y2H transcriptional activation reporter system is sensitive
to interference by bait fusions exhibiting transcriptional activation activity, and bait
fusion proteins displaying DNA binding affinity. We confirmed that our DNA BDMRi3 bait fusion proteins did not activate transcription of HIS3 by observing lack
of growth on -His media of bait plasmid-transfected yeast strains. Based on
known or predicted function of sequenced positive clones, we also excluded from
further consideration genes encoding transcription factors, transcriptional
transactivators, or proteins with other known DNA-binding activity. These clones
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included the transcription factor E4f1 from the M4 and M5 screens; the zincfinger proteins Zcchc17 and Zfp61 from the M4 and Gal4-M1 screens,
respectively; the centromere autoantigen Cenpc (Earnshaw et al., 1987) from the
M1i3-Gal4 screen; and the transcription factors Mllt3 and Aff4 from the M3 screen
(tables 2.2-2.6).
A third factor responsible for the occurrence of false-positive results in
Y2H screens is the fact that, while able to interact when co-localized in the yeast
nucleus, putative interacting proteins may not co-localize spatially or temporally
under normal physiological conditions in the mammalian cell. Thus, for positive
clones with known or predicted function, we considered functional plausibility as
a factor in the ranking of candidates for priority of further study. Based on the
false-positive selection criteria described above, no rescued candidate clones
remained from the M3 screen. Candidates remaining for the other four MRi3
screens are discussed in the following paragraphs.
In the initial M1i3 screen in the Gal4 system, the only rescued clone
passing positive and negative retransformation controls encoded a C-terminal
fragment of the secreted glycoprotein Olfactomedin / Noelin 2 (Barembaum et al.,
2000). Noelin 1/2 has been shown to be expressed during development in the
brain, retina and other structures in the chick, mouse, and zebrafish, and to be
important for early and late brain developmental events (Barembaum et al., 2000;
Moreno and Bronner-Fraser, 2002; Lee et al., 2008). Mutations in human Olfm2
have also been implicated in the genetics of a form of glaucoma (Funayama et
al., 2006). Based on this knowledge of Noelin 2 distribution and function, a
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functional interaction with M1 was determined to be physiologically unlikely, and
we considered the interaction with M1i3 to be false-positive. In the hope of
identifying additional M1i3-interacting proteins, we repeated the screen with the
higher-sensitivity LexA reporter system. Two positive clones emerged from this
screen: Noelin 2 and the lysine acetyltransferase Kat5. Kat5, also known as
TIP60, is a histone acetyltransferase that functions as part of the conserved
NuA4 complex which was shown to be recruited to chromatin by binding to to the
transcription factor MYC, and to play a role in the DNA damage response
pathway and in tumorigenesis (Frank et al., 2003; Squatrito et al., 2006; Gorrini
et al., 2007; Bhoumik et al., 2008). These functions also led us to discount the
Kat5 interaction with M1i3 as a probable false-positive result. Thus, no rescued
clones emerged as likely physiological binding partners of M1 from our screens,
although it was interesting to note the reproducibility of our screen results: Noelin
2 was identified as a positive clone in both screens, and Kat5, the confirmed
positive clone from the LexA screen, was also identified as a HIS3+ / lacZ+ clone
in the initial Gal4 screen, although re-transformation failed to display β-Gal
activation (table 2.2). It is also worth noting the greater number of false-positive
clones obtained in the LexA screen as opposed to the Gal4, which is consistent
with the greater stringency of the Gal4 reporter system and illustrates the
tradeoffs between sensitivity and false-positive rate that is important to consider
in the design and analysis of Y2H screens (Phizicky and Fields, 1995; Toby and
Golemis, 2001).
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The M2i3 screen performed in the Gal4 system yielded no positive inframe clones, and was thus repeated in the LexA system. Eight positive clones
encoding a C-terminal fragment of SNX20 (sorting nexin 20) were confirmed to
interact with M2i3 by plasmid rescue and retransformation (table 2.3). SNX20,
also annotated as SLIC-1, is a member of the sorting nexin family, proteins
characterized by the presence of a phosphoinositide-binding phox homology
(PX) domain (Xu et al., 2001; Worby and Dixon, 2002). Proteins in the sorting
nexin family, of which 33 members have been identified in mammals, have been
shown to function in endocytosis, endosomal sorting of cargo proteins, regulation
of endosomal structure, and coordination of endosomal signaling (Worby and
Dixon, 2002; Cullen, 2008). A recent study (employing the Y2H screen
technique, but subsequent to the analysis of our results) demonstrated SNX20
binding to the P-selectin glycoprotein ligand-1 (PSGL-1) cytoplasmic tail; this
binding is thought to regulate the endosomal distribution of PSGL-1 (Schaff et al.,
2008). As functionally significant interactions of trafficking molecules with
GPCRs are well established (Tan et al., 2004) and since sorting nexins have
been shown to bind to and regulate the trafficking of low-density lipoprotein
receptors, EGF receptors, and protease-activated receptor 1 (Kurten et al., 1996;
Stockinger et al., 2002; Wang et al., 2002), among others, we considered the
identified interaction of SNX20 with M2i3 as a physiologically plausible result and
an intriguing candidate for further study.
The M4i3 screen yielded two positive clones that passed subsequent
retransformation controls: Rbp3 (interstitial retinol-binding protein) and
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UHRF1BP1L (table 2.5). Rbp3, known more commonly as interphotoreceptor
retinol binding protein (IRBP), is a glycoprotein secreted by photoreceptor cells
into the interphotoreceptor matrix of the retina (Liou et al., 1982; GonzalezFernandez, 2003). IRBP functions to shuttle all-trans-retinol and 11-cisretinaldehyde molecules between cells of the retinal pigment epithelium and
photoreceptors, and is critical for resensitization of photoreceptors after light
exposure (Carlson and Bok, 1992; Qtaishat et al., 2005; Jin et al., 2009). Based
on the extracellular distribution and described function of IRBP, we discounted
this M4i3 screen clone as a likely false-positive result.
Fourteen clones encoding two different C-terminal fragments of
UHRF1BP1L (UHRF1 binding protein 1-like) were detected and confirmed by
rescue and retransformation in our M4i3 screen. UHRF1BP1L, also annotated
as KIAA0701, is an uncharacterized protein with no putative functional domains,
named for its sequence similarity to the uncharacterized protein UHRF1BP1.
UHRF1, known also as ICBP90 and Np95, is a multidomain protein containing a
RING-finger ubiquitin E3 ligase domain, and was shown to bind directly to
methylated DNA sequences and to be important for the maintenance of histone
and DNA methylation states (Bronner et al., 2007; Sharif et al., 2007; Hashimoto
et al., 2008a). Though false-positive Y2H results as a result of multiple protein
complex formation is unlikely, the relation of UHRF1BP1L to a known DNAbinding protein was of concern. Nevertheless, as down-regulation of β2
adrenergic receptors has been shown to be mediated by ubiquitination by an E3

61

ligase (Shenoy et al., 2001), and since the function of UHRF1BP1L is unknown,
we selected UHRF1BP1L for further study with respect to its binding to M4.
The M5i3 screen yielded positive clones encoding a C-terminal fragment
of AGAP1 that passed positive and negative retransformation control
experiments (table 2.6). AGAP1 (an acronym for Arf GAP containing GTP
binding protein-like domain, ankyrin repeats and pleckstrin homology domain 1),
also annotated as centaurin γ2, is a member of both the AZAP and centaurin
protein families (Jackson et al., 2000; Nie et al., 2002). AGAP1 is a
phosphoinositide-dependent GAP for members of the small GTPase protein
family Arf, proteins that function to regulate mechanisms of intracellular
membrane trafficking and actin cytoskeleton dynamics (Nie et al., 2002). AGAP1
was shown to bind to and regulate the function of the AP-3 adapter / coat protein
complex, in turn affecting the trafficking of the lysosome-associated protein
LAMP1 (Nie et al., 2003). A number of AZAP and centaurin family proteins have
been shown to affect trafficking of plasma membrane receptors: ACAP1 binds to
sorting signals on the transferrin receptor and integrin β1, promoting their
endocytic recycling (Dai et al., 2004; Li et al., 2005); ASAP1 accelerates the
recycling of internalized EGF receptors (Nie et al., 2006); and centaurin α1
inhibits internalization of the β2 adrenergic receptor (Lawrence et al., 2005). In
addition, the protein PIKE-L / centaurin γ1 mediates the anti-apoptotic effects of
the metabotropic glutamate receptor mGluR1 activation via Homer-coupled
binding to the mGluR1 C-terminal tail (Rong et al., 2003). Taken together, the
known functions of AGAP1 and AZAP / centaurin family proteins led us to
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consider an interaction between M5 and AGAP1 as physiologically plausible, and
so we selected AGAP1 for continued study.
Based on the criteria described above for selecting candidates by the
likelihood of their physiologically relevant interaction with MRs, there were a
number of notable clones identified in our screens for which prey plasmid rescue
failed. From the M1i3-LexA screen, Ywhab- (14-3-3β) and Sharpin- coding
clones were not rescued (table 2.2). The Sharpin protein localizes to the postsynaptic density and interacts with Shank (Lim et al., 2001), while 14-3-3 proteins
serve as molecular scaffolds for signaling regulation, and bind to phosphoserine
motifs and the β1 adrenergic receptor (Tutor et al., 2006; Obsilova et al., 2008).
In addition, it is possible that clones such as Ppp1ca (coding for the catalytic
subunit of protein phosphatase 1a) that failed to exhibit β-Gal activity upon
retransformation with bait plasmid were displaying an MRi3 interaction weak
enough to activate transcription of HIS3, but not the more stringent lacZ (table
2.3). Nonetheless, the group of three candidate MRi3-interacting proteins
described above - SNX20, AGAP1, and to a lesser extent UHRF1BP1L - were
deemed sufficiently promising to allow us to proceed with experiments examining
the characteristics of their binding to MRs.

63

3

ANALYSIS OF THE M5-AGAP1 PROTEIN-PROTEIN

INTERACTION

3.1 Summary
The binding characteristics of muscarinic receptor- interacting protein
candidates identified in Y2H screens were investigated using complementary
protein-protein interaction techniques. We performed deletion mapping using
directed Y2H assays to confirm candidate / MR i3 loop interactions, and to
determine minimum domains of interaction. The interaction between M5i3 and
AGAP1 was determined to be unique to the M5 receptor subtype, and was
shown to require a 23-residue region in the M5i3 loop. Similar mapping
experiments demonstrated that AGAP1 was unique among its most closely
related family members in its association with M5i3, and that a 60-residue region
in the split pleckstrin homology domain region was required for M5i3 binding. In
vitro binding of exogenously expressed AGAP1 to recombinant GST-MRi3 fusion
proteins recapitulated a M5-specific binding pattern across MR subtypes. GSTfusion proteins containing fragments of M5i3 and AGAP1 were also able to
interact, in a DOI-specific manner, with AGAP1 and full-length M5, respectively.
Endogenous AGAP1 from rat brain lysate bound to a GST-M5i3 fusion protein, as
did members of the heteromeric AP-3 adaptor complex. Parallel protein-protein
interaction experiments with SNX20 and M2i3, and with UHRF1BP1L and M4i3
did not provide strong evidence for specific interaction of these proteins. The
results provide support for a subtype-specific interaction of M5 with AGAP1, and
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suggest utility of a M5 DOI-deletion mutant receptor as a tool for the study of
AGAP1-dependent M5 function.

3.2 Introduction
The validation of putative interacting proteins identified in yeast two-hybrid
screens by independent protein-protein interaction techniques is critical. The
Y2H system is subject to artifactual false-positive results as a result of the yeast
nuclear environment, misfolding of mammalian proteins, and DNA BD / AD fusion
junction effects (Van Criekinge and Beyaert, 1999; Lin et al., 2005). While no
protein-protein interaction technique is free from false-positive interference, the
use of complementary techniques (genetic and biochemical; in vitro and in vivo)
provides the strongest evidence for the existence of a physiological protein
complex. “Pull-downs” from cell or tissue lysates using immobilized affinity
matrices of recombinantly expressed glutathione-S-transferase (GST) fusion
proteins are a commonly used and well-characterized method for detecting and
analyzing protein-protein or protein-complex interactions (Lee and Liu, 2005;
Chen et al., 2006; Flajolet et al., 2008; Warner-Schmidt et al., 2009). Coimmunoprecipitation of solubilized receptors expressed exogenously in tissue
culture cells or from endogenous sources is an additional method commonly
employed to verify and study the binding of protein or complexes with receptors,
and is particularly well-suited to the detection of receptor-protein complexes from
native tissues (Hall, 2005; Svenningsson et al., 2006; Daulat et al., 2007; Daulat
et al., 2009). A number of other in vitro techniques are also available for the
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confirmation and analysis of putative protein binding partners, including protein
and peptide arrays (Kung and Snyder, 2006), “Far Western” overlay blots and
arrays (Mahlknecht et al., 2001; Hall, 2004) and peptide competition binding
assays (Badtke et al., 2006).
Protein-protein interactions are commonly dependent on amino acid motifs
or conserved functional binding domains. A large number of short peptide
sequences conferring binding affinity to trafficking, signaling or scaffold proteins
have been characterized; examples include dileucine and YXXΦ (Φ representing
the bulky hydrophobic residues L,I,V,M, or F) motif binding to AP-1 and AP-2
adaptor protein complexes, respectively (Rapoport et al., 1997; Rapoport et al.,
1998) and proline-rich motif binding to the WW and SH3 domains (Pawson and
Nash, 2003). Similarly, many conserved functional domains capable of binding
proteins (as well as lipids and ions) have been described; as these domains are
typically able to fold correctly independent of N- and C- terminal context, they
exhibit modular function and occur repeatedly throughout the proteome (Pawson
and Nash, 2003). Common protein-protein interaction domains include PDZ,
found in the post-synaptic density scaffold protein PSD-95 and important for the
assembly of excitatory synapses (Kim and Sheng, 2004), and the proline-rich
peptide-binding SH3 domain (Kaneko et al., 2008).
In the current study, two of the putative MR-interacting proteins identified
by Y2H screen contain conserved binding domains. SNX20 contains a phox
homology (PX) domain, a defining characteristic of the entire sorting nexin family
(Worby and Dixon, 2002). PX domains are mainly implicated in the binding of

66

phospholipids and phosphoinositides (Xu et al., 2001), although instances of
protein-protein interactions mediated by PX domains have been observed
(Worby and Dixon, 2002; Abdul-Ghani et al., 2005). The PX domain of of SNX20
was shown to bind most strongly to phosphatidylinositol 4-phosphate,
phosphatidylinositol 5-phosphate, and phosphatidylinositol 3,5-bisphosphate; in
addition, PX phospholipid binding was seen to be required for endosomal
localization of SNX20 (Schaff et al., 2008). AGAP1 contains multiple functional
domains, two of which (pleckstrin homology (PH) and ankyrin repeat) potentially
participate in protein-protein interactions (see figure 3.2A). The PH domain is
found in a variety of signaling and membrane-associated molecules; it is known
to bind phospholipids, but is also able to participate in protein-protein interactions
with Arf1 and G-protein βγ subunits (Lodowski et al., 2003; Godi et al., 2004;
Lemmon, 2004). In AGAP1, the PH domain is split by intervening sequence into
N- and C- terminal halves (Nie et al., 2002). The C-terminal end of AGAP1 also
contains a series of ankyrin repeats; the ankyrin domain occurs widely and is
able to mediate binding to a diverse array of protein targets (Li et al., 2006).
The primary goal of the experiments described in this chapter was to
confirm the presence of protein-protein interaction between muscarinic receptors
and the three putative MR-binding proteins identified by Y2H screening. We
used the complementary protein-protein interaction experimental techniques of
directed Y2H, GST pull-down and co-immunoprecipitation to investigate the
binding of AGAP1, SNX20, and UHRF1BP1L to muscarinic receptors M5, M2,
and M4, respectively. Using a similar experimental approach, we also
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determined the specificity of MR-candidate protein interactions with respect to
MR subtype and interacting protein family members. Finally, we performed Y2H
domain-of-interaction mapping of MRi3 loops and candidate interacting proteins
in an effort to determine residues or regions responsible for their binding. In
doing so, our hope was 1) to gain insight into the molecular and/or cellular
implications of MR-protein interactions by identifying known amino acid motifs or
interaction domains mediating binding, and 2) to develop molecular tools for
subsequent study of the function of MRs in a loss-of-interaction context.

3.3 Results
3.3.1 AGAP1 interaction with M5i3 is subtype-specific and is mediated by
discrete binding domains
We first investigated the specificity of the putative AGAP1- M5i3
interaction by Y2H lift assay. Co-transformation of Y187 yeast with the AGAP1coding pACT2 clone obtained from the Y2H screen and with pASII∆∆ bait
plasmid encoding each of the five MRi3s (or empty vector) revealed lacZ reporter
gene activation only with the M5i3 bait (figure 3.1A). We then sought to map the
domain of M5i3 critical to interaction with AGAP1 by deletion mutagenesis and
directed Y2H assays, an approach used successfully in previous domain of
interaction (DOI) studies (Miller et al., 2004; Lin et al., 2005; Flajolet et al., 2008;
Hsu et al., 2009). First, we determined that a prey plasmid encoding a rat
AGAP1 fragment spanning residues 552 to 645 was able to activate β-Gal
activity with a full length M5i3 bait in the Y2H lift assay (table 3.1B). Next, we
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A
rat muscarinic acetylcholine receptor 5
(531aa)
1

clone JI17
(rAGAP1 520-861)
M5i3 (214-442)

extracellular

M1i3 (210-366)
M2i3 (208-388)

intracellular

531
M3i3 (252-491)

i3 loop
214-442

M4i3 (216-400)
pAS2!! vector

B
Bait: M5
214

286

304

354

375

Prey:
AGAP1 (552-645)

393

413

442

Y2H lift assay
"-Gal:
+++
+/-

354-413 (! 369-386)

C

Figure 3.1 AGAP1 interacts with a defined region of the M5 i3 loop in a
receptor subtype-specific manner. (A) Right, X-Gal lift assay results for Y2H
interaction assay between rat MRi3-Gal4 bait proteins and the rat AGAP1 clone
isolated in the M5i3 screen.
pAS2∆∆, negative control.
(B) Cartoon
summarizing X-Gal lift assay results from Y2H interaction assays. M5(214-442)
represents the rM5 i3 loop region. Truncation and deletion mutants were
assayed for AGAP1(542-645) interaction as indicated. Dark blue, strong lacZ
activation; light blue, weak lacZ activation; white, negative result. (C) Multiple
species alignment of the identified M5 i3 domain of interaction with AGAP1. R,
m, h; rat, mouse, human, respectively. Yellow box indicates minimum domain of
interaction. Residues are colored by shared amino acid characteristics.
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used PCR cloning to construct a series of three M5i3 deletion mutants spanning
the 229-residue length of the i3 loop. Only the C-terminal end fragment, M5
(354-442), displayed interaction with AGAP1 (552-645) (figure 3.1B). We then
constructed a series of deletion mutants in order to determine the C-terminal
extent of the putative AGAP1-M5i3 binding domain. While the M5 (354-386) i3
loop bait fragment displayed X-Gal staining intensity with AGAP1 (552-645) prey
equal to that of the full-length i3 sequence, an M5 fragment truncated by a further
3 residues (M5 (354-383)) produced greatly reduced X-Gal staining (figure 3.1B).
Using a similar N-terminal end truncation approach, we observed that an M5
(364-393) bait fragment exhibited full-length i3 X-Gal staining intensity, while
truncation by a further 5 residues (M5 (369-393)) greatly reduced reporter activity
(figure 3.1B). Thus, a 23-amino acid region of M5i3 was identified as a possible
minimum domain of interaction with AGAP1 in the Y2H assay. To confirm this
result, we constructed an M5i3 bait construct spanning the identified binding
region but deleted for an 18-amino acid stretch within this region, M5 (354-413
∆369-386). This deletion-mutant bait construct showed no lacZ activation in the
Y2H assay with the AGAP1 (552-645) prey, indicating successful disruption of
the AGAP1 binding domain (figure 3.1B). Multiple-species alignment of the M5
amino acid sequences available in Genbank revealed the putative critical region
of interaction to be strongly conserved suggesting the presence of a functionally
significant domain (figure 3.1C). This 23-residue M5i3 sequence displayed no
homology with sequences of the other four MRs (figure 1.1).
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We next used deletion mutagenesis and the Y2H lift assay to investigate
the residues on AGAP1 required for interaction with the M5 i3 loop. The pACT2
clone (JI17) isolated from the M5i3 Y2H screen encoded a C-terminal fragment of
rat AGAP1 spanning residues 520-861 (figure 3.2A). A series of truncation
mutants spanning the C-terminal region of AGAP1 covered by the JI17 clone
were tested against the full-length M5i3 bait. An AGAP1 fragment (552-646) that
included the entire C-terminal half of the split PH domain was found to interact
strongly with M5i3 in the X-Gal lift assay (figure 3.2A). Further refinement of the
M5i3-interacting domain of AGAP1 indicated that a 59-amino acid region
spanning residues 552-609 was the minimum domain sufficient for M5i3 binding
in the Y2H assay. The entire C-terminal half of the split PH domain was required
for M5i3 interaction, as an N-terminal truncation of 8 amino acids was sufficient
to eliminate lacZ reporter activation (figure 3.2A). Alignment of the rat AGAP1
(552-609) region sequence with that of other species revealed very high
conservation, with >98% amino acid identity between rat, mouse and human
sequences (figure 3.2B).

3.3.2 M5i3 alanine mutagenesis reveals residues critical for AGAP1 interaction
Based on the previous results, we performed site-directed mutagenesis of
residues falling within the M5i3 domain identified as critical for interaction with
AGAP1. We identified charged and/or bulky hydrophobic residues in this region
that displayed strong conservation across species, and constructed a series of
alanine point mutants of the M5 (332-419) bait construct (figure 3.2B, figure
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Figure 3.2 AGAP1 domain-of-interaction mapping. (A) Cartoon summarizing
X-Gal lift assay results from Y2H interaction assays. Top, AGAP1 functional
domains.
Below, rat AGAP1 truncation mutants were assayed for M5i3
interaction as indicated. Dark blue, strong lacZ activation; white, negative result.
(B) Multiple species alignment of the identified AGAP1 domain of interaction with
M5i3. R, m, h; rat, mouse, human, respectively. Yellow box indicates minimum
domain of interaction.
Residues are colored by shared amino acid
characteristics.
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Figure 3.3 Specificity of the AGAP1 / M5 i3 interaction. (A) Alanine point
mutants were generated from the rat M5 (332-419) bait construct and tested for
interaction with rat AGAP1 (552-645) in the Y2H lift assay. Dark blue, strong lacZ
activation; white, negative result. (B) Top, multiple species sequence alignment
of rat AGAP1, 2 and 3, and human AGAP4. Yellow box, consensus sequence
corresponding to the AGAP1 domain of interaction with M5i3. Residues are
colored by shared amino acid characteristics. Bottom, Y2H X-Gal lift assay
results. Dark blue, strong lacZ activation; white, negative result.
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3.3A). The Y2H lift assay identified two series of mutations, Y378A K379A
F380A and L382A V383A, that completely eliminated AGAP1 interaction as
measured by β-Gal activity (figure 3.3A). Notably, the mutated YKF and LV
sequences resembled YXXΦ and LL motifs, respectively, which are known to
target membrane proteins for endosomal and lysosomal compartments via
interaction with adaptor protein complexes (Canfield et al., 1991; Vowels and
Payne, 1998; Bonifacino and Traub, 2003).

3.3.3 M5i3 interaction with AGAP family proteins is limited to AGAP1
The AGAP subfamily contains four characterized proteins: AGAP1,
AGAP2 (Centaurin γ1) AGAP3 (Centaurin γ3) and AGAP4 (MRIP2 / Centaurin γlike family 1). AGAP4 is present only in humans, and is included in the Centaurin
γ-like family of 7 genes and pseudogenes present as a result of a likely gene
duplication event on chromosome 10q (Kahn et al., 2008). We cloned regions of
AGAP family members homologous to the C-terminal split PH domain-containing
AGAP1 region of interaction (AGAP1 (552-609) from rat brain cDNA library
(AGAP2 and AGAP3) and human brain cDNA library (AGAP4), and tested them
for interaction with the rat M5i3 bait in the Y2H lift assay (figure 3.3B). Only
AGAP1 displayed X-Gal staining, indicating that the putative interaction between
M5 and AGAP1 is AGAP subtype-specific (figure 3.3B).
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3.3.4 AGAP1 interacts with M5i3 in vitro
In order to confirm the Y2H assay M5i3 / AGAP1 interaction results in a
complementary system, we performed in vitro binding studies using recombinant
MRi3 proteins as affinity matrices. MRi3 regions for the five rat MRs were
expressed in E. coli as N-terminal fusions of the Glutathione-S-transferase
protein (GST). Recombinant GST proteins were purified and immobilized by
affinity chromatography with a glutathione-conjugated resin. The GST-MRi3 (or
native GST) affinity matrices were then used in “pull-down” assays to examine
interaction with AGAP1 proteins, with detection by autoradiography or
immunoblot. We first used an in vitro transcription-translation kit to produce
[35S]Met-labeled protein from the JI17 clone DNA template (AGAP1 520-861).
This AGAP1 fragment was seen to interact most strongly with the GST-M5i3
protein, though binding to GST-M3i3 and GST-M4i3 was also observed. No
binding to native GST was apparent (figure 3.4A). Next, we exogenously
expressed full-length AGAP1 with a C-terminal myc tag in COS-7 cells.
Pull-downs of AGAP1-myc- containing lysates and analysis by anti-myc
immunoblot again showed AGAP1 to interact with GST-M5i3 but not native GST,
with weaker interactions between AGAP1 and GST-M1i3, GST-M3i3 and GSTM4i3 observed (figure 3.4A).
We next performed pull-down experiments to confirm the Y2H domain-ofinteraction mapping data described above. We purified GST fusion proteins
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Figure 3.4 AGAP1 interacts with M5 in vitro. (A) through (D) Cell or tissue
lysates were incubated with indicated GST-fusion proteins immobilized on
glutathione resin, and bound proteins were detected by immunoblot or
autoradiography. Where indicated, GST proteins were detected by coomassie
blue or ponceau red stains. Molecular weights are listed in kilodaltons (kD).
(A) Top, autoradiograph of in vitro synthesized [35S]methionine-labeled rat
AGAP1(520-861) protein. Middle, immunoblot detecting myc-tagged AGAP1
expressed in COS-7 cells. (B) and (C) Lysates from COS-7 cells expressing
myc-tagged rat AGAP1 proteins were incubated with indicated M5i3-GST
truncation or point mutant proteins. (D) Indicated GST proteins were incubated
with rat brain lysate (top 7 panels) or human neuroblastoma SK-N-MC cell lysate
(bottom panel).
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containing M5i3 fragments with (M5 (354-393), M5 (354-413)) and without (M5
(354-413) ∆369-386) the critical domain of interaction with AGAP1 as determined
above by Y2H assay. These immobilized proteins were then used in pull-down
assays with lysates from COS-7 cells overexpressing full-length or truncated
(546-861) AGAP1 tagged with the myc epitope. Immunoblot revealed that both
M5 (354-393) and M5 (354-413) proteins were able to pull down full-length
AGAP-myc, whereas the domain of interaction deletion mutant and native GST
were not (figure 3.4B). This pattern of interaction was also observed for the
AGAP1 (546-861)-myc protein, a truncation mutant missing the GLD and Nterminal half of the split PH domain, but retaining the critical domain of M5i3
interaction identified in Y2H experiments (figure 3.4B). Interestingly, exogenous
expression of the AGAP1 (546-861) protein yielded a second mycimmunoreactive band, likely corresponding to a predicted 21-kD truncation
protein formed by translation from a strong internal translation initiation site
(AGAP1 (675-861)). This lower band exhibited no binding to the GST-M5i3
proteins, consistent with the absence of the M5 domain-of-interaction in this
hypothesized protein (figure 3.4B).
Finally, GST-M5i3 fusion proteins containing the alanine point mutations
identified in Y2H experiments as sufficient to disrupt AGAP1 binding were tested
for interaction with AGAP1-myc and AGAP1 (546-861)-myc in the pull-down
assay. While the Y378A K379A F380A mutation was observed to eliminate
binding of AGAP1 proteins, the L382A V383A mutation reduced, but did not
completely eliminate, AGAP1 interaction with M5i3 (figure 3.4C). Taken together,
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the Y2H and in vitro binding data therefore strongly supported the M5i3 YKF
sequence as critical for binding of AGAP1.

3.3.5 Endogenous AGAP1 and AP-3 interact with M5i3 in vitro
Using the GST, GST-M5 (354-413) and GST-M5 (354-413 ∆369-386)
recombinant affinity matrices described above, we next attempted to detect
interaction of M5i3 with endogenous proteins in rat brain lysate by pull-down and
immunoblot analysis. Consistent with our previous data, we observed interaction
of GST-M5 (354-413), but not GST-M5 (354-413 ∆369-386) or native GST, with
AGAP1 (figure 3.4D). Interestingly, the AGAP1 antibody used in this study
detected by immunoblot a multiplet band running at the predicted AGAP1 protein
size (94.5 kD), the significance of which is unknown (figure 3.4D).
AGAP1 has been shown to specifically bind to, and to influence the
activity of, the AP-3 adaptor protein complex (Nie et al., 2003; Nie et al., 2005).
Heterotetrameric adaptor complexes mediate trafficking of membrane-bound
cargo proteins by binding to both target and vesicle coat proteins, as well as
phospholipids and accessory proteins such as the Arf small GTPases (Nakatsu
and Ohno, 2003; Lefrancois et al., 2004). The AP-3 adaptor complex, consisting
of the adaptin subunits δ, β3, µ3, and σ3, is present in mammals as ubiquitous
(AP-3a) and neuron-specific (AP-3b) isoforms (Dell'Angelica et al., 1997; NewellLitwa et al., 2007). Whereas the ubiquitous AP-3 complex is important for
trafficking of proteins to late endosomes, lysosomes, and lysosomal-like
compartments such as melanosomes and platelet dense granules, the neuron-
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specific form of AP-3 is required for the biogenesis of, and trafficking of certain
membrane proteins to, endosomally-derived synaptic vesicles (Ooi et al., 1997;
Bonifacino and Dell'Angelica, 1999; Blumstein et al., 2001; Salazar et al., 2004b).
Using antibodies directed at subunits of AP-3a and AP-3b, we tested the
hypothesis that an AGAP1/AP-3 complex could interact with the M5i3 loop.
Subunits of both the ubiquitous (µ3A) and neuron-specific (β3B / β-NAP) AP-3
adaptor complexes were detected in pull-downs using GST-M5 (354-413), but
not GST-M5 (354-413 ∆369-386) or native GST (figure 3.4D). However, M5i3
interaction with the AP-3 large subunit δ-adaptin was not observed (figure 3.4D).
The association of the AP-3 adaptor complex with M5i3 appeared to be specific,
as AP-1 and AP-2 complex subunits did not bind to GST-M5 (354-413) (figure
3.4D).
The AP-3 adaptor complex interacts physically and functionally with the
heteromeric complex BLOC-1 (biogenesis of lysosome-related organelles
complex 1) (Salazar et al., 2006; Salazar et al., 2009). Mutations in human
genes encoding members of either the AP-3 complex or BLOC-1 are responsible
for Hermansky-Pudlak syndrome, a genetically heterogeneous set of related
autosomal recessive disorders characterized by albinism, platelet storage pool
deficits, and prolonged bleeding (Wei, 2006). A mutation in one of these genes,
DTNBP1, is responsible for Hermansky-Pudlak syndrome type 7 (Li et al., 2003).
The DTNBP1 gene product dysbindin (dystrobrevin binding protein 1) is an
essential member of BLOC-1, and was shown to bind directly to AP-3 via the
µ3A subunit (Li et al., 2003; Taneichi-Kuroda et al., 2009). In order to determine
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whether dysbindin was part of the AGAP1/AP-3 complex that we observed to
interact with M5i3 in vitro, we tested lysate prepared from cultured SK-N-MC
neuroblastoma cells in the GST-M5i3 pull-down assay (use of human tissue was
necessitated by the lack of rat- or mouse- immunoreactivity of our commerciallysourced dysbindin antibody). Immunoblotting for human dysbindin revealed
modest but specific binding to GST-M5 (354-413) (figure 3.4D). Taken together,
our in vitro binding data confirm the the Y2H results indicating a subtype-specific
and domain-delineated interaction between M5 and AGAP1, and suggest that
AGAP1 binding may be mediating the interaction of a larger AP-3 / BLOC-1 containing complex with the M5i3 loop.

3.3.6 Intact AP-3 or phospholipid binding activity of AGAP1 is not required for its
interaction with M5i3
We investigated whether AP-3 could play a role in mediating the binding of
AGAP1 to M5. Although false-positive interaction in the Y2H assay as a result of
an endogenous multi-protein complex is unlikely, our in vitro pull-down
experiments could not exclude the possibility that the observed interaction of
AGAP1 to M5 was indirect, perhaps as a result of AP-3 binding to the YXXΦ or
dileucine-like motifs in the M5i3 domain of interaction. As an indirect measure of
this, we performed co-immunoprecipitations of full-length and truncated forms of
myc-tagged AGAP1 expressed in HEK-293T cells. Full-length AGAP1 was seen
to co-immunoprecipitate the AP-3 subunit µ3A, as previously reported (figure
3.5A) (Nie et al., 2003). However, the AGAP1(546-861) mutant, in which the
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Figure 3.5 AGAP1 interacts with AP-3 and phospholipids. (A) Myc-tagged
rat AGAP1 proteins were expressed in NIH-3T3 cells, immunoprecipitated with
anti-myc antibodies, and immunoprecipitates were analyzed by immunoblot.
(B) Top, Phospholipid dot-blot arrays were incubated with [35S]methioninelabeled AGAP1 proteins as indicated, and bound proteins were visualized by
autoradiography. Bottom, [35S]methionine-labeled AGAP1 proteins used above
were analyzed by SDS-PAGE and autoradiography.
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GLD and N-terminal half of the split PH domain are deleted, was unable to coimmunoprecipitate AP-3 µ3A (figure 3.5A). As both full-length and truncated
forms of AGAP1 were able to bind to M5i3 in the pull-down and Y2H assays, the
co-immunoprecipitation data indicated that AP-3 binding was not required for the
interaction of AGAP1 with M5.
AGAP1 exhibits phosphoinositide-dependent Arf GAP activity, and
contains a PH domain, a functional motif known to exhibit phospholipid binding
activity (Nie et al., 2002; Lemmon, 2004). To investigate the role of
phospholipids in the interaction of AGAP1 with M5, we performed a lipid array
overlay assay using [35S]Met-labeled full-length AGAP1 and the
AGAP1(546-861) N-terminal deletion mutant prepared by in vitro coupled
transcription-translation. Full-length AGAP1 showed binding to a variety of
phospholipids, phosphatidic acid, and phosphatidylserine, with strongest
apparent binding to phosphatidylinositol-4-phosphate and phosphatidylinositol(3,5)-bisphosphate (figure 3.5B). However, AGAP1(546-861), in which the split
PH domain is disrupted but the domain of M5i3 interaction is maintained,
displayed no phospholipid binding (figure 3.5B). Thus, we determined that
AGAP1 does indeed bind phospholipids via its split PH domain, but that this
activity is dispensable for binding to M5.

3.3.7 Studies of M5 / AGAP1 interaction by co-immunoprecipitation
In an effort to demonstrate interaction of M5 receptors with AGAP1 under
physiological conditions, we attempted to co-immunoprecipitate M5 and AGAP1
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Figure 3.6
Co-immunoprecipitation studies of AGAP1-M5 interaction.
COS-7 cells co-expressing rat AGAP1(546-861) and wild-type, point-, or domainof-interaction- mutant rat M5-GFP receptors were left untreated (A) or were
treated as indicated with carbachol (CCh; 1mM) for 30 minutes. Lysates were
incubated with anti-GFP antibodies, and immunoprecipitates were analyzed by
immunoblot for GFP and myc tags. M5-GFP receptors present in COS-7 cell
lysates were detected predominantly as dimers (A) or monomers (B).
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proteins from intact cells. As no specific antibodies appropriate for
immunoprecipitation from native tissue sources exist for M5, we performed the
experiments using M5 receptors fused with GFP on their C-termini expressed in
exogenous cell systems. A number of different detergent conditions for M5
solubilization were employed, including a digitonin-cholate system described
previously as yielding monomeric, non-denatured receptors (Haga and Haga,
1985; Peterson et al., 1995). Although small amounts of AGAP1(546-861)-myc
were seen to co-immunoprecipitate with M5-GFP expressed in tissue culture
cells using anti-GFP antibodies, the specificity of this association did not reflect
our in vitro binding data: neither the Y378A K379A F380A nor ∆369-386 M5
mutations were able to interfere with apparent AGAP1(546-861)-myc binding
(figure 3.6). The specific co-immunoprecipitation of AGAP1 with M5-GFP after
agonist (carbachol) stimulation of M5 (figure 3.6B), in the presence of a protein
cross-linking reagent, or using primary cultured rat neurons as the exogenous
expression system was not observed (data not shown). We therefore were
unable to corroborate our Y2H and in vitro binding data with demonstration of
specific M5/AGAP1 co-immunoprecipitation.

3.3.8 Domain mapping and in vitro binding: SNX20 and M2i3
Using a strategy similar to that described for the study of AGAP1/M5
interaction, we investigated the characteristics and specificity of the putative
interaction of the M2 i3 loop with SNX20. Y2H domain-of-interaction mapping
confirmed the positive interaction with the pACT2 prey clone isolated in the Y2H
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Figure 3.7 SNX20 domain-of-interaction mapping and in vitro binding.
(A) Cartoon summarizing X-Gal lift assay results from Y2H interaction assays.
Top, SNX20 sequence indicating position of the PX domain. Below, rat SNX20
truncation mutants were assayed for M2i3 interaction as indicated. Dark blue,
strong lacZ activation; white, negative result. (B) [35S]methionine labeled SNX20
synthesized in vitro (top; input = 10% of total) or lysate of COS-7 cells expressing
myc-tagged SNX20 (middle; input = 1% of total) were incubated with GST-fusion
proteins immobilized on glutathione resin, and bound proteins were detected by
autoradiography or immunoblot, respectively. Total GST proteins were detected
by coomassie blue staining (lower panel). (C) Rat M2-GFP or M4-GFP receptors
were co-expressed in COS-7 cells with myc-tagged SNX20, cells were treated as
indicated, and MR-GFP proteins immunoprecipitated after cross-linking.
Immunoprecipitates were analyzed by immunoblot with GFP and myc tag
antibodies as indicated.
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screen (JK1, encoding SNX20 residues 92-313) (figure 3.7A). We observed no
reporter gene activation by JK1 when co-expressed with the LexA-M1i3 bait in
L40 yeast (data not shown). Despite extensive coverage of the SNX20 protein
by truncation mapping, we were able to identify only a single mutant,
SNX20(97-313), that exhibited lacZ activation with the pLexA-M2i3 bait in the
Y2H lift assay (figure 3.7A). Additionally, truncation mutants containing both the
SNX20(97-313) domain and an intact PX domain showed no interaction with
M2i3 in this assay (figure 3.7A). We therefore surmised that either SNX20
interaction with M2i3 was dependent on a large protein domain and that the
presence of an active PX domain was able to interfere with the readout of this
interaction in yeast, or that the observed SNX20-M2i3 interaction was a result of
an artifactual sequence present at the fusion junction between the DNA-BD and
M2i3 proteins.
We next attempted to detect binding of full-length SNX20 to GST-M2i3 in
vitro. Using either [35S]Met-labeled SNX20 prepared by in vitro coupled
transcription-translation or lysate from tissue culture cells overexpressing
epitope-tagged SNX20-myc, we performed GST pull-down assays with the five
GST-MRi3 proteins or native GST as affinity matrices. Neither [35S]Met-SNX20
or SNX20-myc displayed specific binding to M2i3 (figure 3.7B). We also
attempted to co-immunoprecipitate M2-GFP receptors with SNX20-myc
expressed in tissue culture cells, with and without carbachol treatment and using
the cell-permeable protein crosslinker DSP prior to solubilization. Using GFP
antibodies for immunoprecipitation, no specific co-immunoprecipitation of
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SNX20-myc was observed (figure 3.7B). Taken together, our data do not provide
strong biochemical support for the existence of a physiological interaction
between SNX20 and M2.

3.3.9 Domain mapping and in vitro binding: UHRF1BP1L and M4i3
The M4i3 Y2H screen yielded β-Gal positive prey clones encoding
UHRF1BP1L with two distinct AD-fusion N-terminal junctions: clones JA54
(UHRF1BP1L(2034-1469)) and JA71 (UHRF1BP1L(1123-1469)) (figure 3.8A).
These clones were observed to activate lacZ reporter activity with the M4i3 bait,
but not the remaining four MRi3 baits, in the Y2H lift assay (data not shown).
However, UHRF1BP1L fragments with N-terminal truncations between (residue
1116) or past (residue 1188) the junctions present in the JA54 and JA71 clones
failed to display interaction with M4i3 (figure 3.8A).
We performed a GST-MRi3 pull-down experiment using COS-7 cell lysate,
in which endogenous UHRF1BP1L (KIAA0701) protein was detectable by
immunoblot using a commercial antibody. Although weak interaction of
UHRF1BP1L with GST-M4i3 was observed, stronger pull-down with the GSTM3i3 and GST-M5i3 affinity matrices was apparent, in contrast to the M4i3
interaction specificity observed in the Y2H system (figure 3.8B). We also
attempted to detect interaction of endogenous UHRF1BP1L in COS-7 cells with
exogenously expressed M4-GFP by DSP cross-linking and immunoprecipitation
with GFP antibodies. We observed no co-immunoprecipitation of UHRF1BP1L
protein with M4-GFP, either with or without carbachol treatment prior to receptor
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Figure 3.8 UHRF1BP1L domain-of-interaction mapping and in vitro binding.
(A) Cartoon summarizing X-Gal lift assay results from Y2H interaction assays.
Rat UHRF1BP1L-encoding clones derived from the M2i3 Y2H screen, or
UHRF1BP1L truncation mutants were assayed for M2i3 interaction as indicated.
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COS-7 cells with myc-tagged UHRF1BP1L, cells were treated as indicated, and
MR-GFP proteins immunoprecipitated after cross-linking. Immunoprecipitates
were analyzed by immunoblot with GFP and myc tag antibodies as indicated.
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solubilization (figure 3.8C). Thus, the in vitro binding studies combined with our
Y2H data do not strongly support the existence of a specific, domain-delineated
interaction between M2i3 and URHF1BP1L.

3.4 Discussion
In this chapter, we provide biochemical evidence for the physical
interaction of muscarinic receptor M5 with AGAP1. The observed interaction was
unique to the M5 muscarinic receptor subtype, and was mediated by a conserved
23-residue region on the M5 i3 cytoplasmic loop sharing no sequence homology
with muscarinic receptors 1 through 4. Similarly, three closely-related AGAP
proteins did not exhibit M5i3 interaction, and the AGAP1 domain mediating this
binding is highly conserved in sequence across species. We are the first to
report direct binding between an AGAP protein and a GPCR, although a related
AZAP family protein ACAP1 has been shown to interact with a number of nonGPCR transmembrane receptors (Dai et al., 2004; Li et al., 2005). We also
observed that, at least in vitro, the M5i3 domain critical for interaction with
AGAP1 was able to bind subunits of the ubiquitous and neuron-specific isoforms
of the AP-3 adaptor complex. As the interaction between AGAP1 and M5 was
apparently direct, and since AGAP1 is known to bind directly to AP-3 (Nie et al.,
2003), we surmised that AGAP1 was mediating binding of AP-3 to M5i3. This
suggested the possibility that in vivo, the identified interaction domain of M5i3
mediates binding of an AGAP1/AP-3 trafficking complex to the receptor, perhaps
implicating the identified protein-protein interaction in the regulated trafficking of
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M5. Indeed, we also detected binding of dysbindin protein to the M5i3 AGAP1interaction domain; dysbindin is a sub-member of BLOC-1, a complex known to
interact physically and functionally with AP-3 (Li et al., 2003; Taneichi-Kuroda et
al., 2009). It should be cautioned, however, that our in vitro data does not
distinguish between binding of a native, pre-formed AGAP1/AP-3/BLOC-1 supercomplex to M5i3 and recruitment of AP-3 / BLOC-1 components to M5i3-bound
AGAP1; in addition, we did not observe M5i3 binding of the large AP-3 subunit δadaptin in our assays.
Site-directed mutagenesis implicated a YKF motif in M5i3 as critical for
AGAP1 binding to M5i3. Phenylalanine- and tyrosine- residue clusters on the
transferrin receptor cytoplasmic tail were similarly shown to be critical for ACAP1
binding and/or endocytic recycling of the receptor (McGraw et al., 1991; Dai et
al., 2004). The YKF sequence resembles, but does not fulfill the functional
identity of, the commonly occurring and well-characterized YxxΦ sorting signal,
which targets host proteins for endocytosis and localization to lysosomes or
lysosome-like compartments via interaction with adaptor protein complex µ
subunits (Rapoport et al., 1997; Ohno et al., 1998; Bonifacino and Traub, 2003).
We also identified by site-directed mutagenesis a leucine-valine residue pair
whose mutation interfered with AGAP1 binding. Although lacking the upstream
acidic residues, this motif resembles the [DE]XXXL[LI] and DXXLL dileucine-type
sorting signals known to mediate receptor internalization, lysosomal targeting
and TGN-to-endosome transport by binding to adaptor protein complex subunits
(Johnson and Kornfeld, 1992; Letourneur and Klausner, 1992; Bonifacino and
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Traub, 2003; Janvier et al., 2003). Notably, dileucine and dileucine-like (LI, LV)
motifs lacking upstream acidic residues have been shown to function as AP-1and AP-3-binding lysosomal targeting motifs in yeast and mammals (Rapoport et
al., 1998; Vowels and Payne, 1998; Kyttala et al., 2005). Although our Y2H and
in vitro binding data demonstrate direct binding of AGAP1 to M5i3, and though
AP-3 subunits bind AGAP1, our data cannot discount the possibility of a direct
AP-3 / M5i3 interaction, perhaps mediated by the leucine-valine motif.
Co-immunoprecipitation of endogenous proteins from native tissue
sources is typically considered the “gold-standard” for proof of molecular
interaction in vivo (Hall, 2005). Such an experiment is not possible in the case of
M5, as no antibodies currently exist that are appropriate for either
immunoprecipitation or immunoblotting, and the receptor is expressed at very low
levels in the brain and periphery (Wess et al., 2003). We investigated a number
of N-terminal, C-terminal, and internal epitope tags on the M5 receptor for their
suitability in immunoprecipitation and immunoblotting experiments in exogenous
expression systems; a C-terminal GFP tag was identified as most appropriate.
However, we were unable to identify conditions under which the wild-type M5GFP receptor, but not the Y378A K379A F380A, L382A V383A or ∆369-386 M5GFP receptors, was able to co-immunoprecipitate either truncated or full-length
forms of AGAP1. Detergent solubilization of M5 receptors was a continuing
technical difficulty; the degree to which the non-denaturing digitonin-cholate
system purified monomeric or oligomeric forms of M5 protein was reagent batchdependent (see figure 3.6), and more stringent solubilization conditions were
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avoided in fear of disrupting the putative AGAP1-M5 complex. Attempts to
stabilize the putative low-affinity AGAP1-M5 complex by chemical cross-linking
also failed, in part due to insolubility of AGAP1 proteins after DSP treatment and
poor reduction of the disulfide crosslink bond under conditions necessary to
avoid M5 aggregation during SDS-PAGE. However, due to the agreement
between in vitro binding and Y2H interaction data and the existence of clearlydelineated interaction domains, we took our results to indicate the existence of a
low-affinity interaction between M5 and AGAP1. Weak protein-protein
interactions are typical of the transient binding of trafficking or signaling
complexes with their cellular targets (Vaynberg and Qin, 2006). Indeed,
physiologically relevant trafficking complex binding to receptor targeting motifs
has been revealed by a combined Y2H / GST pull-down strategy (Voglmaier et
al., 2006) and binding of targeting motif-containing peptides to adaptor complex
proteins was shown to require cryopreservation and/or photo-crosslinking for
detection (Rapoport et al., 1997; Rapoport et al., 1998).
Our data do not provide strong support for the existence of the putative
SNX20-M2i3 and UHRF1BP1L-M4i3 interactions detected in the Y2H screens.
DOI mapping and in vitro binding results cannot rule out the possibility that the
detected interactions were false-positive artifacts of the Y2H system, bait or prey
fusion proteins, or some combination thereof. In the case of SNX20, it is curious
that the presence of a functional PX domain abrogates lacZ reporter activity in
the Y2H lift assay. The possibility exists that phospholipid binding activity of the
AD-SNX20 prey fusion prevents nuclear localization, M2i3 interaction, or AD
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activity in yeast. Nonetheless, based on the strength of the interaction data, our
experimental focus from this point forward was on the functional consequences
of the AGAP1 / M5 protein-protein interaction. As co-immunoprecipitation data
were lacking, we chose to employ the domain-of-interaction deletion mutant
(∆369-386) to study AGAP1 interaction-dependent M5 function, since this mutant
was most likely to maintain the AGAP1 binding loss-of-function observed in yeast
and in vitro.
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4 AGAP1 & M5: DISTRIBUTION

4.1 Summary
We demonstrate in this chapter co-localization of M5 receptors with
AGAP1 in endosomal-like compartments of cultured neurons. Exogenous coexpression of AGAP1-myc and M5-GFP in rat primary hippocampal neurons
revealed a population of partially overlapping AGAP1- and M5- positive puncta
after agonist induced internalization of M5. Live imaging in cultured neurons
indicated a dynamic relationship between mobile, M5-GFP- and AGAP1- or
AP-3B-positive vesicles. Co-immunostaining in cultured neurons confirmed
transit of agonist-internalized M5 through AP-3-positive endosomes and the
recycling and/or degradative trafficking pathways. Results obtained from
membrane fractionation of rat brain tissue are consistent with the association of
AGAP1 with AP-3 endosomes. As AGAP1 is likely a ubiquitously expressed
protein, our results support the cellular and sub-cellular co-localization of AGAP1
and M5, further arguing for their physical interaction in vivo. Our data also
suggest a functional role for AGAP1 in the activity-induced trafficking of M5 in
neurons.

4.2 Introduction
The M5 muscarinic receptor is by far the lowest expressed and most
poorly characterized MR in mammals. Though the lack of subtype-selective
ligands and antibodies appropriate for detection of M5 by immunohistochemistry
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or immunoblotting has hampered investigation of the receptor, a number of
studies have demonstrated functionally significant expression of M5. In the
mouse, M5 mRNA was detected almost exclusively in the brain, with particular
enrichment in the hypothalamus, hippocampus, and striatum, although small
amounts of M5 transcript were detected both in mouse skin and in a human
melanoma cell line (Kohn et al., 1996; Regard et al., 2008). Radioligand
detection of MR sites immunoprecipitated from rat brain using subtype-selective
antibodies suggested that M5 receptors contribute to less than 2% of the total
MR population, a result confirmed more recently in the M5 knockout mouse
(Yasuda et al., 1993; Oki et al., 2005). In situ hybridization studies in mouse and
rat brain confirm a low overall level of M5 transcription; interestingly, however, M5
mRNA, but not M1-4 mRNA, was detected in the midbrain dopaminergic neurons
of the SNc and VTA (figure 4.1) (Weiner et al., 1990; Lein et al., 2007).
Phenotypic (loss-of-function) analysis of the M5 knockout mouse has indicated
functional expression of M5 in two main areas: first, in both pre- and postsynaptic terminals of midbrain dopaminergic neurons innervating the dorsal and
ventral striatum (Yeomans et al., 2001; Forster et al., 2002; Zhang et al., 2002b),
and second, in cerebral arteries and arterioles (Yamada et al., 2001a). The
subcellular distribution of M5 has not been directly investigated. However, MR
1-4 have been shown to localize to the plasma membrane of tissue culture cells,
and undergo the stereotypical GPCR trafficking cycle of agonist-induced
internalization, followed by either endocytic recycling or targeting for lysosomal
degradation, depending on subtype (Tolbert and Lameh, 1996; Volpicelli et al.,
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AP3 !3A

AP3 !3B

Figure 4.1 Allen Mouse Brain Atlas in situ hybridization data. Sagittal
C57BL/6J mouse brain sections labeled with digoxigenin-conjugated riboprobes
for indicated genes were obtained from the on-line Allen Mouse Brain Atlas
(Seattle (WA): Allen Institute for Brain Science. ©2009. Available from: http://
mouse.brain-map.org). Arrow indicates substantia nigra pars compacta region
labeled with ChrM5 riboprobe.
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2001; Delaney et al., 2002; Popova and Rasenick, 2004).
AGAP1 is an AP-3-associated Arf GAP protein expressed widely in
mammalian tissues. Expression of AGAP1 mRNA was detected at equal levels
in a variety of human organs, including brain, by RT-PCR (Nie et al., 2005).
Northern blot analyses of AGAP1 mRNA isolated from human and mouse tissues
have described the presence of large (9 kb), medium (4.5 kb) and small (2.4 kb)
transcripts expressed at various levels in a number of tissues; as Genbank
indicates a message length of 9.5 kb and 4.5 kb for mouse and human AGAP1
mRNAs, these results likely indicate the presence of splice forms, the
significance of which is unclear (Xia et al., 2003; Meurer et al., 2004). AGAP1
protein was also detected in lysates from human cell lines derived from
lymphocyte, epithelial, gastric, liver, and glial sources (Nie et al., 2005). In the
mouse brain, AGAP1 mRNA is highly expressed in the fore- and mid-brain during
development (Xia et al., 2003), and exhibits a ubiquitous and uniform pattern of
expression in adults (figure 4.1) (Lein et al., 2007). Epitope-tagged AGAP1
expressed exogenously in tissue culture cells was shown to exhibit either a
uniform or punctate distribution pattern, apparently depending on host cell type
and overexpression levels (Nie et al., 2002; Xia et al., 2003). These AGAP1
puncta were shown by biochemical and immunocytological methods to
correspond to a population of AP-3-positive endosomes (Nie et al., 2003).
The heterotetrameric adaptor protein complex AP-3 exists as ubiquitous
and neuron-specific isoforms. The ubiquitous AP-3A, composed of the large
adaptin subunits δ and β3A, the medium subunit µ3A, and the small subunit σ3A/
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B, is expressed in all mammalian cells and tissues, including the brain (figure
4.1) (Dell'Angelica et al., 1997; Lein et al., 2007). The neuron-specific AP-3B
isoform shares the δ and σ3A/B subunits with the ubiquitous form, and includes
the neuron-specific subunit proteins β3B / β-NAP and µ3B (Newman et al., 1995;
Seong et al., 2005). β3B is likely expressed in all CNS and peripheral neurons
(figure 4.1) (Newman et al., 1995; Lein et al., 2007). AP-3 is distributed
subcellularly in both cytosolic and membrane-bound pools, the latter consisting of
clathrin- and non-clathrin- coated vesicles seen to associate by biochemical and
immunofluorescence techniques with TGN- and endosome-like structures
(Dell'Angelica et al., 1997; Simpson et al., 1997; Dell'Angelica et al., 1998). An
immuno-electron microscopy study of δ-adaptin in tissue culture cells found AP-3
localized to early endosome-associate membrane tubules co-localized with the
lysosome-target protein LAMP1, but found no evidence for AP-3 localization in
the TGN (Peden et al., 2004). In neurons, distribution of the ubiquitous AP-3A
isoform is apparently restricted to neuronal soma, whereas the neuron-specific
AP-3B is distributed in axons and dendrites, and is associated with nerve
terminal vesicles (Newman et al., 1995; Seong et al., 2005).
Using biochemical methods, we identified AGAP1 as an M5-interacting
protein, potentially present as a part of an AGAP1/AP-3 complex. In this chapter,
we describe experiments examining the cellular and subcellular distribution of
M5, AGAP1, and AP-3. As antibodies appropriate for immunocytological labeling
of AGAP1 and M5 are not available, we used epitope tags for the
immunofluorescent localization of M5 and AGAP1 expressed exogenously, under
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both basal and agonist-stimulation conditions expected to induce internalization
and endocytic traffic of the M5 receptor. Using a similar strategy, we also studied
the distribution of M2 and SNX20. We used both tissue culture cells and rat
primary hippocampal neurons for exogenous expression, the latter due to the
possible involvement of the functionally divergent, neuron-specific AP-3B
complex in the interaction of AGAP1 with M5. In primary neurons, we took
advantage of the recently developed monomeric red fluorescent protein
derivative mCherry (Shaner et al., 2004), along with M5-GFP, to perform twocolor live imaging of M5, AGAP1, or AP-3. Finally, we investigated the
distribution of M5, AP-3 and AGAP1 in comparison to membrane-associated
endosomal markers in an effort to further characterize the distribution of these
proteins. The main goal of this chapterʼs experiments was to confirm the
temporal and spatial co-localization of M5 and AGAP1, and possibly AP-3, that is
required for the existence in vivo of the proteinsʻ physical interaction. A
secondary goal was to gain knowledge as to the functional implications of
AGAP1 interaction with M5, with particular attention paid to trafficking pathways.

4.3 Results
4.3.1 AGAP1 mRNA exhibits widespread expression in mouse tissues and brain
subregions
We first analyzed mouse AGAP1 mRNA distribution by Northern blot to
confirm the widespread pattern of AGAP1 expression described previously in
human and mouse tissues (Xia et al., 2003; Meurer et al., 2004; Nie et al., 2005).
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Using a [33P]-labeled antisense riboprobe targeting the 3ʼ-UTR of mouse
AGAP1, we detected hybridization signals in most of the tissues represented
(figure 4.2A). An AGAP1 transcript of approximately 9.5 kilobases (kb) was
expressed predominantly in brain, while a 4.4 kb message was most prevalent in
kidney, and a smaller, approximately 3.5 kb transcript was detected only in testis
(figure 4.2A). Additionally, immunoblot detection of AGAP1 protein revealed
AGAP1 expression in all tested tissue sources, including tissue culture cells
derived from a variety of species (human, rat, mouse, chinese hamster, african
green monkey) and pre- and post-natal rat and mouse brain tissues (data not
shown), in agreement with previous reports examining AGAP1 expression in
human cell lines (Nie et al., 2005).
Next, we performed in situ hybridizations of adult mouse brain tissues
using the same [33P]-labeled AGAP1 3ʼ-UTR antisense riboprobe described
above. AGAP1 mRNA was detected widely, with an autoradiography signal
consistent with brain subregion cell body density (figure 4.2B). A control sensestrand riboprobe prepared from the AGAP1 3ʼ-UTR template produced no signal
(data not shown). The uniform expression of AGAP1 mRNA in the rodent brain is
consistent with previously published mouse brain gene expression atlas data
(figure 4.1) (Lein et al., 2007). Thus, the expression of AGAP1 mRNA and
protein products was confirmed to be widespread in mammals both across
tissues and within the brain.
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Figure 4.2 AGAP1 mRNA expression. (A) Mouse Multiple Tissue Northern blot
hybridized with [33P]-labeled AGAP1 antisense riboprobe. Transcript size is
indicated in kilobases. (B) Autoradiograph of C57BL/6 mouse brain coronal (top)
and sagittal (bottom) sections labeled by in situ hybridization using the [33P]
AGAP1 riboprobe from (A).
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4.3.2 Exogenously expressed M5-GFP and AGAP1-myc do not extensively colocalize in tissue culture cells
In the next series of experiments, we aimed to investigate by confocal
microscopy the degree to which M5 receptors and AGAP1 co-localize when
overexpressed in mammalian tissue culture cells. Since detection of
endogenous M5 and AGAP1 proteins in cultured cells was not possible due to
the lack of antibodies suitable for immunocytochemistry, we performed
immunofluorescence experiments using exogenously expressed epitope-tagged
M5 and AGAP1 proteins. An M5 receptor tagged at the cytosolic C-terminus with
GFP was seen to localize predominantly at the plasma membrane when
expressed in a variety of mammalian tissue culture lines (CHO, COS-7,
HEK293T) after fixation and detection with anti-GFP antibodies (figure 4.3A). In
addition, treatment of M5-GFP -transfected cells with the muscarinic agonist
carbachol (CCh) led to a predominantly intracellular, punctate GFP
immunofluorescence pattern, consistent with agonist-induced internalization of
surface M5 receptors into endocytic vesicles, as has been described in similar
systems for muscarinic receptor subtypes 1-4 (Tolbert and Lameh, 1996;
Volpicelli et al., 2001; Delaney et al., 2002; Popova and Rasenick, 2004).
In previous studies, exogenously expressed AGAP1 protein exhibited
either a uniform/cytosolic or punctate distribution, apparently depending on the
degree to which the protein was overexpressed (Nie et al., 2002; Nie et al., 2003;
Xia et al., 2003). In experiments examining the immunocytological distribution of
overexpressed rat AGAP1-myc, we observed a mainly uniform expression

102

A

M5-GFP

M5-GFP +CCh

B

AGAP1-myc

AGAP1-myc (extracted)

C

M5-GFP

AGAP1-myc

merge

Figure 4.3 Immunofluorescence staining of AGAP1 and M5 in
tissue culture cells. (A) CHO cells were transiently transfected with
M5-GFP construct, treated with (right) or without (left) 100µM carbachol
for 30 minutes, fixed, immunostained for GFP and imaged by confocal
microscopy. (B) COS-7 cells were transiently transfected with AGAP1myc construct, extracted with detergent (right) or not (left), fixed, immunostained for myc tag and imaged by confocal microscopy. (C) COS-7
cells were transiently co-transfected with M5-GFP and AGAP1-myc
constructs. Cells were treated with 100µM carbachol for 1 hour,
extracted with detergent, fixed, immunostained for GFP (green) and
myc tag (red) and imaged by confocal microscopy. Scale bars = 50µm.
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pattern consistent with cytosolic localization (figure 4.3B). In some cases, higher
expression levels of AGAP1-myc led to what appeared to be a punctate
localization pattern, as had been previously reported (Nie et al., 2003); however,
AGAP1-enriched puncta were localized to numerous peripheral membrane blebs
of cells displaying unusual gross morphology, indicating that such cells may have
been apoptotic (Coleman et al., 2001). In some cases (including that of the
AZAP protein ACAP1), cytosol extraction prior to fixation and immunostaining
can reveal the otherwise-obscured membrane-bound pool of membraneassociated proteins (Morris and Cooper, 2001; Dai et al., 2004). We observed a
punctate, vesicular-like distribution of AGAP1-myc when overexpressing cells
were subjected to a mild detergent extraction before fixation (figure 4.3B).
We next investigated whether M5 and AGAP1 co-localized under
conditions in which subcellular vesicle-like distribution patterns were evident. We
co-expressed M5-GFP and AGAP1-myc in tissue culture cells, treated with CCh
to induce M5 internalization, and performed cytosol extraction before fixation and
immunostaining. Although both M5-GFP and AGAP1-myc were seen to localize
mainly to subcellular puncta, little overlap was observed between the M5- and
AGAP1- positive compartments in this expression system (figure 4.3C).

4.3.3 AGAP1-myc co-localizes with endocytosed M5-GFP in primary cultured
neurons
Our previous data confirmed the biochemical association of AGAP1 with
the AP-3 adaptor complex (Nie et al., 2003). The neuron-specific isoform of AP-3

104

exhibits distinct functions from that of ubiquitous AP-3, and the complex isoforms
are expressed in neurons in a spatially-segregated manner (Seong et al., 2005;
Newell-Litwa et al., 2007). Immunocytological studies have indicated association
of AGAP1 protein with AP-3-positive endocytic compartments in tissue culture
cells; however, the subcellular localization of AGAP1 in neurons has not been
reported (Nie et al., 2003; Nie et al., 2005). In order to investigate both the
localization and spatial overlap of M5 and AGAP1 in neurons, we transfected
primary rat embryonic hippocampal neurons with AGAP1-myc and M5-GFP, and
analyzed cells by confocal microscopy. M5-GFP was seen to localize to the
soma, dendrites, and axons of transfected neurons (figure 4.4A). Whereas M5GFP was localized mainly to the plasma membrane of neurons, treatment of cells
with CCh led to an endosomal-vesicle-like distribution of M5-GFP (figure 4.4B).
Detergent extraction prior to fixation revealed a punctate, vesicular-like
distribution of AGAP1-myc in neuronal soma and processes that was otherwise
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Figure 4.4 Co-localization of agonist-internalized M5 with AGAP1 and AP-3
in cultured neurons (following page). (A) Neurons were transfected with
AGAP1-myc and M5-GFP plasmids, fixed and immunostained for myc tag (red)
and GFP (green), and imaged by confocal microscopy. Scale bar = 20 μm.
(B and C) Neurons were transfected as in (A) and treated without (ctl) or with
1mM carbachol (CCh) for indicated times. Cells were fixed, immunostained for
GFP (green) and myc (red) and imaged by confocal microscopy. In (C), cytosolic
extraction with 0.03% saponin was performed prior to fixation to visualize the
membrane-bound pool of exogenously expressed AGAP1-myc. Yellow arrows
indicate green / red puncta overlap. Scale is bar in top panel of (B) = 5 μm and
applies to all images in (B) and (C). (D) Neurons were transfected with M5-GFP
and treated without (ctl) or with 1mM CCh for 60 minutes, followed by fixation
and immunostaining for GFP (green) and the AP-3a / AP-3b subunit δ-Adaptin
(red) Yellow arrows indicate green / red puncta overlap. Scale is identical to (B).
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obscured by the predominant cytosolic AGAP1 pool (figure 4.4C). In cells fixed
after 30 or 60 minutes of CCh treatment, we observed overlap of M5-GFP- and
AGAP1- positive puncta in neuronal projections (figure 4.4C). We therefore
concluded that in neurons, agonist-internalized M5 co-localized with AGAP1,
possibly in an endocytic vesicle compartment.

4.3.4 Agonist-internalized M5-GFP appears in AP-3-positive vesicles
In an effort to confirm the identity of vesicular compartments containing
internalized M5 and AGAP1 as AP-3-positive endosomes, we performed CCh
agonist treatments and immunostaining on M5-GFP- and/or AGAP1- transfected
primary rat hippocampal neurons as described above. Staining with a δ-Adaptin
antibody as a marker for AP-3, we observed in neuronal processes some
instances of overlap between agonist-internalized M5-GFP and AP-3 puncta,
suggesting transit of M5-GFP through AP-3-positive endosomal compartments
(figure 4.4D). However, we were unable to confirm the identity of AGAP1containing puncta as AP-3 endosomes, as both AGAP1 overexpression and
cytosol extraction appeared to interfere with the normal pattern of AP-3
distribution, as indicated by δ-adaptin and µ3A immunostaining (data not shown).

4.3.5 Live imaging in cultured neurons reveals association of M5- and AGAP1or β3B- positive vesicles
To further investigate the dynamic relationship between the population of
M5-, AGAP1-, and AP-3- positive endosomes observed in immunofluorescent
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staining of fixed specimens, we performed live imaging studies of GFP- or
mCherry- tagged proteins expressed in primary cultured rat hippocampal
neurons. In apparent axons and dendrites of transfected neurons, nearsimultaneous two-color live imaging revealed mobile populations of M5-GFP- and
AGAP1-mCherry- positive puncta (figure 4.5A). In general, vesicular motility was
observed to be highest in axon-like processes, and AGAP1-mCherry puncta
appeared less mobile than those containing M5-GFP. In some cases, we were
able to observe events resembling fission of doubly-positive compartments into
separate M5-GFP and AGAP1-mCherry compartments, and transient overlap of
highly mobile M5-GFP and AGAP1-mCherry vesicles (figure 4.5A). Although not
extensively observed, the results were consistent with the co-localization of M5
and AGAP1 in an endosome-like vesicular compartment.
We also investigated the association of M5-GFP and AP-3 vesicles using
the neuron-specific AP-3B complex marker mCherry-AP3β3B expressed in
primary cultured neurons. Although mCherry-AP3β3B puncta were difficult to
detect, we did observe instances of apparent juxtaposition of AP-3- and M5-GFPpositive vesicles both with and without CCh agonist treatment; in addition,
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Figure 4.5 Live imaging of M5, AGAP1 and AP-3 β3B in cultured neurons
(following page). Primary cultured rat hippocampal neurons were cotransfected
with M5-GFP (green) and AGAP1-mCherry (A; red) or mCherry-AP3β3B (B and
C; red) plasmids, treated with 1mM carbachol for 1 hour (A and C), and imaged
by two-color spinning disk confocal microscopy at two second intervals. Images
on right depict time-lapse series of enlarged areas from images at left. Red,
green and yellow arrows indicate mobile GFP, mCherry, or GFP + mCherry
puncta, respectively. Scale bars = 10μm.
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fission-like events between these vesicles were observed (figure 4.5B,C). In
both of these cases, although cytosolic expression was apparent in neuronal
projections, AP3β3B puncta were clearly visible only in soma or soma-proximal
areas. In addition, the appearance of M5-GFP in dynamic, tubular-like structures
after agonist treatment in an imaged cell soma is indicative of their presence in
tubular-vesicular recycling endosomes (Stoorvogel et al., 1996; Grant and
Donaldson, 2009). Although these results are consistent with the co-localization
of M5- and AP-3- positive vesicle populations, we were unable to successfully
image simultaneously AGAP1-mCherry and AP-3 (using GFP-AP3β3A and GFPAP3β3B markers) in single neurons. Additionally, despite previous reports
suggesting that the distribution in neurons of the ubiquitous AP-3 isoform was
restricted to soma (Seong et al., 2005), we observed in neurons expressing both
GFP-AP3β3A and mCherry-AP3β3B somatic, dendritic and axonal localization of
these ubiquitous and neuron-specific AP-3 isoform markers, respectively (figure
4.6C).

4.3.6 Agonist-internalized M5-GFP traffics through characterized endocytic
compartments
We next performed co-immunostainings of primary cultured neurons
expressing M5-GFP to investigate the endocytic compartments encountered by
agonist-internalized receptor. After 60 minutes of CCh treatment, numerous
puncta co-labeled for M5-GFP and transferrin receptor (TfrR) are apparent (figure
4.6A). TfrR is a constitutively recycled receptor with distribution in neurons
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restricted to the somatodendritic compartment (West et al., 1997a); thus,
internalized M5-GFP is trafficked at least partially through this recycling pathway.
We also observed in CCh-treated neurons some instances of co-localization of
M5-GFP with the early endosome marker rab5 in dendrite-like compartments, but
little overlap between M5-GFP and the late endosome marker rab7 (figure 4.6A).
Thus, our data suggested that endocytosed M5 may traffic mainly through the
recycling pathway.

4.3.7 AP-3 endosomes are perisynaptically localized in axons
Our previous data demonstrated overlap of M5-GFP and AGAP1 puncta
in axon-like neuronal processes, although the AP-3 content of these puncta was
not determined (figure 4.4B). The neuron-specific isoform of AP-3 as been
shown to function in the biogenesis of synaptic vesicles from endosomes and in
the targeting of synaptic vesicle proteins such as the vesicular zinc (ZnT3) and
GABA (VGAT) transporters (Faundez et al., 1998; Blumstein et al., 2001;
Nakatsu et al., 2004; Salazar et al., 2004b). In addition, the neuronal AP-3
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Figure 4.6 Distribution of M5 and endocytic markers in cultured rat
hippocampal neurons (following page). (A) Neurons were transfected with
M5-GFP plasmid, treated with 1mM carbachol for 30 (Transferrin receptor, TfrR)
or 60 (Rab5, Rab7) minutes, fixed, co-immunostained for GFP (green) and with
antibodies as indicated (red) and imaged by confocal microscopy. Scale bars,
20μm (top) and 5μm (bottom). (B) Neurons were fixed and co-immunostained for
Synapsin I (red) and δ -Adaptin (green) and imaged by confocal microscopy.
Scale is identical to (A). (C) Primary cultured rat hippocampal neurons were cotransfected with mCherry-AP3β3B (red) and GFP-AP3β3A (green) plasmids and
imaged by two-color spinning disk confocal microscopy. Scale bar, 10μm.
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subunit β3B (β-NAP) was shown to associate with nerve terminal vesicles
(Newman et al., 1995). To investigate the distribution of AP-3 endosomes in
axons, we performed co-immunostaining of long-term cultures of primary rat
hippocampal neurons containing mature synapses. We observed numerous
instances of AP-3-positive puncta juxtaposed, but not superimposed, with
synapsin I-positive varicosities of thin, aspiny projections, consistent with a
perisynaptic distribution of AP-3 endosomes in axons (figure 4.6B). As AP3β3A/
B antibodies appropriate for immunostaining were not available, however, we
were unable to determine whether the observed AP-3 endosomes were of the
ubiquitous or neuron-specific subtype.

4.3.8 Subcellular fractionation analysis of AGAP1 and AP-3 content of rat brain
membranes
In order to take advantage of the wider array of antibodies available for
immunoblotting of native AGAP1 and AP-3 proteins, we performed a biochemical
separation of rat brain membranes by iodixanol step gradient centrifugation (Lee
et al., 2003). Immunoblot analysis of separated membrane fractions revealed a
distribution of AGAP1, the ubiquitous AP-3 isoform marker µ3A, and the neuronspecific AP-3 marker β3B roughly similar to that of the early, late and recycling
endosome markers Rab5, Rab7, and Rab11 (figure 4.7). The fractional
distribution of the TGN-associated, AP-1 adaptor subunit γ-adaptin and the
integral plasma membrane protein Na+,K+ ATPase β2 were distinct (figure 4.7).
We noted 1) that the pattern of AGAP1 membrane association resembled that of
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Figure 4.7 Subcellular fractionation analysis of AGAP1 and AP-3 content of
rat brain membranes. Total rat brain membranes were separated by iodixanol
density gradient centrifugation as described. Membrane fractions were analyzed
for protein content by immunoblot as indicated.

AP3β3B most closely, 2) AP3µ3A exhibited a considerable distribution in lowdensity membrane fractions, and 3) AP-3β3B, rab7 and γ-adaptin shared peak
immunoreactivity at fraction 24 (figure 4.7). Thus, the fractionation data confirm
that AGAP1 is associated with AP-3 like endosomal membranes, and suggest
that neuron-specific AP-3 endosomes may differ physically from that of
ubiquitous AP-3 endosomes, perhaps resembling late endosomal or TGN-like
compartments.
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4.3.9 Agonist-internalized M2-GFP associates with SNX20-positive vesicles
Finally, we investigated the subcellular distribution of muscarinic receptor
M2 and its putative interactor SNX20. Expression of SNX20 in COS-7 cells
revealed a predominant distribution in vesicle-like structures, with some cytosolic,
perinuclear, and nuclear staining variously present, consistent with reports
published subsequent to the performance of these experiments (figure 4.8)
(Schaff et al., 2008). While M2 receptors C-terminally tagged with GFP exhibited
plasma membrane localization in untreated cells, agonist stimulation with CCh
induced internalization and redistribution to endosome-like compartments (figure
4.8). Extensive co-localization of M2-GFP- and SNX20- positive vesicles was
apparent after 15 and 60 minutes of agonist treatment (figure 4.8). Thus,
although our biochemical data was inconclusive with regard to the physical
interaction of M2i3 and SNX20, the current results strongly suggest that agonistinduced internalization of M2 leads to trafficking through an SNX20-positive
endosomal compartment.

4.4 Discussion
Our data provide qualitative evidence for the co-localization of agonistinternalized M5 muscarinic receptors with AGAP1 in an endosomal compartment.
The demonstration of such co-localization was a primary goal of this chapterʼs
experiments, and suggests that AGAP1 and M5 are temporally and spatially
juxtaposed in a manner consistent with, or conducive to, their physical
interaction. Although we were unable to study the distribution of natively
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Figure 4.8 Co-localization of agonist-internalized M2 with SNX20 in
COS-7 cells. COS-7 cells were transiently co-transfected with M2-GFP and
SNX20-myc constructs, treated with 100µM carbachol for 0 (top) 15 (middle) or
60 (bottom) minutes, fixed, immunostained for GFP (green) and myc tag (red)
and imaged by confocal microscopy. Scale bar = 20 µm.
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expressed M5 receptors, the use of epitope-tagged GPCRs in exogenous
expression systems has been widely used to study the constitutive and activitydependent trafficking of a number of receptors (Cao et al., 1999; Oksche et al.,
2000; Hanyaloglu and von Zastrow, 2008). In light of our biochemical data
demonstrating a specific, but likely low-affinity interaction between M5 and
AGAP1, our observation of a partially-overlapping pool of AGAP1- and agonistinternalized M5- positive vesicles, including apparent instances of fusion, fission,
and budding-like events in AGAP1-mCherry and/or M5-GFP vesicles in live
neurons, suggests that AGAP1 may play a functional role in the trafficking of M5.
Importantly, 1) this vesicular overlap was observed only in neurons, and 2)
associative evidence supports the identification of AGAP1 vesicles as AP-3
endosomes. As the function of neuronal AP3B is distinct from that of AP3 in nonneuronal tissues (Newell-Litwa et al., 2007), our results suggest that an AGAP1/
AP-3B complex may mediate the activity-induced trafficking of M5 by binding to
recognition sequences in the M5 i3 loop. Interestingly, we also observed
apparent interaction of M5-GFP- and mCherry-AP3β3B in unstimulated neurons,
perhaps due to the presence of constitutive receptor endocytosis. To our
knowledge, interaction-mediated trafficking of a membrane protein by AGAP1
has not been described; however, the AZAP family Arf GAP ACAP1 was shown
to direct the endocytic recycling of TfrR and integrin β1 by binding to sorting
signals present in their cytoplasmic regions (Dai et al., 2004; Li et al., 2005), and
interaction with AP-3 was shown to direct the intracellular localization of the
cannabinoid CB1 receptor in neurons (Rozenfeld and Devi, 2008) and is known
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to mediate the sorting of lysosome-targeted proteins such as LAMP1 and CD63
(Dell'Angelica et al., 1999; Peden et al., 2004). In addition, we observed in tissue
culture cells a clear co-localization of agonist-internalized M2-GFP with SNX20 in
vesicle-like structures; in light of the inconclusive SNX20-M2 biochemical data,
however, we continued to focus our experimental efforts on the study of the M5AGAP interaction.
Although M5 co-localization with AGAP1 and AP-3 was apparent in
neurons, we were unable to extend these findings to the determination of the
functional ramifications of AGAP1 / M5 interaction. Our efforts were
compromised by a number of technical limitations inherent to the experimental
system we employed. First, AGAP1 overexpression was seen to adversely effect
cell morphology and viability in both tissue culture and primary neuronal cells,
likely as a result of its effect on the critical secretory pathway regulator Arf1 and
by its previously reported actin cytoskeleton-modulating function (Nie et al., 2002;
D'Souza-Schorey and Chavrier, 2006). Additionally, we did not observe
restriction of the AP-3A complex (visualized with β3A fluorescent fusion proteins)
to the soma of cultured neurons, as has been previously described (Seong et al.,
2005); overexpression may have played a role in this distribution pattern.
Second, visualization of membrane-associated exogenous AGAP1 or AP3β3 in
the presence of M5 required either cytosol extraction in fixed cells, or the use of
mCherry fusions in live cells. Cytosol extraction left only a minority of neurons
morphologically intact, and the mCherry tag provided a low contrast signal, and
though reportedly monomeric, was seen to induce immobile aggregates when
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fused to the proteins investigated in this study (the vesicular association of both
AP3β3A and B were more readily visualized with GFP fusion tags; however, M5mCherry aggregated to an unacceptable degree). Third, as the localization and
trafficking characteristics of native M5 have not been described, it was
impossible to determine whether the C-terminal GFP tag interfered with the
normal trafficking of the receptor. It should be noted, however, that M5-GFP was
clearly plasma-membrane localized and underwent agonist-induced
internalization, and that the GFP tag was seen to offer superior performance to
that of a number of extracellular and intracellular epitope tagging strategies
attempted on M5. Although we attempted to investigate the effect of AGAP1
interaction on localization and/or activity-induced trafficking of M5 through the
use of the AGAP1 interaction (∆369-386) deletion mutant, no gross differences
were apparent, and due to the selective nature of neurons imaged, quantitative
analysis was not successful. We thus elected to pursue a biochemical approach
to the study of AGAP1/AP-3 - dependent M5 function and activity-induced
trafficking, as described in the following chapter.
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5

REGULATION OF M5 ENDOCYTIC RECYCLING BY AGAP1

5.1 Summary
We studied the effect of AGAP1 interaction loss-of-function on the steadystate and activity-induced trafficking of the M5 muscarinic receptor. In tissue
culture cells, the total protein level and cell surface expression of the AGAP1
domain-of-interaction mutant M5∆ was higher than that of wild-type receptor.
AGAP1 knockdown decreased surface expression of both M5wt and M5∆. Both
mutant and wild-type M5 receptors underwent agonist-induced internalization
and subsequent endocytic recycling to the plasma membrane after washout, the
magnitude of which was similar between M5wt and M5∆. In primary cultured
neurons, however, the M5∆ receptor displayed a significant endocytic recycling
deficit as compared to wild-type. Knockdown of AGAP1 or the neuron-specific
AP-3 subunit β3B reduced the extent of M5wt recycling, as did treatment with the
AP-3 inhibitor brefeldin-A. In addition, chronic agonist treatment in cultured
neurons significantly increased down-regulation of cell surface M5∆ compared to
wild-type. The results demonstrate a novel, neuron-specific function of AGAP1 /
AP-3 in the mechanism of M5 receptor endocytic recycling. This function
suggests that in vivo, AGAP1 interaction is required for sustained M5 signaling in
neurons.
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5.2 Introduction
Cell-surface receptor density and localization is a key determinant of
GPCR signaling sensitivity. As described in chapter 1, trafficking of GPCRs to
and from the plasma membrane by functionally and spatially defined classes of
subcellular membrane vesicles or endosomes regulates the surface expression
of receptors in both a constitutive and activity-dependent manner. The Rab and
Arf families of small GTPases regulate the trafficking of transmembrane proteins
by recruitment of effector proteins in their GTP-bound “on” state, serving to
regulate the formation, motion, fission, fusion, and functional identity of
subcellular membrane vesicles (D'Souza-Schorey and Chavrier, 2006; Stenmark,
2009). The heterotetrameric adaptor protein complexes are a class of Arf
effectors that mediate transmembrane protein traffic by binding to both signal
sequences in cargo proteins and to membrane coat proteins (Nakatsu and Ohno,
2003). In the current report, we have described a physical interaction between
the Arf GAP AGAP1 and the i3 intracellular loop of the M5 muscarinic receptor.
As AGAP1 binds to the adaptor protein complex AP-3 (Nie et al., 2003) and was
observed to interact with M5 as part of an AGAP1-containing complex, we
hypothesized that in vivo, AGAP1 functions as an adaptor complex scaffold
protein by binding to recognition sequences in the M5 i3 loop and targeting the
receptor for AP-3-dependent trafficking.
Much of the initial knowledge of AP-3ʼs cellular function has resulted from
study of spontaneously occurring mutants in flies, humans, and mice. The
Drosophila melanogaster eye color mutant garnet exhibits a reduced number of
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pigment granules in the eye and other tissues as a result of a near-null mutation
in the δ-adaptin coding Ap3d1 gene (Ooi et al., 1997). Similarly, the mouse coat
color mutants mocha and pearl were found to result from null mutations in the
Ap3d1 and Ap3b1 (coding for the ubiquitously expressed AP3 β3A subunit)
genes, respectively (Kantheti et al., 1998; Feng et al., 1999). Both pearl and
mocha are categorized as platelet storage pool deficiency phenotypes,
characterized by hypopigmentation, lysosome abnormalities, and deficient
storage ability of platelet dense granules leading to prolonged bleeding (Lane
and Deol, 1974; Novak et al., 1984; Kantheti et al., 1998; Feng et al., 1999). In
humans, the Hermansky-Pudlak syndrome (HPS) is a collection of related
autosomal recessive platelet storage pool deficiency disorders (Wei, 2006). Of
the 8 genetically unique forms of HPS yet described, one (HPS-2) is caused by a
near-null mutation in the Ap3b1 gene, while another (HPS-7) is due to a mutation
in DTNBP1, encoding dysbindin, a member of the AP-3 associated BLOC-1
complex (Dell'Angelica et al., 1999; Li et al., 2003).
The ubiquitously expressed AP-3A isoform functions mainly to traffic
membrane proteins to lysosomes and lysosome-like organelles (figure 5.1). In
fibroblasts derived from HPS-2 patients (in which function of the ubiquitous AP-3
complex is disrupted), the lysosomal membrane proteins Lamp-1, Lamp-2 and
CD63 were seen to mis-localize to the plasma membrane (Dell'Angelica et al.,
1999). Similarly, intact AP-3 function in yeast was shown to be required for
vacuole localization of membrane proteins containing a lysosome targeting
sequence (Vowels and Payne, 1998). An AP-3-dependent trafficking mechanism
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Figure 5.1 AP-3-dependent trafficking pathways. Inset, GTP-bound Arf1
recruits AP-3 to membranes. Subsequent binding of AGAP1 catalyzes hydrolysis
of GTP to GDP, resulting in dissociation of AP-3 (and AGAP1) and release of
integral membrane cargo proteins. Top, endocytosed membrane proteins are
delivered to early / sorting endosomes and are trafficked to specific cellular
compartments by recognition of sorting motifs by AP-3.
The ubiquitously
expressed AP-3A isoform targets membrane proteins such as Tyrosinase or
LAMP-1 to melanosomes or the lysosome limiting membrane, respectively. The
neuron-specific isoform AP-3B is responsible for both biogenesis of endosomallyderived synaptic vesicles (SVs) and for delivery of proteins such as ZnT3 to
these SVs.
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has also been demonstrated for cannabinoid CB1 receptor localization to late
endosome-like compartments (Rozenfeld and Devi, 2008), delivery of Notch to
the limiting (outer) lysosomal membrane in Drosophila (Wilkin et al., 2008), and
the targeting of tyrosinase to melanosomes (Huizing et al., 2001). AP-3dependent targeting to lysosomes or lysosome-like organelles is mediated by
recognition of dileucine-like or tyrosine-based sorting signals present on
cytoplasmic regions of cargo proteins (Ohno et al., 1998; Vowels and Payne,
1998; Bonifacino and Traub, 2003; Janvier et al., 2003). An immuno-EM study
identified AP-3 localized to membrane buds emanating from early endosomeassociated, recycling compartment-like tubular structures; no AP-3
immunoreactivity was detected in the TGN, however (Peden et al., 2004). The
lysosomal membrane protein Lamp-1, apparently in transit from the plasma
membrane, was seen to co-localize with AP-3 at these budding structures
(Peden et al., 2004). Additionally, although some AP-3 trafficking events appear
to proceed via non-clathrin coated vesicles, AP-3 is able to bind clathrin in vitro
and is seen to partially co-localize to clathrin-positive vesicular structures
(Dell'Angelica et al., 1998; Vowels and Payne, 1998; Peden et al., 2004). Thus,
the current model of AP-3-dependent sorting suggests that targeted proteins first
undergo delivery to the plasma membrane, followed by endocytosis and
trafficking from the early endosome to a recycling endosome-like structure, after
which target proteins are sorted to and sequestered in distinct clathrin or nonclathrin coated vesicles by AP-3 (in concert with the associated trafficking
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complex BLOC-1), followed finally by delivery to lysosomal or lysosome-like
organelle membranes.
The neuron-specific AP-3B isoform, consisting of the ubiquitously
expressed δ and σ3 subunits and neuron-specific µ3B and β3B, is functionally
distinct from the ubiquitous AP-3A complex (figure 5.1). In vitro studies
demonstrated that AP-3B, but not AP-3A, is able to mediate the formation of
synaptic vesicles from endosomes (Faundez et al., 1998; Blumstein et al., 2001).
In Ap3b2-/-, Ap3m2-/- or Ap3d1-/- (mocha) mutant mice, the zinc transporter ZnT3
and the vesicular GABA transporter VGAT are absent from a subpopulation of
synaptic vesicles, resulting in impaired GABA release and reduced zinc content
in the hippocampus and cortex (Kantheti et al., 1998; Nakatsu et al., 2004;
Salazar et al., 2004b). In addition, the chloride channel ClC-3, the vesicular
glutamate channel Vglut1, TI-VAMP and phosphatidylinositol-4-kinase type IIα
were seen to be absent from a subpopulation of synaptic vesicles in cells derived
from mocha mice or after disruption of AP-3 targeting with by the Arf GEF
inhibitor brefeldin-A (Martinez-Arca et al., 2003; Salazar et al., 2004a; Salazar et
al., 2005a; Salazar et al., 2005b; Scheuber et al., 2006). Ap3b2-/-, Ap3m2-/- and
mocha mice are hyperactive and epileptic (Newell-Litwa et al., 2007). Mocha
mice display deficient spontaneous and evoked glutamate release in
hippocampal synapses (Scheuber et al., 2006) and decreased synaptic vesicle
recycling rates under high-frequency stimulation conditions (Voglmaier et al.,
2006); in addition, GABAergic neurotransmission was seen to be disrupted in
Ap3m2-/- mice (Nakatsu et al., 2004). It should be noted, however, that the
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phenotypic penetrance of the Ap3b2-/- and Ap3m2-/- mutations does not reach
that of mocha (Ap3d1-/-), suggesting a neuron-specific functional role for the
ubiquitous AP-3A complex (Newell-Litwa et al., 2007). Additionally, the assembly
of neuron-specific and ubiquitous β3 and µ3 subunits into AP-3A and AP-3B
heterotetramers may not be exclusive (Peden et al., 2002).
AP-3 is targeted to membranes via recruitment by GTP-bound Arf1
(Lefrancois et al., 2004). The proper function of AP-3 in the transport of cargo
proteins requires its coating and uncoating of membrane vesicles in a regulated
manner. The Arf1 GAP AGAP1 plays a key role in this process, as release of the
AP-3 coat requires hydrolysis of GTP to GDP by Arf1, and the intrinsically low
GTPase activity of Arf1 necessitates stimulation by GAPs (Nie et al., 2002; Nie
and Randazzo, 2006). AGAP1 binds directly to the AP-3 complex via its PH
domain, spatially coordinating Arf1 GAP activity with the AP-3 coat (Nie et al.,
2003). Up- or down- regulation of AGAP1 levels interferes with the targeting of
AP-3 to vesicles and with the trafficking of the lysosomal cargo protein Lamp-1
(Nie et al., 2003). In addition, the PH domain of AGAP1 confers upon it
membrane lipid-binding activity and phospholipid-dependent GAP activity, and
AGAP1 / AP-3 binding was seen to be specific with regard to related adaptor
protein complexes (Nie et al., 2002; Nie et al., 2005). Although AGAP1 thus
plays an indirect role in the AP-3-dependent trafficking of target proteins, an
intrinsic cargo recognition or AP-3-independent trafficking function of AGAP1 has
not been described. However, the related AZAP protein ACAP1 was
demonstrated to bind to recognition sequences in the cytoplasmic tails of the
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transferrin receptor and integrin β1, and to be required for their endocytic
recycling to the plasma membrane (Dai et al., 2004; Li et al., 2005). In addition,
the AGAP1-related protein centaurin α1 was shown to inhibit the agonist-induced
internalization of the β2 adrenergic receptor (Lawrence et al., 2005).
Although the steady state and activity-induced trafficking characteristics of
muscarinic receptors 1 through 4 have been described, the trafficking pattern of
the M5 receptor is unknown. In this chapter, we describe experiments
investigating the basal and agonist-induced trafficking of M5 in exogenous
cellular expression systems. We employed both the AGAP1 region-of-interaction
deletion mutant M5(∆369-386) (M5∆) and RNAi-mediated knockdown of
endogenous AGAP1 to study the effects of AGAP1 interaction loss-of-function on
the trafficking of M5. Knockdown of ubiquitous and brain-specific AP-3 subunits
was used to investigate the hypothesized involvement of this trafficking pathway
on M5 regulation. We took advantage of the availability of a hydrophilic, cellimpermeant muscarinic antagonist radioligand [3H]-N-methyl-scopolamine to
quantitatively monitor cell surface M5 receptor density in intact, living cells
(Toews, 2000). This approach allowed for the measurement of M5 surface
density under basal conditions, and allowed us to indirectly monitor the rate of
internalization and endocytic recycling of M5 receptors after agonist stimulation.
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5.3 Results
5.3.1 Transfected M5(∆369-386) is expressed at higher levels than M5wt in
tissue culture cells
We first examined the effect of the AGAP1 domain-of-interaction (DOI) i3
loop deletion on the expression of M5 in mammalian tissue culture cells.
HEK-293T or CHO cells were transiently transfected with equal quantities of
M5wt-GFP and M5∆-GFP coding plasmids, and then assayed for total M5 protein
content by GFP immunoblot 48 hours later. We observed, on average, a nearly
2.5-fold greater amount of M5∆-GFP than M5wt-GFP protein present in cell
lysates, a pattern also present with M5 receptors extracellularly-tagged with the
HA epitope, and in cell lines stably expressing wild-type and ∆369-386 M5 (figure
5.2A; data not shown). Next, to determine whether the mutant M5 receptor also
exhibited an increased abundance at the cell surface compared to wild-type, we
performed radioligand binding experiments on intact, transiently transfected
HEK-293T cells using the cell-impermeant tritiated muscarinic antagonist [3H]-Nmethyl-scopolamine ([3H]NMS) to quantitatively label extracellular M5 ligand
binding sites (we previously detected negligible specific [3H]NMS binding to the
cell lines used in these experiments). We observed a significantly higher surface
expression of the non-GFP-tagged AGAP1 DOI mutant M5∆ compared to M5wt
(figure 5.2B).
The increased total and surface levels of deletion-mutant receptor protein
suggested that AGAP1 interaction may function to decrease expression of M5 in
our system. To test this, we performed siRNA-mediated knockdown concurrent
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Figure 5.2 Expression of wild-type and ∆369-386 M5 receptors in HEK-293T
cells. (A) HEK-293T cells were transiently transfected with GFP-tagged wildtype or domain-of-interaction deletion mutant constructs, and lysates were
analyzed by quantitative immunoblot for GFP with data normalized to M5wt-GFP.
(B) HEK-293T cells were transiently transfected with M5wt or M5∆ constructs,
and cell surface muscarinic receptor density was assayed by [3H]NMS
radioligand binding. (C) HEK-293T cells were transiently transfected with siRNA
targeting AGAP1 or with non-targeting control, and 24 hours later transfected
with M5wt-GFP or M5∆-GFP constructs. Left, surface receptors density was
assayed as in (B).
Right, representative immunoblot displaying AGAP1
knockdown. Lower panels, Actin loading controls. (*): P< 0.05, paired two-tailed
Studentʼs ratio T-test.
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to exogenous expression of M5wt- or M5∆- GFP, and assayed for surface MR
sites by [3H]NMS binding in HEK-239T cells. We predicted that, due to the
inability of the DOI mutant receptor to physically interact with AGAP1, knockdown
of AGAP1 would increase surface expression of M5wt but not effect M5∆ levels.
As with rat brain tissue, the AGAP1 antibody detected a multiplet band by
immunoblot in lysate from the human HEK-293T cell line; siRNA targeting
hAGAP1 was able to knock down AGAP1 expression with moderate efficacy
compared to transfection of a non-targeting siRNA duplex (figure 5.2C).
However, AGAP1 knockdown decreased cell-surface binding of [3H]NMS in both
M5wt-GFP and M5∆-GFP transfected cells (figure 5.2C). We also observed a
decrease in M5wt-, M5∆, and M3-GFP total protein levels after AGAP1
knockdown (data not shown). This result argued against an AGAP1-related
mechanism for the increased expression of M5∆ compared to wild-type receptor
in this system.

5.3.2 M5wt and M5∆ exhibit similar patterns of activity-induced trafficking in
HEK-293T cells
We asked whether deletion of the AGAP1 ROI in M5 could affect activityinduced trafficking of the receptor. We expressed wild-type and ∆369-386 M5
receptors exogenously in HEK-293T or CHO cells, treated cells with the
cholinergic agonist carbachol (CCh) for various times in the presence of the
translation inhibitor cycloheximide (to eliminate interference from the appearance
of newly-synthesized M5 protein) and assayed intact cells for surface M5
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Figure 5.3 Activity-induced trafficking of M5 receptors in HEK-293T cells.
HEK-293T cells were transiently transfected with M5wt or M5∆ contructs, and cell
surface M5 receptors were assayed by [3H]NMS radioligand binding as
described. (A) Time course of M5 receptor internalization after treatment with
0.1mM carbachol (CCh) for indicated periods. (B) Receptor recycling assay. M5expressing cells were left untreated, or treated with 0.1mM CCh for 30 minutes
with or without a subsequent 60 minute washout period. Cell surface M5
receptors were assayed as in (A), with data expressed as a percent of untreated
control values. (*): P< 0.05, two-way ANOVA (treatment).

131

receptor binding sites by [3H]NMS radioligand binding. In these experiments, we
observed a time-dependent reduction of cell-surface [3H]NMS binding after CCh
incubation for both M5wt and M5∆, confirming the agonist-induced internalization
of these receptors (figure 5.4A). However, the temporal characteristics and
magnitude of CCh-induced internalization did not differ between M5wt and M5∆
(figure 5.3A,B). Next, we examined endocytic recycling of agonist-internalized
M5 expressed in HEK-293T cells using an experimental system similar to the one
described above. Cycloheximide-pretreated cells were left untreated, treated
with 100µM CCh for 30 minutes to induce M5 internalization, or CCh-treated
followed by a 1-hour washout period to allow for endocytic recycling of
internalized receptors. An increase of cell surface [3H]NMS binding sites after
washout was taken as a quantitative measure of M5 recycling. Wild-type and
deletion-mutant M5 receptors did not differ in the degree to which they were
recycled to the cell surface after agonist-induced internalization (figure 5.3B).
We therefore concluded that the AGAP1 ROI deletion, and presumably
interaction with AGAP1, did not play a role in the activity-dependent trafficking of
M5 in HEK-293T and CHO cells.

5.3.3 Development of a primary cultured neuron system for the study of
exogenous M5 receptor trafficking
Our previous data suggested that the function of M5/AGAP1 interaction
may be neuron-specific, as we observed activity-induced co-localization of M5GFP-positive and AGAP1-positive vesicles in neurons only, and since the M5 i3
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Primary cultured neuron radioligand binding assay
development.
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loop physically interacted with the neuron-specific AP3B complex, whose role in
membrane protein trafficking is distinct from that of the ubiquitously expressed
AP-3A complex (Danglot and Galli, 2007). We wished to study the trafficking of
exogenously expressed M5 receptors in cultured neurons, as endogenous M5
sites are both low in abundance and pharmacologically indistinguishable from
non-M5 MRs with currently available tools (Wess et al., 2007). We were able to
achieve exogenous expression of wild-type and mutant M5 receptors in primary
cultured cortico-hippocampal cultures using the nucleofection technique to
introduce expression plasmids (Gartner et al., 2006). However, the detection of
exogenous M5 by [3H]NMS radioligand binding was complicated by the presence
of a considerable amount of endogenous muscarinic receptor binding sites;
based on radioligand binding studies of MR knockout mouse cortex and
hippocampus, these receptors are predominantly M1/M2 subtypes, with little to
no endogenous M5 present (Oki et al., 2005). With the aim of improving the M5to-non-M5 “signal-to-noise” ratio of our cell surface radioligand binding assay, we
identified an antagonist, AF-DX 384, displaying 10-fold less binding affinity for the
M5 receptor than endogenous, non-M5 sites present in nucleofected primary
neurons, in accordance with previous pharmacological reports (figure 5.4A)
(Dorje et al., 1991). Importantly, the binding affinity (measured by the
concentration-dependent ability to displace [3H]NMS binding) of AF-DX 384 for
M5wt and M5∆ was identical (figure 5.4A). Therefore, by preferentially displacing
[3H]NMS binding to non-M5 sites, the inclusion of an appropriate concentration
(5 µM) of AF-DX in the radioligand binding assay allowed for an M5-to-non-M5
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signal sufficient to allow quantitative analysis of cell surface M5 site densities
(figure 5.4A).
Next, we investigated the feasibility of performing RNAi-mediated
knockdown experiments in primary cultured neurons. Though nucleofection of
primary hippocampal neurons can, under ideal conditions, yield up to 70% of
cells positive for transgene expression (Gartner et al., 2006), near-pure
populations of nucleofected cells are most appropriate for gene knockdown
experiments to be analyzed biochemically. Immunosorbent strategies for the
enrichment of nucleofection-positive cells from a mixed population have been
described (Tahvanainen et al., 2006). We observed previously that puromycin
selection of primary neurons nucleofected with a plasmid encoding the
puromycin resistance gene was able to effectively enrich for a transgeneexpressing population of neurons (data not shown). We designed a series of
puromycin-selectable short hairpin RNA (shRNA)-encoding plasmids targeting rat
AGAP1, AP3β3B, and δ-adaptin sequences and tested them for knockdown
efficiency in mature (12-14 DIV) rat cortico-hippocampal cultures after
nucleofection and puromycin selection. With at least one shRNA per gene, we
were able to effectively knock down endogenous protein levels, with nearly 100%
efficiency observed for AP3β3B and δ-adaptin compared to a non-targeting
control shRNA (figure 5.4B).
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5.3.4 Increased expression of M5∆ in primary neurons is not mediated by
AGAP1 or AP-3
Using the M5-specific radioligand assay and shRNA knockdown method
described in the preceding section, we first investigated the effect of AGAP1/
AP-3 disruption on the steady-state surface expression of M5. As in tissue
culture cells, nucleofection of equal quantities of M5wt- or M5∆- coding
expression plasmids resulted in a near two-fold greater surface expression of the
AGAP1 DOI mutant as measured by cell-surface [3H]NMS radioligand binding
(2-way ANOVA p<.01) (figure 5.5A,B,C). However, knockdown of either AGAP1
or the neuron-specific AP-3B subunit β3B had no effect on the surface
expression of either the wild-type or deletion mutant receptor (figure 5.5A,B).
Knockdown of ubiquitously expressed δ-adaptin, a component of both the AP-3A
and AP-3B complexes, was seen to decrease M5 surface expression; however,
M5wt and M5∆ receptors were affected to a similar extent (figure 5.5C). Thus,
our data did not support a role for AGAP1 / AP-3 interaction in the steady-state
surface expression of M5 in cultured neurons.

5.3.5 M5wt, but not M5∆, undergoes efficient endocytic recycling in cultured
neurons
We next investigated whether disruption of the AGAP1 binding site on the
M5 i3 loop affected the activity-induced trafficking of the receptor in neurons.
M5wt and ∆ receptors were expressed exogenously in primary corticohippocampal neurons, subjected to agonist-induced internalization, recycling, or
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Figure 5.5 AGAP1- and AP-3-dependent surface expression of wild-type
and ∆ 369-386 M5 receptors in primary cultured neurons. Rat embryonic
cortico-hippocampal neurons were co-nucleofected with M5wt, M5∆, or empty
vector control plasmids and targeting or non-targeting control shRNA plasmids
and cultured for 13 days. Cell surface muscarinic receptors were assayed by
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Knockdown of AGAP1, AP3β3B and δ-Adaptin proteins was verified by
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control conditions as described in section 5.3.2, and assayed for surface
[3H]NMS sites as described above. We observed that the M5∆ receptor was
deficient in its ability to recycle to the cell surface after a 60 minute washout of
agonist treatment as compared to M5wt (figure 5.6A). To control for the
possibility that this recycling deficiency was related to the overall higher level of
M5∆ present, we repeated the experiment under slightly altered nucleofection /
culture conditions, in which we observed no difference in the steady-state surface
expression of M5wt and M5∆ (figure 5.6B, inset). Although overall M5 endocytic
recycling levels were slightly lower, the M5∆ recycling deficiency phenotype was
maintained (figure 5.6B).

5.3.6 Knockdown of AGAP1 or AP3β2 in neurons inhibits endocytic recycling of
wild-type M5 receptors
To confirm that the observed deficit in the ability of M5∆ to undergo
endocytic recycling after activity-induced internalization was due to an AGAP1dependent mechanism, we repeated the experiment described in section 5.3.5
after shRNA-mediated knockdown of endogenous AGAP1 protein (figure 5.4B).
Although AGAP1 protein was not completely eliminated, we observed a
significant decrease in the extent of recycling of M5wt in primary cultured
neurons co-nucleofected with AGAP1 shRNA plasmid (figure 5.7A). Importantly,
there was no significant difference in the degree to which the M5∆ receptor
recycled after AGAP1 knockdown, as would be predicted for the interaction lossof-function mutant with a mechanism of trafficking requiring recognition of i3 loop
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Figure 5.6 Deficient endocytic recycling of M5∆ receptors expressed in
cultured neurons. (A) Rat embryonic cortico-hippocampal neurons were
nucleofected with M5wt, M5∆, or empty vector control plasmids and cultured for
13 days. Cells were left untreated, or treated with 0.1mM CCh for 30 minutes
with or without a subsequent 60 minute washout period. Cell surface muscarinic
receptors were assayed by [3H]NMS radioligand binding and M5-specific signal
was calculated as described. Data are expressed as a percent of untreated
control values. (*/**): P< 0.05/ P< 0.01, Bonferroni post-test / two-way ANOVA.
(B) Experiment in (A) performed with equalized M5wt and M5∆ steady-state
surface receptor levels (inset). Data are expressed as a percent of CChinternalized receptors recycled after 1 hour washout. (*): P< 0.05, paired twotailed Studentʼs T-test.
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Figure 5.7 Knockdown of AGAP1 or AP3β3B inhibits endocytic recycling of
M5 receptors in cultured neurons.
Rat embryonic cortico-hippocampal
neurons were co-nucleofected with M5wt, M5∆, or empty vector control plasmids
and targeting or non-targeting control shRNA plasmids and cultured for 13 days.
Cells were left untreated, or treated with 0.1mM CCh for 30 minutes with or
without a subsequent 60 minute washout period. Cell surface muscarinic
receptors were assayed by [3H]NMS radioligand binding and M5-specific signal
was calculated as described. Knockdown of AGAP1 and AP3β3B proteins was
verified by immunoblot. Data are expressed as a percent of CCh-internalized
receptors recycled after 1 hour washout. (A)(*): P< 0.05, Bonferroni post-test /
two-way ANOVA. (B)(*): P< 0.05, one-sample T-test (versus 100).
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sorting signals by AGAP1 (figure 5.7A).
To test whether the endocytic recycling of M5wt was AP-3-dependent, we
performed the same experiment after knockdown of the neuron-specific AP-3B
subunit β3B. Similar to the AGAP1 results, AP3β3B knockdown reduced
recycling of agonist-internalized M5wt, but did not effect M5∆ (figure 5.7B).
Although the reduction in receptor recycling values did not reach significance by
two-way ANOVA, AP3β3B knockdown significantly reduced M5wt, but not M5∆
recycling as measured by the Studentʼs T-test (p<.05) and only M5wt conucleofected with non-coding shRNA did not differ significantly from a
hypothesized recycling rate of 100% (one-sample T-test, p<.05). Thus, we
concluded that efficient endocytic recycling of M5 in neurons requires interaction
with AGAP1 and AP-3B, likely as part of a single trafficking complex.

5.3.7 Inhibition of AP-3 activity reduces endocytic recycling of M5 in an AGAP1
ROI-dependent manner
The fungal metabolite brefeldin-A (BFA) is an Arf1 GDP exchange factor
(GEF) that has been used previously to chemically inhibit the assembly,
membrane targeting and/or function of the AP-3 complex (Donaldson et al., 1992;
Ooi et al., 1998; Salazar et al., 2004b). To further test whether the mechanism of
M5 endocytic recycling is AP-3- dependent, we performed the M5 internalization /
recycling assay in primary cortico-hippocampal neuron cultures nucleofected with
wild-type or deletion-mutant M5 receptors after a 2 hour pre-incubation with BFA
or vehicle. BFA treatment was able to eliminate M5wt recycling, but had no effect
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Figure 5.8 Activity-induced trafficking characteristics of M5 receptors in
cultured neurons.
Rat embryonic cortico-hippocampal neurons were
nucleofected with M5wt, M5∆, or empty vector control plasmids, cultured for 13
days, and treated as indicated. Cell surface muscarinic receptors were assayed
by [3H]NMS radioligand binding and M5-specific signal was calculated as
described. (A) Cultures were pre-treated with 5µM brefeldin-A (BFA) for two
hours before assaying for endocytic recycling as in figure 5.7.
Data are
expressed as a percent of CCh-internalized receptors recycled after 1 hour
washout. (*): P< 0.05, Bonferroni post-test / two-way ANOVA. (B) Cultures were
treated for 4 days with 10µM CCh and assayed for cell-surface M5 receptor
binding. (*): P< 0.05, paired two-tailed Studentʼs T-test. (C) Cultures were
treated with 45mM KCl for 5 minutes, with and without a subsequent 1 hour
washout. (*): P< 0.05, paired two-tailed Studentʼs T-test.
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on the levels of M5∆ recycled to the cell surface after 1 hour washout from a 30minute CCh treatment (figure 5.8A). This result further supports the hypothesis
that M5 undergoes endocytic recycling via an AP-3-dependent mechanism, and
suggests that residual recycling seen in the AGAP1 DOI deletion mutant may
proceed by an alternate, AP-3 independent mechanism.

5.3.8 Down-regulation of cell surface M5 receptors after chronic agonist
treatment is increased in the M5∆ mutant
Long-term activation of GPCRs can result in their down-regulation by
targeting of agonist-stimulated receptors for lysosomal degradation (Tsao and
von Zastrow, 2000). The striatum, in which M5 receptors are present in midbrain
dopaminergic afferent terminals, is characterized by the presence of tonically
active, extensively arborized cholinergic interneurons, and has the highest
acetylcholine tone found in the CNS (Zhou et al., 2002a; Pisani et al., 2007). As
the M5∆ receptor was observed to be deficient in its ability to undergo endocytic
recycling after agonist-induced internalization, we asked whether its long-term
activation could lead to down-regulation as a result of aberrant targeting to the
lysosomal degradative pathway. We treated primary cultured neurons
expressing wild-type of AGAP1 ROI mutant M5 receptors with a moderate dose
(10µM) of the non-hydrolyzable ACh analogue carbachol for 4 days, and then
assayed for cell surface M5 receptor sites by radioligand binding as described
above. As a percentage of untreated controls, we observed a significantly
greater reduction in the density of cell surface M5∆ receptors as compared to
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M5wt (figure 5.8B). This result supports the hypothesis that AGAP1-mediated
recycling is required for maintenance of surface M5 expression under sustained
ACh stimulation conditions.

5.3.9 Chemical depolarization decreases surface density of M5 receptors
expressed in primary cultured neurons
AP-3 is known to be required for the targeting of certain proteins (ZnT3,
VGAT) to nerve-terminal synaptic vesicles (Nakatsu et al., 2004; Salazar et al.,
2004b). One interpretation of our recycling data is that M5 is trafficked to a
synaptic vesicle-like compartment via an AGAP1 / AP-3 sorting mechanism, and
that stimulation with CCh serves to increase cell surface M5 density by
depolarization-induced exocytosis of receptors held in subcellular stores. To test
this, we expressed M5wt or M5∆ in cultured neurons, and 1) chemically induced
depolarization with 45mM KCl for 5 minutes, 2) depolarized with KCl, followed by
a 60-minute washout / recovery, or 3) left cells untreated. We observed a
decrease in surface M5 [3H]NMS binding sites that was significantly greater after
5 minutes of KCl treatment in the wild-type as compared to deletion mutant
receptors (Studentʼs paired two-tail T-test, p<.05; however, 2-way ANOVA
showed a significant difference (p<.05) only between M5wt and M5∆ groups)
(figure 5.8C). After washout / recovery, surface levels of both mutant and wildtype M5 increased (figure 5.8C). These results do not support depolarizationdependent synaptic vesicle fusion as a mechanism for M5 surface expression

144

up-regulation. The significance of the differential response of M5wt and M5∆ to
neuronal depolarization with regard to endocytic recycling is unclear.

5.3.10 M5∆ couples normally to downstream signaling pathways
To insure that the i3 loop AGAP1 ROI deletion (∆369-386) did not interfere
with the coupling of M5∆ to signaling effectors, we compared the Gq and MAP
kinase responses of the M5 wild-type and M5∆ receptors. In HEK-293T cells
transiently transfected with M5wt, M5∆, or control expression plasmids, cells
were stimulated with various concentrations of CCh, and PLC-β activation was
assayed by the accumulation of the inositol-3-phosphate metabolite inositol-1phosphate. No difference in agonist efficacy (EC50) was observed between wildtype and mutant receptors, while signal magnitude was greater in M5∆ than wildtype, in line with its pattern of surface expression (figure 5.9A). Similarly, CCh
was able to stimulate intracellular calcium release in cells stably transfected with
both M5wt or M5∆ receptors, with a larger signal magnitude in the higherexpressing M5∆ line (figure 5.9B). We also observed that both M5wt and M5∆
were able to activate the MAP kinase pathway in HEK-293T cells (as measured
by phosphorylation of Erk 1/2) after stimulation with CCh in a similar range of
concentrations (figure 5.9C).

5.3.11 Analysis of M5 trafficking by subcellular membrane fractionation
Finally, we performed subcellular membrane fractionation of nucleofected
cultured primary neurons in an effort to further understand the activity-induced
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Figure 5.9 The ∆369-386 mutation does not affect M5 signaling properties.
(A) HEK-293T cells transiently transfected with M5wt, M5∆ or empty vectors were
stimulated with various concentrations of CCh and assayed for inositol-1phosphate accumulation as described. EC50 values were calculated by nonlinear curve fitting to a sigmoidal dose-response model (GraphPad Prism).
(B) HEK-293T cells stably expressing M5wt or M5∆ receptors monitored for
intracellular Ca2+ concentration by Fluo-3 fluorometry. Cells were stimulated
with CCh (1mM) at the indicated time point. (C) HEK-293T cells transiently
transfected with M5wt, M5∆ or empty vectors were stimulated with various
concentrations of CCh for 10 minutes. Activated (phospho-Tyr 202/204; pErk 1/2)
and total Erk 1/2 were detected from cell lysates by immunoblot.
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trafficking of M5 receptors. In the first experiment, primary cultured corticohippocampal neurons expressing wild-type or deletion-mutant M5-GFP were
treated with CCh for 1 hour, homogenized, and then subject to glycerol velocity
gradient centrifugation in order to synaptic vesicle-containing fractions (West et
al., 1997b). The isolation of synaptic vesicle-containing membrane fractions was
confirmed by immunoblot for synaptophysin; however, neither M5wt- nor M5∆GFP protein was detected in a pattern consistent with enrichment in a synaptic
vesicle-like compartment, arguing against an AP-3 mediated endosome-tosynaptic vesicle pathway in the recycling of M5 to the cell surface (figure 5.10A).
In the second experiment, membrane fractionation was performed in an
effort to confirm the hypothesis that agonist-internalized M5∆ is mistargeted to
the late endosome / lysosome degradative pathway. Primary cultures expressing
M5wt- or M5∆-GFP were incubated with CCh in the presence of the lysosomal
protease inhibitor leupeptin for 4 hours, and then fractionated by self-forming
percoll density gradient centrifugation (Schaub et al., 2005). A dense membrane
fraction corresponding to late endosomes / lysosomes was observed by
immunoblot to be relatively enriched in the late endosome marker rab7, but
showed little AGAP1 or plasma membrane marker (Na+,K+ ATPase β2)
immunoreactivity (figure 5.10B). While small amounts of M5wt- and M5∆-GFP
protein were detected in the peak lysosomal membrane fraction, their overall
lysosome-like distribution was similar (M5wt-GFP, 6.7% of total immunoreactivity;
M5∆-GFP, 4.1%) (figure 5.10B). We therefore could not conclude from this
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Figure 5.10 Analysis of M5 receptor trafficking in cultured neurons by
subcellular fractionation. Rat embryonic cortico-hippocampal neurons were
nucleofected with M5wt-GFP or M5∆-GFP plasmids, and cultured, treated and
fractionated as indicated. (A) 14 DIV cultures were treated with 0.1mM CCh for 1
hour and synaptic vesicle-like membranes were isolated by glycerol velocity
gradient centrifugation. Isolated membranes and post-nuclear supernatant (PNS)
were analyzed by immunoblot. (B) 21 DIV cultures were treated for 4.5 hours
with 1mM CCh and 0.1mM leupeptin. Membranes were fractionated through a
self-forming Percoll density gradient, and fractions were analyzed by immunoblot
as indicated.
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experiment that the AGAP1 DOI deletion mutant M5 receptor is targeted to the
degradative pathway upon agonist induced stimulation.

5.4 Discussion
This chapter describes evidence of an AGAP1-dependent, neuron-specific
mechanism for the recycling of agonist-internalized M5 muscarinic receptors to
the plasma membrane. Induction of AGAP1 interaction loss-of-function by
deletion of the M5 i3 loop region of interaction or by RNAi-mediated depletion of
endogenous AGAP1 protein decreased the magnitude of cell surface M5 binding
site reappearance after agonist-induced intracellular sequestration, indicating
inhibition of M5 endocytic recycling. The recycling deficit was reproduced by
both knockdown of the brain-specific AP-3B subunit β3B and by chemical
inhibition of AP-3 membrane recruitment with the Arf GEF inhibitor brefeldin-A,
demonstrating that M5 endocytic recycling proceeds through an AP-3-dependent
pathway. Taken together with our biochemical and imaging data demonstrating
physical, spatial and temporal interaction between M5 and an AGAP1/AP-3
complex, our results strongly suggest that efficient endocytic recycling of M5 is
mediated by recognition of i3 loop trafficking motifs by an AGAP1/AP-3B
complex, and that this mechanism is specific to the M5 muscarinic receptor
subtype. This proposed mechanism, whereby AGAP1 serves as a cargointeracting scaffold protein for the AP-3 complex, has not been described.
However, AP-3 -dependent trafficking of the cannabinoid CB1 GPCR to
intracellular compartments was reported (Rozenfeld and Devi, 2008), as was
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endocytic recycling of membrane proteins by the AGAP1-related AZAP family
protein ACAP1 (Dai et al., 2004; Li et al., 2005).
Further details of the mechanism by which AGAP1 and AP-3 mediate
recycling of M5 receptors await elucidation. Muscarinic receptors M1-4 have
been reported to undergo agonist-induced endocytosis via clathrin-dependent
and -independent mechanisms (Tolbert and Lameh, 1996; Vogler et al., 1998;
Delaney et al., 2002; Popova and Rasenick, 2004; Madziva et al., 2005).
Though we did not determine the mechanism of M5 internalization, clathrin and
non-clathrin endocytic routes may imply differing downstream trafficking
pathways (Weigert et al., 2004). As we were unable to detect M5 recycling after
short-duration agonist washout periods in pilot experiments (data not shown), the
route of receptor recycling is likely not through the Rab4- / Rab35- dependent
“fast” route, but rather via the Rab11-dependent “slow” endocytic recycling
pathway (Grant and Donaldson, 2009). Since the slow pathway requires transit
of cargo proteins through the tubulovesicular endocytic recycling compartment
(ERC), and since ubiquitous AP-3A was seen to localize to membrane buds in
ERC-like compartments (Peden et al., 2004), we speculate that in neurons,
agonist internalized M5 is targeted to a recycling pathway by sorting from the
ERC to an AGAP1/AP-3B-positive compartment. We found no evidence that
internalized M5 is localized to synaptic vesicle-like structures; therefore, M5 may
sort to recycling endosomes for transit back to the plasma membrane. In
addition, our biochemical assays employed a heterogeneous neuronal cell
population for exogenous expression, and could not distinguish between
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trafficking events occurring in axonal and somatodendritic compartments. As
neuron sub-class and axon-specific trafficking mechanisms are known to exist
(Yap et al., 2008), studies employing purified cell populations and/or single-cell
analysis could help identify the mechanisms of AGAP1-mediated M5 trafficking
with further precision.
The mechanism responsible for the increased total and cell surface
expression of M5∆ receptors compared to M5 wild-type remains unclear. The
phenotype seemed to be unrelated to interaction with AGAP1 or AP-3, since
knockdown of AGAP1 or β3B had no effect on steady-state M5 surface
expression in neurons, and δ-adaptin and AGAP1 knockdown did not
differentially effect M5 expression in neurons or tissue culture cells, respectively.
It is possible that a second, unknown trafficking motif was inadvertently
eliminated in the deletion of the AGAP1 ROI from the M5 i3 loop, or that mutation
of the M5 coding sequence disrupted an miRNA binding site that served to downregulate wild-type M5 in vivo. Although the degree of M5 overexpression in
neurons was not high (M5 binding site density was comparable to that of
endogenously expressed MRs), it is also possible that the increase in M5∆
expression compared to wild-type was related to transient expression conditions.
The use of primary cultured neurons as an exogenous expression system
for radioligand assays, along with an enhanced protocol for RNAi-based
expression knockdown in long-term cultures, were novel technical developments
that proved crucial to the identification of the AGAP1-dependent endocytic
recycling pathway. We used cell-surface radioligand binding as an indirect
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measure of M5 trafficking, as related methodologies (including biotinylation,
antibody feeding / stripping, and covalent receptor labeling) proved either
unfeasible or lacking adequate sensitivity for use in this experimental system.
Based on pilot experiments in tissue culture cells and primary cultured neurons,
we chose time points for agonist treatment and receptor recycling (washout)
conditions that corresponded to steady-state MR binding site labeling. It should
be noted that 1) our assay could not identify the origin of binding sites appearing
at the cell surface after agonist washout, and 2) the agonist-internalized receptor
values reflect not the total percentage of cell surface receptors internalized, but
rather the surface density reached by virtue of steady-state balance between
rates of internalizing and recycling M5 (Szekeres et al., 1998b). Given the time
frame of our primary neuron experiments compared to their time of culture, and
since interference from newly synthesized receptors was reduced by
cycloheximide inhibition in tissue culture cell experiments, M5 surface density
values obtained after agonist washout almost certainly reflect the re-appearance
of endocytically recycled receptors. Additionally, since we observed M5∆ to be
deficient in terms of the magnitude of receptor reappearance after agonist
washout, differential internalization rates are likely not confounding our
interpretation of the recycling assay data.
We observed a significantly larger reduction in the steady-state surface
expression of M5∆ receptors compared to wild-type after chronic (4-day) agonist
treatment. This result implies that AGAP1-dependent endocytic recycling may
play a role in the avoidance of M5 receptor down-regulation under conditions of

152

sustained stimulation. To test this hypothesis directly would require
determination of the effects of AGAP1-mediated trafficking abrogation on
signaling pathways coupled to M5 activation. The cultured neuron exogenous
expression system is not appropriate for such experiments, as the presence of
non-M5 muscarinic receptors and the stoichiometric effects of overexpression
greatly complicate data interpretation. In addition, endogenous M5 receptors are
expressed at very low abundance in neurons, and M5-selective agonists do not
exist. The dopaminergic neurons of the ventral midbrain have been reported to
express M5 receptors to the exclusion of other MR subtypes, and their activation
potentiates the release of dopamine (Weiner et al., 1990; Yeomans et al., 2001).
However, the heterogeneous nature of primary midbrain cultures precludes their
use in biochemical assays of M5 effector activation. In the following chapter, we
describe an experimental approach whereby dopamine release magnitude is
examined as a functional readout of endogenous M5 receptor activity in genetic
models of M5 and AP-3 dysfunction.

153

6

ACETYLCHOLINE-STIMULATED DOPAMINE RELASE:

PHYSIOLOGICAL CONSEQUENCES OF AGAP1-MEDIATED M5
RECYCLING

6.1 Summary
Acetylcholine modulates the release of dopamine in the striatum through a
complex pattern of muscarinic and nicotinic receptor-mediated mechanisms. In
this chapter, we describe ongoing, collaborative experiments examining the role
of AGAP1 / AP-3-mediated endocytic recycling on the function of M5 in the
striatum. We use mouse models of M5 and AP-3 dysfunction to investigate
stimulated dopamine release in the context of muscarinic receptor activation. We
confirm in vitro and ex vivo that presynaptic M5 is required for the dopamine
release-potentiating activity of muscarinic receptor agonists in the striatum.
Preliminary data suggest that loss of AGAP1 / M5 i3 loop interaction leads to a
long-term down-regulation of M5 signaling efficacy, resulting in decreased levels
of stimulated dopamine release.

6.2 Introduction
The M5 muscarinic acetylcholine receptor mediates the ability of ACh to
potentiate dopamine release from midbrain dopaminergic neurons. M5 is the
only muscarinic receptor detectably expressed in ventral tegmental area (VTA)
and substantia nigra pars compacta (SNc) dopaminergic neurons of the
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nigrostriatal and mesolimbic pathways, respectively (Weiner et al., 1990). These
midbrain dopaminergic neurons are innervated somatodendritically by brainstem
Ch5/Ch6 cholinergic afferents, and receive modulatory ACh input at striatal
presynaptic terminals through the synaptic or volumetric action of the giant
aspiny cholinergic interneurons. An in vivo electrochemical study demonstrated
that electrical stimulation of Ch5/Ch6 cholinergic nuclei resulted in a slowly
activating, sustained release of dopamine in the nucleus accumbens (NAcc).
This ACh-stimulated dopamine release event was observed in wild-type mice and
rats, was blocked by the muscarinic receptor antagonist scopolamine, and was
completely abolished in M5 -/- mice (Yeomans et al., 2001; Forster et al., 2002).
In addition, infusion of either the muscarinic antagonist atropine or antisense
oligonucleotides directed against M5 into the rat ventral midbrain was seen to
decrease the behavioral sensitivity to rewarding hypothalamic stimulation, a
process dependent on the mesolimbic dopamine system (Yeomans et al., 2001).
Electrophysiological studies indicate that sustained activation of midbrain
dopaminergic neuron muscarinic receptors increases firing rate and bursting
activity as a result of depolarization, most likely through an inhibition of K+
currents (Gronier and Rasmussen, 1998; Fiorillo and Williams, 2000).
M5 muscarinic receptors also mediate the presynaptic modulatory actions
of ACh on dopaminergic neurons projecting to the striatum. In studies of
superfused acute mouse striatal slices, the genetic ablation of M5 was seen to
decrease the ability of a muscarinic receptor agonist to potentiate K+-stimulated
dopamine release. As this M5-mediated potentiation mechanism was insensitive
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to the action potential blocker tetrodotoxin, receptors located at dopaminergic
neuron terminals were implicated (Yamada et al., 2001a; Zhang et al., 2002b).
Further support for a presynaptic M5 receptor mechanism came from studies of
dopamine release from rat striatum synaptosomes (an isolated nerve terminal
preparation); the muscarinic agonist oxotremorine-M was seen to be releasepotentiating in the absence of intact neurons. In the synaptosomal system, MRmediated dopamine release potentiation was dependent on KCNQ2/3 K+ channel
activity; thus, local depolarization via Im inhibition is likely responsible for M5ʼs
activity at the dopaminergic presynaptic terminal (Martire et al., 2007).
In the preceding chapters, we demonstrated that interaction between
AGAP1 and M5 is required for efficient endocytic recycling of agonist-internalized
receptors in neurons. By maintaing cell surface pools of signaling-competent
receptors, this endocytic recycling mechanism may underlie the ability of M5 to
maintain activity under conditions of sustained stimulation. In this chapter, we
describe experiments examining the role of AGAP1 / AP-3 mediated recycling of
presynaptic M5 receptors in the potentiation of dopamine release. In
collaboration with outside laboratories, we studied evoked striatal dopamine
release using the techniques of synaptosome superfusion and fast scan cyclic
voltammetry. While the former technique allows definitive isolation of presynaptic
mechanisms, the latter electrochemical approach provides high temporal
resolution and quantitative dopamine concentration measurements in a tissue
system with intact local morphology. To model M5 activity and/or trafficking
dysfunction, we used the M5 -/- (knockout) and the spontaneous δ-Adaptin-null
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mocha mouse models. The development of an AGAP1 -/- mouse was not
pursued, as we reasoned that genetic deletion of this protein would result in a
generalized and severe secretory pathway disruption phenotype as a result of
Arf1 dysregulation. Instead, we developed a mouse in which the previously
characterized M5∆ receptor was expressed in place of wild-type M5. We
hypothesized that inhibition of AGAP1 or AP-3 function would inhibit recycling of
desensitized M5 receptors at striatal dopaminergic terminals, resulting in a
decreased basal or activity-dependent sensitivity to MR-stimulated dopamine
release.

6.3 Results
6.3.1 Generation of the M5 ∆369-386 mouse
In order to study the effect of AGAP1-mediated trafficking on the function
of the M5 muscarinic acetylcholine receptor in vivo, we generated a mutant
mouse in which the domain-of-interaction deleted M5 ∆369-386 receptor (M5∆)
was expressed in place of wild-type M5. A homologous recombination-based
“knock-in” approach was used to replace the single-exon wild-type Chrm5 coding
sequence with the mutant Chrm5∆369-386 allele in C57BL/6 mouse ES cells. The
targeting strategy was designed and M5∆ mutant mouse generation was
performed by Ozgene Pty. Ltd. (Bentley, Australia) as summarized in figure 6.1A.
Targeted ES cell colonies were sequenced to confirm deletion of the M5 369-386
coding region. Blastocyst injection of targeted ES cells resulted in germline
transmission of the Chrm5∆369-386 allele. The resultant mouse was subsequently
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Figure 6.1 M5∆369-386 knock-in mouse generation.
(A) Targeting and
screening strategy was designed by Ozgene, Pty. Ltd.
Top, wild-type M5
(Chrm5) locus; middle, targeted (Chrm5 ∆369-386 / M5∆) locus; bottom, ∆Neo
locus after Cre-mediated excision of LoxP-flanked selection cassette. Restriction
fragment lengths indicate expected band sizes for Southern blot screening of
targeted ES clones. (figures courtesy of Ozgene) (B) PCR genotyping of mice
using primers flanking the ∆369-386 site. (C) RT-PCR from total RNA extracted
from midbrains of M5 ∆/∆ and wt/wt mice. Primer set was identical to (C). RT,
reverse transcriptase. (D) [3H]NMS binding to mouse cerebral blood vessel
membranes isolated from mice of indicated genotypes. Data represent a single
experiment performed in triplicate on tissue pooled from two animals.
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mated to a Cre recombinase-expressing transgenic line to excise the loxP siteflanked neomycin selection cassette from the Chrm5 locus (figure 6.1A). From
these founder animals, a congenic C57BL/6 background M5∆ mouse colony was
established. M5 ∆/∆ animals were healthy and fertile, and we observed no
obvious phenotypic differences (gross appearance or home cage behavior)
between ∆/∆, ∆/wt and wt/wt mice. Polymerase chain reaction (PCR)-based
genotyping of mouse tail genomic DNA using oligonucleotide primers flanking the
deleted region of M5∆369-386 yielded products of expected sizes for M5 ∆/∆, ∆/
wt and wt/wt mice (figure 6.1B). We next confirmed that the M5 ∆ mRNA was
expressed in vivo by reverse transcription PCR (RT-PCR) of total RNA isolated
from midbrains of M5 ∆/∆ and wt/wt mice. Using the genotyping primer set, we
detected PCR products of the expected sizes from reverse transcribed ∆/∆ and
wt/wt mouse RNA (figure 6.1C). Confirmation of M5∆ protein expression was
complicated by the lack of subtype-selective antibodies or radioligands
appropriate for the detection of low-abundance native M5 receptors. Since M5 is
the sole muscarinic receptor responsible for the dilatory effects of ACh on
cerebral arteries and arterioles (Yamada et al., 2001a), we reasoned that an
absence of M5 expression would be detectable in this tissue by quantification of
the total MR population. To test this, we prepared membranes from cerebral
blood vessels isolated by density centrifugation from M5 wt/wt, ∆/∆, and -/mouse brains and assayed for muscarinic receptor density by [3H]NMS
radioligand binding. In a single experiment consisting of tissue pooled from two
animals of each genotype, binding of [3H]NMS was greater in both wt/wt and ∆/∆
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blood vessel membranes than in -/-, consistent with the expression of M5
receptor protein in M5 ∆/∆ animals (figure 6.1D).

6.3.2 Expression of AP-3 and AGAP1 in dopaminergic neuron terminals
As we wished to study the effects of AGAP1- and AP-3-mediated
endocytic recycling on presynaptic M5 receptor function at striatal dopaminergic
terminals, we first examined the distribution of the AP-3 complex in primary
cultured rat midbrain dopaminergic neurons. Mature (14 DIV) midbrain cultures
yielded a heterogeneous population of neurons, of which 25-50% were positive
for the dopaminergic marker tyrosine hydroxylase (TH) (figure 6.2A). We
observed punctate δ-Adaptin staining in thin, aspiny processes of TH-positive
neurons, consistent with the presence of AP-3 endosomes in the axons of
dopaminergic neurons (figure 6.2A). Next, we prepared synaptosomes from
wild-type mouse striatal tissue in order to confirm the presence of AP-3 and
AGAP1 proteins in presynaptic terminal compartments. Immunoblot analysis of
synaptosome-containing fractions detected the presence of AGAP1, ubiquitously
expressed AP3µ3A, and brain-specific AP3β3B, with possible enrichment of
AGAP1 and AP3β3B indicated (figure 6.2B). The results of these experiments
were consistent with the imaging data presented in chapter four, which
demonstrated δ-Adaptin localization in presynaptic-adjacent compartments of
cultured hippocampal neurons.
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Figure 6.2 Expression of AGAP1 and AP-3 in dopaminergic neurons and
nerve terminals. (A) Primary cultured rat ventral midbrain neurons were fixed,
immunostained and imaged by confocal microscopy. Left: Cells immunostained for
the dopaminergic neuron marker tyrosine hydroxylase (TH; green) and the panneuronal marker MAP-2 (red). Right: Cells immunostained for !-adaptin (green)
and TH (red), with area enlarged as indicated. Scale bars = 50 µm. (B) AGAP1,
ubiquitous AP3µ3A, neuron-specific AP3"3B and the synaptic vesicle marker synaptophysin were detected by immunoblot in synaptosomes prepared from mouse
striatum. H, homogenate; S1, supernatant 1 fraction; P1, pellet 1 fraction; P2!,
synaptosome fraction. Protein content of each fraction was equalized before
SDS-PAGE separation.
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6.3.3 M5 receptor activation potentiates stimulated dopamine release from
striatal synaptosomes
In order to confirm previous reports of a dopamine release-potentiating
function of M5 receptors localized to presynaptic dopaminergic terminals,
neurotransmitter release experiments were performed in collaboration with Dr.
Hugh Hemmings (Weill Cornell Medical School, New York). Synaptosomes
isolated from the striata of M5 wt/wt or M5 -/- animals were loaded with
[3H]dopamine and [14C]glutamate, and stimulated release of neurotransmitter
was measured in a superfusion device. Incubation of striatal synaptosomes with
the muscarinic receptor agonist oxotremorine-M (oxo-M) significantly potentiated
the K+-stimulated release of [3H]dopamine from wild-type, but not M5 -/- animals
(figure 6.3A). Oxo-M treatment did not alter the magnitude of [14C]glutamate
release in either M5 wt/wt or -/- animals (figure 6.3B). Thus, activation of
presynaptic M5 muscarinic receptors potentiated stimulated dopamine release in
a neurotransmitter-specific manner, confirming previous studies performed in
wild-type and M5 -/- mouse striatal slices (Yamada et al., 2001a) and in rat
striatal synaptosomes (Martire et al., 2007).

6.3.4 Fast scan cyclic voltammetric studies of striatal dopamine release
Although the neurotransmitter release studies described above positively
identified presynaptic M5 as a dopamine release-modulating receptor, the
relatively low (≥ 2 minute) temporal resolution and in vitro nature of synaptosome
superfusion limits the utility of this experimental system to the study of trafficking-
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Figure 6.3 Activation of M5 receptors potentiates dopamine release from
mouse striatum synaptosomes. Striatal synaptosomes prepared from mice of
indicated genotypes and were simultaneously loaded with [3H]dopamine and
[14C]glutamate. K+-stimulated neurotransmitter outflow was measured in the
presence and absence of oxotremorine-M. (*): (A)(*): P< 0.05, Bonferroni posttest / two-way ANOVA P= 0.06.
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dependent functions of M5. To overcome this, we collaborated with Dr. David
Sulzer (Columbia University, New York) to perform fast scan cyclic voltammetric
(CV) recordings of stimulated dopamine release from acutely prepared mouse
striatal slices. We first compared dopamine release magnitude after electrical
stimulation in M5 -/- and wild-type mouse dorsolateral striatum, an area primarily
innervated by nigrostriatal dopaminergic neurons projecting from the SNc. An
approximately 40% reduction in the extracellular concentration of released
dopamine was observed in M5 -/- mice as compared to wild-type (figure 6.4A).
Next, we performed experiments in which striatal dopaminergic terminals were
repeatedly electrically stimulated before and after the addition of the nonselective muscarinic receptor agonist oxo-M to the perfusion buffer. In contrast
to our observations in superfused synaptosomes, oxo-M rapidly and strongly
decreased the concentration of dopamine released after electrical stimulation in
both wild-type and M5 -/- slices. However, this effect was larger in magnitude for
M5 -/- as compared to wild-type mouse striata, consistent with a releasepotentiating function of M5 receptors (figure 6.4B).
Next, we examined the role of AGAP1 interaction and AP-3 in the
dopamine release-potentiating function of M5. We first used striatal slices from
M5∆ mice to model M5 recycling dysfunction through AGAP1 interaction loss-offunction. Extracellular concentrations of dopamine released after electrical
stimulation were decreased in M5 ∆/∆ striata compared to wild-type controls, with
a magnitude comparable to that seen in M5 -/- animals (figure 6.4A). However,
we observed no difference in magnitude or pattern of stimulated dopamine
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Figure 6.4 Analysis of dopamine release in M5 -/- and M5 ∆/∆ animals by
fast-scan cyclic voltammetry. (A) Measurement of dopamine release evoked
from single electrical stimuli in striatal slices prepared from mice of indicated
genotypes. (B) and (C) Evoked dopamine release from M5 +/+, -/- and ∆/∆
striata was measured at two minute intervals after addition of 10µM
oxotremorine-M (oxo-M) to the perfusion bath where indicated. In (C), oxo-M
treatment is followed by a 20-minute washout period. Data are normalized to
release at time=0.
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release inhibition between M5 ∆/∆ and wild-type striata after either ten minutes of
oxo-M administration or subsequent washout (figure 6.4C). We next examined
the suitability of the mixed genetic background, Ap3d1-null mutant mocha (mh)
mouse as a model for neuronal AP-3 dysfunction. Immunoblot analysis of wholebrain lysate from Ap3d1 wt/wt, wt/mh, and mh/mh mice confirmed the absence of
both ubiquitous and brain-specific AP-3 subunits in mh/mh animals, with
decreased AP-3A and AP-3B subunit abundance apparent in wt/mh
heterozygotes as compared to Ap3d1 wt/wt or C57BL/6 controls. AGAP1 protein
levels were not affected by Ap3d1 genotype, however (figure 6.5A). We
observed no difference in the ability of oxo-M to inhibit stimulated striatal
dopamine release between Ap3d1 mh/mh and mh/wt heterozygote mice,
although the overall degree of oxo-M inhibition was larger than that observed in
C57BL/6N background mice (figure 6.5B). Taken together, these preliminary
data suggest a decreased steady-state activity of M5∆ receptors as compared to
M5 wild-type, but do not support the involvement of either AGAP1 interaction or
AP-3 activity in the dynamic regulation of presynaptic M5 function.

6.4 Discussion
The experiments described in this chapter examined muscarinic receptor
modulation of dopamine release as a functional readout of M5 receptor activity.
We confirmed a presynaptic function of the M5 muscarinic acetylcholine receptor
in the potentiation of stimulated dopamine release through superfusion of nerve
terminal isolates (synaptosomes) derived from wild-type and M5 -/- mice. By
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Figure 6.5 Analysis of dopamine release in mocha mice by fast-scan cyclic
voltammetry. (A) Immunoblot detection of AP-3 subunits and AGAP1 from
mouse brain lysates of indicated genotypes. (B) Evoked dopamine release from
mocha (Ap3d1 mh/mh) or heterozygous control (+/mh) mouse striatum was
measured at two minute intervals after addition of 10µM oxotremorine-M (oxo-M)
to the perfusion bath where indicated. Data are normalized to release at time=0.
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examining this phenomenon in striatal slices with the quantitative and temporally
sensitive CV method, we determined that elimination of M5 receptors 1)
decreased the concentration of dopamine released by electrical stimulation, and
2) increased the degree to which a saturating concentration of the non-selective
muscarinic agonist oxo-M depressed evoked dopamine release. These novel
observations are consistent with a presynaptic release-potentiating function of
M5, and indicate that this potentiation occurs within an overall context of MRmediated inhibition of dopamine release.
Our subsequent experiments in the CV system aimed to determine the
effect of the AGAP1 domain-of-interaction deletion and the absence of AP-3 on
the identified M5-mediated dopamine release effect. Although the results
described have not been finalized, a number of trends are clear. Stimulated
dopamine release is decreased in the M5 ∆/∆ mouse compared to wild-type,
suggesting that M5∆ receptor signaling efficacy is down-regulated. However,
oxo-M treatment did not differentially attenuate stimulated dopamine release in
M5 ∆/∆ and wild-type mice, nor was desensitization-like rundown of dopamine
release potentiation observed for ∆/∆. Similarly, we observed no difference
between mocha mutants (mh/mh) and heterozygous controls (mh/wt) in the oxoM treatment experiment. In the latter case, we chose to use mh/wt controls, as
the Ap3d1wt allele is maintained in repulsion to the recessive grizzled (gr)
mutation in this strain. Homozygous gr/gr animals are sub-viable, and the
genetic mechanism resulting in the grizzled phenotype has not been determined
(Burwinkel et al., 1998). We are currently examining evoked and oxo-M
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modulated dopamine release for animals of all genotypes in the mocha strain
(mh/mh, mh/wt, and wt/wt). However, interpretation of these dopamine release
data may be complicated by the generalized dysfunction of nerve terminals in
Ap3d1 -/- animals (Newell-Litwa et al., 2007). In addition, examination of oxo-Minduced [3H]dopamine outflow from synaptosomes prepared from M5 ∆/∆ striata
may lend further support for our model of down-regulation of M5∆ receptors in
vivo.
While our preliminary data do not support a role of either AGAP1
interaction or AP-3 in the short-term maintenance of M5 sensitivity under
sustained agonist stimulation, the evoked release of dopamine was apparently
lower in animals expressing the M5∆ receptor. If these results are confirmed in
further experimental replicates, how do we reconcile the seemingly M5 -/- -like
evoked release and +/+ -like oxo-M stimulated release results observed in
M5 ∆/∆ striata? Based on our observation that long-term agonist stimulation of
M5 receptors expressed in cultured neurons leads to significant down-regulation
of M5∆, but not M5 wild-type, receptors, we propose the following mechanism:
Under normal conditions, dopaminergic terminal M5 receptors receive constant
ACh input from the highly arborized, tonically active giant aspiny cholinergic
interneurons. A slow, AGAP1-dependent recycling mechanism is required for the
maintenance of cell-surface M5 receptor density under this constant stimulation
condition. In the absence of AGAP1 interaction, activated M5 receptors fail to
recycle, leading to long term down-regulation of plasma membrane receptors. In
our evoked dopamine release experiments, a moderate striatal ACh tone results
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in partial receptor occupancy and stimulation; the greater surface density of M5
wild-type as compared to M5∆ receptors leads to an increase in Gαq-stimulated
PIP2 hydrolysis and greater KCNQ2/3 channel inhibition, resulting in enhanced
membrane depolarization and an increase in the magnitude of dopamine release
detected. In the oxo-M stimulation experiments, however, the agonist was
applied at a high concentration, leading to saturation of the Gαq-PIP2-KCNQ2/3
signaling pathway even at the low M5 surface receptor density hypothesized to
exist in the M5 ∆/∆ mouse. Further complicating interpretation of the latter
experiment was the fact that muscarinic receptor agonist application is expected
to decrease tonic ACh release through activation of cholinergic interneuron M4
autoreceptors, which may in turn influence the activity of nicotinic ACh receptors
present on dopaminergic terminals. Confirmation of our proposed model
mechanism awaits further experimental replicates; in addition, the use of
muscarinic and/or nicotinic antagonists in the electrically-evoked dopamine
release experiments could provide evidence supporting a role of M5 receptor
density in the observed M5 ∆/∆ phenotype.
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7

CONCLUSIONS AND FUTURE DIRECTIONS

Muscarinic receptors play an essential role in the regulation of mammalian
physiology. Nearly every tissue in the body depends on the regulated
transduction of cholinergic signals by a combination of muscarinic receptors for
normal function. In the brain, mediation of cholinergic neurotransmission by
muscarinic receptors is required for such basic processes as attention, arousal,
movement, motivation, learning and memory, the disruption of which is implicated
in the pathology of a number of currently intractable diseases. However, the
ubiquity of MRs, their overlapping mechanisms of signal transduction, and their
pharmacological similarity have greatly hindered progress towards understanding
the cell- and subtype-specific function and regulation of these receptors. Indeed,
development of compounds or techniques capable of identifying or modulating
the activity of individual muscarinic receptor subtypes in isolated populations of
cells would be of great use both scientifically and clinically.
The function of GPCRs depends critically on temporally and spatially
coordinated protein-protein interactions between cytoplasmic receptor domains
and signal-transducing and/or regulatory molecules. In the muscarinic receptors,
one of these cytoplasmic regions, the third intracellular loop, is exceptionally
large and divergent in sequence across the five MR subtypes. Although some
functions have been assigned to the MR i3 loops, the phylogenetic sequence
conservation of this region implies the presence of critical protein interaction
domains that have yet to be identified. In an effort to uncover such molecules,
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we performed yeast two-hybrid screens using as baits the five muscarinic
receptor i3 loop domains. We isolated three potential muscarinic receptor
interacting proteins, AGAP1, SNX20, and UHRF1BP1L, on which biochemical
protein-protein interaction analysis was performed with the intention of identifying
a single candidate for subsequent investigation. We chose to study the M5i3
binding protein AGAP1, as we observed clear, domain-delineated interaction
between M5 and AGAP1 in vitro, and since published functional characterizations
of this Arf GAP protein suggested a potential role in receptor trafficking.
The M5 muscarinic receptor is the least-expressed MR in mammals, and
its molecular biology and regulation have been little studied. Thus, a number of
our basic findings on the expression and trafficking patterns of this receptor were
novel. For instance, we demonstrate that exogenously expressed M5 receptors
undergo endocytic recycling in HEK-293T cells, with a time course consistent
with trafficking through the “slow” endocytic recycling compartment-dependent
pathway (Grant and Donaldson, 2009). We also show that M5 receptors
expressed in primary cultured hippocampal neurons distribute uniformly in the
plasma membrane and are not excluded from either the somatodendritic or
axonal compartments. On the functional level, we confirmed a dopamine
release-potentiating activity of M5 receptors localized to nigrostriatal and
mesolimbic neuron terminals. Although this presynaptic modulatory function was
previously examined in [3H]dopamine release experiments performed on rat
striatum synaptosomes and both wild-type and M5 -/- mouse striatal slices
(Yamada et al., 2001a; Martire et al., 2007), our study is the first to apply the fast
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scan cyclic voltammetry method to the examination of M5-specific modulation of
endogenous dopamine release in mouse striatum.
Of greatest overall significance, however, is our demonstration of a
neuron-specific trafficking function for the AGAP1-M5 interaction. Our results
demonstrate that in the primary cultured rat neuron exogenous expression
system, interaction with AGAP1 is required for efficient endocytic recycling of M5
receptors after agonist-stimulated endocytosis. In non-neuronal cells, AGAP1
was previously demonstrated to regulate the trafficking of lysosomally-targeted
integral membrane proteins by virtue of its ability to bind to the AP-3 adaptor
protein complex (Nie et al., 2003). We found that subunits of both the
ubiquitously expressed AP-3A and neuron-specific AP-3B complexes associated
with the M5 i3 loop in an AGAP1-dependent manner, and that the endocytic
recycling of M5 in neurons was sensitive to depletion of AP-3B. The AP-3A
complex has been shown to regulate the endocytic trafficking of membrane
proteins to lysosomes and lysosome-like organelles, while in neurons the AP-3B
complex is known to mediate the formation of a subset of synaptic vesicles, and
is required for the targeting of certain membrane proteins to the nerve terminal
(Kantheti et al., 1998; Blumstein et al., 2001; Salazar et al., 2004b). To our
knowledge, however, neither AGAP1, AP-3A nor AP-3B have been implicated in
the mechanism of endocytic recycling, although the AGAP-like protein ACAP1
was found to promote the recycling of internalized transferrin receptors (Dai et
al., 2004). Our observation of AGAP1- and AP-3-dependent M5 receptor
recycling is therefore indicative of a previously undescribed GPCR trafficking
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pathway. In addition, our results strongly suggest that the mechanism of M5
recycling in neurons relies upon a protein-protein binding event between the M5
i3 loop and an AGAP1-AP-3B complex. Thus, AGAP1 may possess targetrecognition properties in addition to its characterized Arf1 regulatory function,
which further suggests that members of the AP-3 holocomplex (such as AGAP1
and BLOC-1) may function in the recognition of sorting signal sequences to a
greater degree than previously recognized.
Further characterization of the AGAP1-mediated recycling of M5 receptors
may reveal sorting signals or regulatory mechanisms important for the function of
other classes of GPCRs. We identified a 23-amino acid region in the i3 loop of
M5 that was required for AGAP1 interaction and efficient endocytic recycling in
neurons. We also identified a series of residues in this i3 loop domain of
interaction whose mutation eliminated or reduced AGAP1 binding activity. The
sequence of these critical residues resembled, but did not exactly conform to
recognized tyrosine- and dileucine-based sorting signals commonly present on
GPCR i3 loop or C-terminal tail regions (Bonifacino and Traub, 2003). To date,
relatively few endocytic targeting motifs have been identified; thus, the precise
identification of an AGAP1 binding motif would expand our understanding of the
structural determinants of GPCR recycling, and could help identify other GPCRs
whose endocytic traffic is AGAP1-dependent. In addition, a deeper mechanistic
understanding of AGAP1 / AP-3-mediated M5 recycling could potentially reveal
points at which this putative trafficking pathway is regulated. The targeting of
endocytosed GPCRs to the degradative or recycling pathways plays a critical
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role in determining the effect of sustained stimulation on surface receptor density,
and in turn the magnitude of second messenger responses to neurotransmitters.
An emerging model of neuronal plasticity implicates regulation of glutamate
channel trafficking as a key mechanism of signal “gain”-tuning, by which a
neuronʼs up- or down-regulation of surface receptor levels acts to alter its
response to a given synaptic input (Turrigiano, 2008). An analogous mechanism
has been shown to tune GPCR signaling responses in neurons and other cells,
the regulation of which may occur at the level of GPCR targeting sequence
recognition (Hanyaloglu and von Zastrow, 2008). For example, activity-induced
receptor ubiquitination was shown to shift targeting of a GPCR from the recycling
to the degradative pathways (Shenoy et al., 2001) and phosphorylation of the
AGAP1-like molecule ACAP1 is required for its binding to, and its recycling
pathway targeting of β-Integrin (Li et al., 2005). Continuing biochemical and cell
biological studies of the M5 - AGAP1 interaction may shed light upon such posttranslational modifications regulating M5 trafficking.
The study of M5 function in vivo is complicated by the receptorʼs low
abundance relative to other muscarinic receptors and the lack of pharmacological
tools appropriate for the isolation of subtype-specific signaling events. In order to
better understand the physiological consequences of AGAP1-dependent M5
receptor recycling, we generated an i3 loop domain-of-interaction mutant (M5∆)
mouse. M5 is the only muscarinic receptor detectably expressed in midbrain
dopaminergic neurons, in which it mediates the dopamine release-potentiating
activity of ACh (along with ionotropic nicotinic ACh receptors) (Forster et al.,
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2002). From terminals of these neurons present in striatal slices, we detected a
decrease in the magnitude of evoked dopamine release in mice expressing M5∆
receptors as compared to wild-type. As we observed chronic agonist treatment
to result in surface density down-regulation of M5∆, but not M5 wild-type
receptors in vitro, we hypothesized that abrogation of AGAP1 / AP-3-mediated
endocytic recycling of M5 results in down-regulation of M5 receptor signaling at
striatal dopaminergic terminals in vivo. If these data are indeed confirmed by
additional replicates, our model predicts an important role for the AGAP1-M5
interaction in the maintenance of tonic basal ganglia function. The interaction
between cholinergic and dopaminergic activity in the striatum influences the
activity and plasticity of the medium spiny output neurons, and is in turn required
for proper coordination of motivated locomotor activity (Pisani et al., 2007). As
the giant aspiny cholinergic interneurons provide a constant ACh tone in the
striatum, an efficient endocytic recycling mechanism may be required for the
maintenance of M5 signaling efficacy at the presynaptic dopaminergic terminal.
Our experiments examined the release-modulating functions of dopaminergic
nerve terminal receptors. However, M5 receptors localized to somatodendritic
compartments of midbrain dopaminergic neurons also function to stimulate
dopamine release (Yeomans et al., 2001; Miller and Blaha, 2005). Indeed, Ch5/
Ch6 cholinergic afferent-stimulated dopamine release from VTA neurons is
characteristically prolonged in duration, suggesting that M5 endocytic recycling
may play a role in sustaining sensitivity to ACh (Forster et al., 2002). In vivo
chronamperometric measurements of dopamine release in the M5∆ mouse could
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reveal AGAP1 interaction-dependent postsynaptic functions of M5, as could
electrophysiological or Ca2+ imaging studies of isolated dopaminergic neurons.
In the process of examining the functional role of the putative AGAP1-M5
interaction, we developed novel technical approaches whose application extends
beyond the present project. First, the use of primary cultured rat neurons as an
expression system for the analysis of exogenously-expressed receptors by
radioligand binding has, to our knowledge, not been described. Such a system
may prove useful for experiments involving brain-expressed receptors, as many
GPCRs are regulated in a cell type-specific manner, and the more commonly
utilized tissue culture cell systems may not adequately model neuronal
physiology. We also describe in this report a selection-based method for the
enrichment of shRNA-expressing primary neurons. For some targeted proteins,
we were able to achieve knockdown efficiencies of near 100%, which is a
considerable improvement upon previously reported techniques (Zeitelhofer et
al., 2007). We have recently developed cell-penetrating peptides targeting the
M5i3 domain of interaction with AGAP1, with the aim of using these molecules in
vitro and in vivo to acutely inhibit binding of AGAP1 to M5. In combination with a
recently described M5 receptor positive allosteric modulator with >30-fold
selectivity over the other four muscarinic receptor subtypes (Bridges et al., 2009),
such tools may greatly facilitate the investigation of M5-specific and AGAP1dependent physiology.
The dysfunction of both M5 receptors and the AP-3 complex have been
linked to the pathophysiology of schizophrenia. Schizophrenia is associated with
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increased activity of the mesolimbic dopaminergic pathway, and neuroleptic
drugs used to treat the disorder typically target the D2 dopamine receptor. The
M5 -/- mouse displays abnormalities in schizophrenia-related sensorimotor
behaviors, and is hyposensitive to psychostimulants, a condition indicative of a
reduction in striatal dopamine levels and consistent with a release-potentiating
effect of VTA M5 receptors (Wang et al., 2004; Thomsen et al., 2005; Thomsen et
al., 2007). Alterations in synaptic terminal morphology and function, including
decreased abundance of the AP-3 associated BLOC-1 protein Dysbindin, have
been observed in both schizophrenic humans and in the AP-3 null mocha mouse
(Talbot et al., 2004; Harrison and Weinberger, 2005). In addition, genetic linkage
studies have implicated variations of the M5 (Chrm5) and Dysbindin (Dtnbp1)
genes as conferring susceptibility to schizophrenia, the former in combination
with the dopaminergic neuron-expressed α7 nicotinic acetylcholine receptor
(Chrna7) gene (Schwab et al., 2003; De Luca et al., 2004). While the function of
AGAP1 had not been previously associated with the pathology of schizophrenia,
we observed binding of Dysbindin to the M5 i3 loop (presumably through an
indirect AGAP1/AP-3 interaction), and our data suggest a dopamine releaserelated functional link between M5 and an AGAP1/AP-3 trafficking protein
complex. Intriguingly, a recent genome-wide association study of common
variants linked with schizophrenia susceptibility in populations of European
ancestry identified the AGAP1 gene as the strongest single locus association,
though below the studyʼs significance threshold (P<5x10-8) (Shi et al., 2009).
Given these observations, further studies of the relationship between the M5 /
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AGAP1 interaction and schizophrenia are warranted, including 1) direct
examination of the role of Dysbindin in M5 trafficking; 2) investigation of the
dopamine release characteristics of mesolimbic tract terminals in the
medioventral striatum of M5∆ mice; 3) behavioral analyses of M5∆ mice; and 4)
determination of whether variations in the Chrm5, Dtnbp1, and AGAP1 genes
interact to confer schizophrenia risk.
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8

MATERIALS AND METHODS

8.1 Rodent Strains
All procedures involving animals were performed in accordance with the
National Institutes of Health Guide for the Care and Use of Laboratory Animals
and were approved by the Rockefeller University Institutional Animal Care and
Use Committee. Female adult (3-6 month old) timed pregnant Sprague-Dawley
rats were obtained from Charles River Labs or Taconic Labs. Breeding pairs of
C57Bl/6N mice were obtained from Charles River, and were bred in-house. The
M5-/- strain was a kind gift from Jürgen Wess (National Institute of Diabetes and
Digestive and Kidney Disease, Bethesda MD), generated as described (Yamada
et al., 2001a). The M5-/- strain was extensively backcrossed (>10 generations)
onto the C57Bl/6N background before receipt; mice were maintained as -/homozygotes, and heterozygote matings were performed when necessary for
generation of wild-type littermates. STOCK gr +/+ Ap3d1mh/J mice carrying the
mocha allele (mh), a spontaneous null mutation of the Ap3d1 gene (Lane and
Deol, 1974; Kantheti et al., 1998), were obtained from the Jackson Laboratory.
In this strain, the Ap3d1mh allele is maintained on a mixed background in
repulsion to the pigmentation mutant gr allele. Mice were maintained as
heterozygotes, as mh homozygotes were observed to be infertile. The Chrm5∆/∆
strain was generated and maintained as described below.
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8.2 Genotyping of Mice
Tail biopsies (0.5mm) of 3-4 week old weanling mice were solubilized
overnight at 55℃ in 130µl DirectPCR tail lysis reagent containing 0.75mg/ml
proteinase-K (Viagen Biotech). Proteinase K was deactivated at 85℃ for 45
minutes, and crude lysates (0.6µl) were used directly as template DNA for PCR
reactions (12µl). For PCR genotyping of the M5- allele (in which the Neo
selection cassette was still present (Yamada et al., 2001a)) a single PCR reaction
(annealing temp. 55℃) included a set of 3 primers: a Neo-specific forward primer
(5ʼ-TGG ATG TGG AAT GTG TGC GAG G), M5wt forward (5ʼ-TCC GTC ATG
ACC ATA CTC TA), and an M5 reverse primer (5ʼ-CCC GTT GTT GAG GTG
CTT CTA C) in a region of the M5 gene 3ʼ to the NEO disruption. For PCR
genotyping of the M5∆ allele, forward (5ʼ-AAG CCA AGG CCA CTG ACC CTG
TCT TTC A) and reverse (5ʼ-CCA GGC CTT TTG TTG AAG GGT CTT TGG ACA)
primers flanking the deleted region were used with a 61℃ annealing step. PCR
products were resolved by electrophoresis through a 2.5% agarose gel and
detected by UV illumination in the presence of ethidium bromide. Direct
sequencing of M5wt and M5∆ loci was performed on 2 purified PCR products
(QIAquick PCR purification kit, Qiagen) spanning the M5 coding sequence
amplified from tail DNA prepared as described above. Forward (5ʼ-AGA GGG
GAG GTA GCT CCA AAC AGA GAG TAG) and reverse (5ʼ-AGT TGG TAA CCT
GCT CAG CCT TTT CCC AGT) primer pairs for the 5ʼ product, and forward (5ʼTGG CAG AAG TCA AGA AGA GAA AAC CGG CTC ) and reverse (5ʼ-GGC AGA
TGA CAT TCC TTT AAC AAG CAA ACC) primer pairs for the 3ʼ product were
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amplified with the Expand High Fidelity PCR System (Roche) according to the
manufacturerʼs protocol, with 60.4℃ annealing steps. Mocha (+ Ap3d1mh / +
Ap3d1mh), grizzled (gr + / gr +) and heterozygote (+ Ap3d1mh / gr +) mice were
identified by coat color phenotype.

8.3 Generation of the M5∆369-386 Mutant Knock-in Mouse
Mutant mice carrying an AGAP1-domain-of-interaction deletion mutation in
the Chrm5 gene (“M5∆”) were generated by a homology-based “knock-in”
strategy by Ozgene, Inc. Briefly, PCR cloning from C57Bl/6 genomic DNA was
used to generate a targeting vector containing a PKG promoter-driven neomycin
resistance cassette (Neo) flanked by loxP sites , and 5ʻ and 3ʻ homology arms
used to target homologous recombination of the construct to the endogenous M5
locus. The 5ʻ homology arm contained the single M5 exon, in which the region
coding for residues 369-386 was deleted by PCR mutagenesis. In order to
facilitate screening of target clones, an SphI restriction site was engineered
following the 5ʼ LoxP sequence, and KpnI and BglII sites engineered following
the 3ʼ LoxP sequence. C57Bl/6-derived ES cells were electroporated with the
linearized targeting vector, and neomycin-resistant colonies were selected with
G418. Resistant clones were screened for proper homologous recombination by
Southern blot using a Neo probe with EcoRV digestion, and probes external to
the 5ʼ and 3ʼ targeting regions derived by PCR from C57Bl/6 genomic DNA: 5ʻ
probe (SphI digestion), 5ʼ-CTT TAG AAG GAA TGG TTT CAG GGC (forward), 5ʼCAT ACC TGG ATG GAA GGA CAT GG (reverse); 3ʻ probe (KpnI digestion), 5ʻ-
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CCT TAT TAG CAC TTG TCT GCT TCC G (forward), 5ʼ-AGG CTA TGT AGG
TAG GGA GAT GGC (reverse). Integration of the mutant M5∆ locus was
confirmed in targeted ES clones by sequencing, and clones were injected into
C57BL/6J-TyrcBrd blastocysts and implanted into pseudopregnant females.
Strongly chimeric male mice were crossed to transgenic C57Bl/6-Cre
recombinase females, and offspring were tested by Southern blot for
transmission of the M5∆ allele (with 5ʼ and 3ʼ probes as described above) and for
excision of the Neo cassette with BglII digestion using a probe directly 5ʼ to the
remaining LoxP site (PCR primers for probe were 5ʼ-TGT TAC GCT CTC TGC
AAC AGA ACC (forward), 5ʼ-TAT CTG GAG GTG CAA CTG GCT TAC (reverse)).
Males carrying the M5∆/∆Neo allele were crossed to C57Bl/6 females, and offspring
of genotype M5∆/∆Neo / ∆Cre were selected for breeding.

8.4 Constructs
The following expression vectors were used: for mammalian expression,
pcDNA 3.1(+) myc/His (Invitrogen), pEGFP-N3 and -C2 (BD Biosciences
Clontech), and pAAV-MCS (Stratagene); for yeast expression, pACTII, pAS2∆∆
and pLEX9 (Fromont-Racine et al., 1997); for bacterial expression, pGEX-4T and
pGEX-5X (Amersham / GE Life Sciences). For subcloning and/or TA cloning,
pCR Zero Blunt and pCR II Topo (Invitrogen) vectors were used, the latter
employing Taq polymerase for PCR amplification, and ligated according to the
manufacturerʼs protocol. The following plasmids were kind gifts, and were used
as templates for PCR cloning into appropriate expression vectors: pRSET-B-
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mCherry (R. Tsien), pCD-hM1,2,& 3 (E. Hulme), pcDNA3.1(-)-rM4 and pCD2-rM2
(T. Bonner).
Plasmid constructs were prepared using standard molecular cloning
techniques. PCR amplification was performed with Accuprime Pfx polymerase
(Invitrogen), and ligations with the Rapid DNA Ligation Kit (Roche). For
amplification of protein coding sequences from mouse, rat or human cDNA
libraries, a 2-step nested PCR approach was used to generate PCR products
with 5ʼ and 3ʼ restriction sites, allowing direct cloning into expression vectors
(primer sets are summarized in table 9.5). Most mammalian expression
constructs included a Kozak translation initiation sequence (5ʼ-GCC-ACC-ATGG-3ʼ) engineered into the coding sequence start position. mCherry N- and Cterminal fusion mammalian expression vectors were generated by PCR
amplification of the mCherry coding sequence and cloning into the XhoI PspOMI
or Asp718I and HindIII sites of pcDNA3.1(+) A, respectively. C-myc epitope tags
and GFP / mCherry fusions were created by in-frame cloning of cDNA PCR
products into appropriate vectors, with stop / start codons omitted as required.
N- or C-terminal HA or FLAG epitope tags were introduced by appending PCR
primers (HA, 5ʼ- TAT CCA TAT GAC GTC CCA GAC TAT GCC; FLAG, 5ʼ- GAT
TAC AAG GAT GAC GAC GAT AAG). Short (<75nt) coding sequences were
cloned by ligation of oligo duplexes containing 5ʼ and 3ʼ overhangs into
complimentary restriction sites. Sequences of all cloned fragments derived by
PCR or oligo duplex ligation were confirmed by sequencing.
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Point mutations were generated by site-directed mutagenesis from
plasmid DNA template using the Quick Change kit (Stratagene), DpnI digestion
of template DNA, and primer sets summarized in table 9.4. Deletion mutants and
internal HA tags were generated by amplification of appropriate 5ʻ and 3ʻ PCR
products containing, respectively, complimentary 3ʻ and 5ʻ sites for the 3ʼ distal
cutter BbsI, and subsequent 3-way ligation into expression vectors. Point- or
deletion- mutated regions were validated by sequencing, and restriction
fragments containing the desired mutations subcloned into the parent plasmid.
Truncation mutants for Y2H domain-of-interaction mapping were generated by
PCR from full-length template and cloned into pAS2∆∆ or pACT2.
Short hairpin RNAs (shRNAs; 19nt) targeting rat AGAP1, AP3β3B, and
δ-Adaptin (or non-targeting negative control) were designed using Oligoengine 2
software. Oligonucleotides were annealed and ligated into the BglII and XhoI
sites of pSuper.puro (Oligoengine) according to the manufacturerʼs protocol.
Transcribed shRNAs included a hairpin loop sequence of 5ʼ-UUC AAG AGA, and
yielded cleaved dsRNA products of 19nt with 3ʼ UU overhangs. At least 3
shRNA constructs for each target were created, and validated for target
knockdown by immunoblot before use in functional experiments. Targeted
sequences used for this study were 5ʼ-ACC CTA GAC GTG TCT CTC C
(AGAP1), 5ʼ-AAC GCA TCG ACC TGA TTC A (AP3β3B), GAG GAA ATG AAG
ACC ACG C (δ-Adaptin), and 5ʼ-GTT CCG AAC ACA CGC ACA A (non-targeting
control).
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8.5 RT-PCR
Wild-type, M5-/-, and M5∆/∆ mice were sacrificed by CO2 inhalation, and
ventral midbrains were dissected and snap-frozen in LN2. Tissue was
homogenized in 0.6ml TRIzol (Invitrogen) and total RNA extracted and EtOHprecipitated according to the manufacturerʼs protocol. RNA pellets were
dissolved in 45µl nuclease-free ddH20 and treated with 2U TURBO DNase
(Ambion) at 37℃ for 30 minutes. DNase was deactivated and RNA isolated by
TRIzol extraction / EtOH precipitation, and RNA pellets dissolved in 20µl ddH20.
RNA content was quantified by 260nm absorbance with a Nanodrop
spectrophotometer (Thermo Scientific), and 2µg total RNA was denatured and
reverse-transcribed with the High Capacity RNA-to-cDNA kit (Applied
Biosystems) according to the manufacturerʼs protocol. Negative control reactions
that omitted reverse transcriptase enzyme were performed in parallel. 1µl
reverse-transcribed cDNA (or negative controls) was used as template for a PCR
reaction performed exactly as described for the genotyping of M5∆ animals.

8.6 Yeast Methods
Saccharomyces cerevisiae haploid strains CG1945, Y187 and L40 were
obtained from BD Clontech, and used as described below (genotypes are listed
in table 9.7). The bait plasmid pAS2∆∆ and the prey plasmid pACTIIst were
derived from pAS2 and pACTII (BD Clontech), respectively, the former by
deletion of the CYH2 gene and HA fusion epitope (Fromont-Racine et al., 1997).
The pLEX9 bait plasmid was derived from pBTM116 (Vojtek et al., 1993).
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For transformation of yeast with plasmid DNA, cultures were grown in YPD
medium at 30℃ until log-growth phase (OD600 = 0.5-0.8). Cells were collected
by centrifugation (2000g, 10 minutes), washed with ddH20, centrifuged again,
and washed in TE-LiOAc (10mM tris, pH=7.5, 1mM EDTA, 100mM LiOAc). Cells
were centrifuged and resuspended in TE-LiOAc containing 45% polyethylene
glycol, 40µg heat-denatured herring testes carrier DNA, and 1µg plasmid DNA.
The transformation mixtures were incubated at 30℃ for 45 minutes, heat
shocked at 42℃ for 15 minutes, and the cells were collected by centrifugation.
After a final ddH20 wash and centrifugation, cells were plated on YNB-agar plates
supplemented with appropriate selection mixtures: For pAS2∆∆ and pLEX9
contructs, CSM-Trp; for pACTII contructs, CSM-Leu; for co-transformation, CSMTrp-Leu. Yeast plates were incubated at 30℃ for 3 days before assay or
isolation of clonal inoculum.
β-Galactosidase activity in yeast was determined by an X-Gal lift assay.
Yeast colonies were transfered from agar plates to Hybond-C membranes
(Amersham / GE Healthcare). Membranes were subjected to 2 freeze-thaw
cycles in LN2 to lyse yeast cells, and were then transferred to filter paper
saturated with Z-buffer (60mM Na2HPO4, 60mM NaH2PO4, 10mM KCl, 1mM
MgSO4, pH=7.0) containing 0.35% (v/v) β-mercaptoethanol, 1.67% (v/v) DMF
and 0.33 mg/ml X-Gal. Filters were incubated in sealed containers at 37℃ for
indicated intervals, and X-Gal chromogen development was fixed by incubation
of filters in 1M Na2CO3 for 1 minute, followed by a 1 minute rinse in ddH2O.
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Yeast two-hybrid (Y2H) screens were performed using a mating protocol
as previously described (Fromont-Racine et al., 1997; Flajolet et al., 2000). Y187
yeast was transformed as described above with pACTIIst or pACTII cDNA
libraries (rat and human, respectively), in which cDNAs were cloned-in frame with
the Gal4 AD. For each library, 20 million transformant colonies were collected,
pooled in YPD, and frozen in aliquots at -80℃. Rat or human MR i3 loops were
cloned into pAS2∆∆ or pLex9 vectors in-frame with the Gal4 or LexA DNA BD,
respectively, and transformed into the CG1945 or L40 strains, respectively. For
each screen, transformed bait strains were cultured to log growth in YNB + CSMTrp, and then mixed with a single thawed vial of the appropriate prey library
strain. Yeast were plated onto YPD-agar plates, and mating was allowed to
proceed for 4.5 hours at 30℃. Yeast was then collected in ddH20 and distributed
to 40 YNB-agar +CSM-Trp-Leu-His plates. A small amount of each screen was
reserved for plating on control YNB-agar+CSM plates: -Trp, total bait CFUs; -Leu,
total prey CFUs; and -Trp-Leu, total diploids (measuring mating efficiency).
Screen plates were incubated at 30℃ for 3-4 days, until interaction-positive
diploid colonies were observed on the His -selective media. [His+] colonies were
counted, and then assayed for activation of the LacZ reporter by X-Gal overlay:
10ml of warm liquid X-Gal mixture (0.5% (w//v) agar, 0.1% (w/v) SDS, 6% (v/v)
DMF, 0.04% (w/v) X-Gal was poured on each of the screen plates, allowed to
solidify, and incubated at 30℃ for 30 minutes to 18 hours (depending on speed
of color development). Blue colonies were then streaked onto -Trp-Leu-His
plates, grown for 3 days at 30℃, and β-Galactosidase activity was confirmed by
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lift assay as described above. Yeast cells from [His+][LacZ+] clones were
collected, lysed by heat and mechanical disruption, and cDNA library fragments
from pACTII plasmid DNA were amplified by PCR with the primer set 5ʼ-CGC
GTT TGG AAT CAC TAC AGG GAT G (forward) and 5ʼ-GAA ATT GAG ATG GTG
CAC GAT GCA C (reverse). PCR products were sequenced and analyzed by
BLAST. Clones with in-frame ORF sequences were cultured for 3 passages in
liquid YNB+CSM-Trp media, yeast was collected at log-phase growth by
centrifugation, extracts were prepared by heat and mechanical disruption of cells,
and DNA purified by NH4OAc precipitation. Rescued prey plasmid was
transformed into E. coli, amplified, and purified with standard techniques.

8.7 Mammalian Cell Culture and Transfection
Mammalian tissue culture cell lines unavailable from Greengard Lab
cryopreserved stocks were obtained from the American Type Culture Collection.
Cells were maintained in a humidified 5% CO2 atmosphere incubator, passaged
by trypsinization (0.25% [w/v] trypsin, 1mM EDTA in HBSS [Invitrogen]) every 3-4
days, and were cultured in the following media: HEK-293T, COS7 and A2058,
10% (v/v) in DMEM; CHO, 10% FBS in F12K; NIH-3T3, 10% BCS in DMEM;
RIN-m5f, 10% FBS in RPMI-1640. Cells were transfected with plasmid DNA
according to the manufacturerʼs protocols using Lipofectamine 2000 (Invitrogen)
for NIH-3T3 and RIN-m5f cells, or Fugene6 (Roche) for all other cell lines.
Lipofectamine 2000 was used for transfection of siRNA (Stealth; Invitrogen) in all
cell lines, with the medium GC Stealth control duplex (Invitrogen) used for
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negative controls. Stable transfection of neomycin resistance-containing
plasmids in CHO or HEK-293T cells was achieved by selection with 1mg/ml
G-418 (Invitrogen) 72 hours after transfection. After die-off was complete
(approximately 10 days), G-418 was reduced to a maintenance concentration of
100µg/ml, and individual clones were selected for growth by dilution plating and
subsequent cloning ring isolation.

8.8 Rat Hippocampal Neuron Primary Culture and Transfection
The culture of embryonic rat hippocampal neurons was performed
essentially as described (Goslin et al., 1998). Hippocampi from embryonic day
18-19 Sprague-Dawley rat embryos were dissected into 4℃ Ca+2 / Mg+2 -free
HBSS. The collected tissue was dissociated in 0.25% (w/v) trypsin / 1mM EDTA /
HBSS at 37℃ for 30 minutes. Hippocampi were rinsed twice in plating media
(Neurobasal medium [Invitrogen] containing 10% (v/v) FBS and 0.5mM Lglutamine), dissociated by trituration with a fire-polished Pasteur pipette, strained
through a 40µm filter, and collected by centrifugation. Cells were counted and
plated (at 10,000 cells / cm2 or 50,000 cells / cm2 for transfection experiments) in
plating media on either poly-L-Lysine -coated glass coverslips (BD Biosciences)
or poly-L-Lysine (PLL) -coated glass-bottomed dishes (Mattek) that had been recoated with 1mg/ml PLL. Cells were cultured in 24-well dishes at 37℃ in a
humidified 5% CO2 tissue culture incubator. After 24 hours, plating media was
replaced with NBM complete media (Neurobasal medium containing 2% B27 and
1% N2 supplements [Invitrogen], 0.5mM L-glutamine, and 10µM
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5-fluorodeoxyuridine [FDU]). Subsequently, 50% of the media was changed
every 5-6 days.
Mature hippocampal neurons (DIV 10-13) were transfected according to a
modified calcium phosphate method (Jiang and Chen, 2006) using a commercial
transfection kit (Invitrogen). Growth media was reserved and replaced with new
NBM complete. Plasmid DNA (1µg) combined with CaCl2 was added slowly to
2x HBS, mixed gently, and incubated for 15-20 minutes. Precipitates were added
to coverslips or glass-bottomed dishes, and neurons were incubated for 2.5
hours. Media was then removed and replaced with NBM complete previously
equilibrated in a 10% CO2 incubator, after which dishes were immediately
returned to the 5% CO2 incubator. After 30 minutes, precipitates were observed
to be largely dissolved and the acidulated media had returned to normal pH;
media was then replaced with reserved NBM complete. Experiments were
performed on neurons 24 hours after transfection.

8.9 Rat Cortico-hippocampal Culture and Nucleofection
Rat embryonic cortico-hippocampal tissue was dissected, trypsinized, and
dissociated as described above, except that trypsinization proceeded for 1 hour,
and 10% (v/v) FBS in DMEM was used as plating media. Cells were centrifuged,
and media was aspirated and replaced with 100µl supplemented rat neuron
nucleofection solution (Amaxa) per 5 million cells, according to the
manufacturerʼs protocol. DNA (either 3µg receptor-coding plasmid, or 2µg each
receptor-coding and shRNA-coding) along with 100µl cell suspension was added
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to an amaxa cuvette and electroporated with program O-03. Cells were
immediately removed to FBS/DMEM, and plated in 24-well dishes pre-coated
with 0.1mg/ml PLL. Plating density was 1 million cells / well for shRNA
experiments, and 800,000 cells / well for all other experiments. After 24 hours,
media was removed and replaced with NBM complete. For shRNA experiments,
NBM complete was supplemented with 1µg/ml puromycin. Cultures were
maintained for up to 14 days, with 50% media changes (NBM complete)
performed every 3 days.

8.10 Mouse Midbrain Dopaminergic Neuron Culture
Mouse midbrain dopaminergic cultures were prepared according to the
method of Sulzer (Rayport et al., 1992) with modifications (Brewer and Torricelli,
2007). One to three- day old mouse pups were euthanized by CO2, and
sterilized by immersion in 70% EtOH. Brains were removed to ice-cold HABG
media (Hibernate-A media (BrainBits LLC) supplemented with 2% B27 and
0.5mM L-glutamine), meninges were removed, and ventral midbrains were
dissected and chopped. Tissue was rinsed in Hibernate-A -Ca+2 (BrainBits LLC),
and then digested with 34 units / ml papain (Worthington) in Hibernate-A -Ca+2
containing 0.5mM kynurenic acid (Sigma) with stirring for 1.5h at 37℃. The
digested tissue was then rinsed twice in HABG, and dissociated by 3 rounds of
trituration with a fire-polished Pasteur pipette followed by straining through a
40µm filter. Cells were collected by centrifugation and resuspended in DAergic
media (Neurobasal-A [Invitrogen] containing 2% B27, 0.5mM L-Glutamine,
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0.5mM kynurenic acid, 1mM HCl, and 1% (v/v) heat-inactivated FBS). Viable
cells were indicated by trypan blue dye exclusion, counted, and cells were plated
on PLL -coated glass coverslips at a density of 100,000 cells / coverslip. 24
hours after plating, coverslips were moved to new DAergic media containing
10ng/ml GDNF (Millipore). One to two days later (or when glia were observed to
be nearly confluent), 10µM FDU was added; 50% media changes were
performed every 3 days thereafter.

8.11 Immunoblotting and Sample Preparation
Rodent brain lysates were prepared in RIPA buffer (PBS, pH=7.4, 1% (v/v)
Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1%(w/v) SDS, 1% (v/v)
protease inhibitor cocktail III (Calbiochem), 0.5mM PMSF) including phosphatase
inhibitors (50mM NaF, 200µM Na3VO4, 2mM EDTA, 5mM Na4P2O7) by
homogenization in a Potter-Elvehjem tissue grinder, incubation at 4℃ for 1 hour,
and centrifugation at 20,000xg for 30 minutes (pellets were discarded). Lysates
from other tissues were prepared as indicated. When required, protein content
was determined with a bicinchoninic acid (BCA) assay kit (Pierce / Thermo
Scientific). Samples were resuspended in 1x LDS buffer (Invitrogen) containing
100mM DTT and incubated at 70℃ for 10 minutes. Samples to be blotted for
muscarinic receptors were incubated at 24℃ for 1 hour, as heating led to
aggregation of receptor protein. Reduced samples were loaded onto NuPage
Bis-Tris 4-12% polyacrylamide gels (Invitrogen), separated by SDS-PAGE, and
electro-transferred to nitrocellulose membranes. To visualize transferred
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proteins, membranes were rinsed in ddH2O, incubated in 0.5% ponceau red / 5%
HOAc for 1 minute, rinsed in ddH2O, and scanned. For visualization by
enhanced chemiluminescence (ECL), membranes were blocked either 1h at
24℃ or overnight at 4℃ in PBST (0.1% Tween-20 in PBS, pH=7.4) containing
5% nonfat dry milk (w/v). Membranes were then incubated with primary
antibodies (see table 8.2) diluted in blocking buffer for either 1 hour at 24℃ or
overnight at 4℃, followed by 4 washes with PBST. Appropriate horseradish
peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch) were
diluted in PBST (1:10,000) and incubated with membranes for 1h at 24℃,
followed by 4 washes in PBST and a final rinse in PBS. Immunoreactive signals
were detected by ECL (Perkin Elmer) and exposure to BioMax XAR film (Kodak).
For ECL detection of M3-phospho-S577, 3% (w/v) BSA / 0.1% (v/v) Tween-20 /
TBS (pH=8.0) was used for blocking and dilution of primary antibody. For
detection by infrared fluorescence, membranes were blocked in Odyssey
blocking buffer (Li-Cor Biosciences) for 1 hour at 24℃, followed by overnight
incubation at 4℃ with antibodies diluted in Odyssey blocking buffer containing
0.1% Tween-20. After washing, blots were incubated 45 minutes with IR-dye
conjugated secondary antibodies diluted in Odyssey blocking buffer / 0.1%
Tween-20. Membranes were then washed and visualized by scanning on an
Odyssey infrared imager (Li-Cor Biosciences) for fluorescent emission at 680
and 800 nm.
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8.12 Coomassie Staining
Samples were prepared and separated by SDS-PAGE as for
immunoblotting. Gels were either stained 1 hour in 40% (v/v) MeOH / 10% (v/v)
HOAc / 0.25% (w/v) Coomassie R-250, followed by overnight destaining in 40%
MeOH / 10% HOAc, or rinsed 3 times in ddH2O, followed by 1 hour staining in
SimplyBlue SafeStain (Invitrogen) followed by overnight destaining in ddH2O.

8.13 Immunofluorescence Staining
Cells grown on glass coverslips were rinsed and fixed either in 4% (w/v)
paraformaldehyde / 4% (w/v) sucrose in PBS (pH=7.4) for 30 minutes at 24℃ ,
or with -20℃ MeOH for 2.5 minutes, followed by rinsing in PBS. In some cases,
cells were pre-extracted before fixation with 0.03% saponin in cytosolic buffer
(25mM HEPES-KOH, pH=7.4, 25mM KCl, 2.5mM Mg acetate, 5mM EGTA,
150mM K-glutamate) for 30 seconds at 37℃, rinsed at 37℃ with intracellular
buffer, and fixed for 30 minutes at 24℃ with 4% (w/v) paraformaldehyde in
cytosolic buffer (Morris and Cooper, 2001). Fixed cells were permeabilized with
0.25% (v/v) Triton X-100 in PBS for 10 minutes, rinsed in PBS, and blocked for
30 minutes in antibody diluent (2% [w/v] BSA, 0.05% (v/v) Triton X-100, 0.02%
NaN3 in PBS), followed by incubation with primary antibodies diluted in antibody
diluent for either 1.5 hours (24℃) or overnight (4℃) in a humidified chamber
(table 8.1). Coverslips were washed 4 times in PBS containing 0.05% (v/v) Triton
X-100, and were incubated with appropriate fluorescent dye - conjugated
secondary antibodies diluted in antibody diluent for 45 minutes at 24℃. After
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washing, coverslips were mounted in Fluoromount-G (Southern Biotech) and
imaged with a LSM510 confocal system (Zeiss Microimaging) using either 40x
1.3NA or 100x 1.4NA oil objectives. In some cases, staining was limited to
extracellular epitopes by eliminating the permeabilization step and excluding all
detergents from the staining procedure.

8.14 Live Imaging of Primary Cultured Hippocampal Neurons
Primary cultures of embryonic rat hippocampal neurons were prepared as
described above, and plated on glass-bottom tissue culture dishes (MatTek). DIV
10-13 cultures were transfected with GFP- and/or mCherry- tagged expression
constructs by the calcium phosphate method. Twenty four hours after
transfection, media was replaced with imaging buffer (Hibernate-E low
fluorescence [BrainBits LLC], 2% B27, 0.5mM L-glutamine) and pre-incubated 30
minutes at 37℃ in an ambient CO2 incubator. Cells were imaged at 37℃ with a
Axiovert 200M microscope (Zeiss Microimaging) equipped with an UltraView
spinning disk confocal head (Perkin Elmer), EMCCD camera (Hamamatsu),
piezo-actuated specimen stage (Prior Scientific) and 100X 1.46NA α-PlanApochromat objective (Carl Zeiss Microimaging). CCh (1mM) was added to the
imaging buffer as indicated. Near-simultaneous GFP and mCherry emission was
detected with a FITC / Texas Red filter set, respectively, and acquired and
analyzed using Metamorph software (Molecular Devices).
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8.15 Production of Recombinant GST-fusion Protein
Desired cDNA fragments were cloned into pGEX 4T or 5X vectors inframe with the glutathione-S-transferase (GST) coding sequence (under
transcriptional control from the Lac operon) as described above, and transformed
into the E. coli strain BL21(DE3)pLysS. Cultures were grown at 37℃ in LuriaBertani media until log-phase, induced with 1mM of the allolactose analogue
IPTG, and incubated at 24℃ for 3 hours. Bacteria were collected by
centrifugation, and lysed by a freeze-thaw cycle in LN2 followed by incubation at
4℃ in lysis buffer (PBS, pH=7.4, 1% (v/v) Triton X-100, 1mM DTT, 1% (v/v)
protease inhibitor cocktail III (Calbiochem), 0.5mM PMSF, 1 mg/ml lysozyme).
The lysate was sonicated to disrupt genomic DNA, and was then cleared by
centrifugation at 20,000g for 30 minutes. Recombinant GST-fusion proteins were
then purified by batch affinity chromatography using Glutathione Sepharose 4B
(Amersham / GE Life Sciences) at 4℃ for 12 hours. The affinity matrix was then
washed 3 times in lysis buffer with decreasing detergent concentrations (0.5%,
0.1%, 0%), and then stored at -20℃ in 1:1 (v/v) PBS:glycerol. Purity, integrity,
and concentration of recombinant GST proteins were analyzed by SDS-PAGE
and coomassie staining as described above (with standardized BSA included as
necessary for quantification).

8.16 GST Pulldown Assay
For pulldown of exogenously expressed proteins, COS-7 or HEK-293 cells
were transfected with c-myc -tagged protein expression plasmids as indicated.
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48 hours later, cells were lysed for 1 hour at 4℃ in L-100 buffer (PBS, pH=7.4,
100mM KCl, 0.5% (v/v) Triton X-100, 1mM DTT, 1% (v/v) protease inhibitor
cocktail III (Calbiochem), 0.5mM PMSF). Lysates were cleared by centrifugation,
a sample was reserved (“input”), and remaining lysate (1ml) was incubated with
5µg glutathione sepharose-bound GST fusion proteins overnight at 4℃.
Alternatively, [35S]methionine-labeled proteins were prepared from cDNA
templates using the TNT quick coupled transcription-translation kit as described
for the phospholipid binding assay, and labeled proteins were diluted in L-100
buffer and incubated with sepharose-bound GST proteins as described above.
The affinity matrix was washed 3 times for 5 minutes at 4℃ with respective lysis
buffers, and bound proteins were eluted in 2X LDS loading buffer / 100mM DTT.
Eluted and input samples were processed for immunoblotting as described
above, with GST fusion protein content verified by ponceau staining, and bound
proteins detected by anti-HA 3F10, rabbit anti-GFP, or anti-c-myc 9E10 primary
antibodies as indicated.
For pulldown of endogenously expressed proteins from rodent brain
lysates, whole mouse or rat brains were homogenized in L-100 buffer containing
0.1% (v/v) Triton X-100 with a Potter-Elvehjem tissue grinder and incubated at
4℃ for 1 hour. Lysates were cleared by centrifugation at 20,000g for 30 minutes,
Triton X-100 concentration was adjusted to 0.5% (v/v), and GST-pulldown
experiments were performed as described above, except using 40µg GST fusion
proteins per 1ml lysate, performing 2 washes, and using indicated primary
antibodies against endogenous rodent brain proteins as indicated.
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8.17 Co-Immunoprecipitation
For co-immunoprecipitation of proteins with muscarinic receptors, tissue
culture cells (HEK-293T, COS-7, CHO) or primary cultured rat corticohippocampal neurons were transfected / nucleofected with expression vectors for
GFP- or HA- tagged MRs with or without co-transfection / co-nucleofection of
myc-tagged putative interacting protein expression plasmids as indicated. Cells
were treated with CCh as indicated, and were lysed on ice in Co-IP buffer (50mM
Tris-HCl, pH=8.0, 50mM NaF, 200µM Na3VO4, 1% (v/v) protease inhibitor
cocktail III (Calbiochem), 0.5mM PMSF) including either 0.86% (w/v) digitonin /
0.17% (w/v) Na Cholate, 1% (w/v) CHAPSO, or 0.5% (w/v) Triton X-100. For
cross-linking experiments, cells were rinsed twice in PBS, incubated with 0.2 mg/
ml of the disulfide-cleavable bifunctional crosslinker Dithiobis[succiniminyl
propionate] (DSP) (Pierce / Thermo Scientific) for 20 minutes at 24℃, washed/
quenched for 15 minutes in TBS, and solubilized in RIPA buffer. Lysates were
cleared by centrifugation, an aliquot was reserved (“input”), and lysates were
incubated with anti-GFP antibodies (1:500 rabbit polyclonal ab290 (Abcam);
mouse monoclonal (19C8 10.2ul 19F7 3.4ul) (M. Heiman)) or 20ul HA.11agarose slurry (Covance) for 3 hours at 4℃. GFP immunocomplexes were
precipitated by incubation with protein A- (Amersham / GE Life Sciences) or
protein A/G- (Pierce / Thermo Scientific) sepharose for 2 hours at 4℃, all resins
were washed 3 times in respective lysis buffer (or 0.1% (w/v) digitonin), and
proteins eluted by incubation at room temperature with LDS loading buffer / DTT
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as described above. Samples were analyzed by immunoblotting for immunoand co-immuno- precipitated proteins as described above.
Co-immunoprecipitation of AP-3 components with myc-tagged AGAP1
was performed as previously described (Nie et al., 2003). Briefly, NIH-3T3 cells
transfected with expression plasmids encoding full length or truncated AGAP1myc were lysed in 3T3 buffer (25mM tris, pH=8.0, 100mM NaCl, 1% (v/v) Triton
X-100, 10% (v/v) glycerol, 1% (v/v) protease inhibitor cocktail III (Calbiochem),
0.5mM PMSF) with 3 freeze-thaw cycles in LN2. Lysates were cleared by
centrifugation, and then incubated with 20µl / ml anti-myc 9E10 agarose
(Covance) for 14 hours at 4℃. The affinity matrix was washed 3 times with 3T3
buffer, proteins were eluted with LDS sample buffer / DTT at 70℃, and samples
analyzed by immunoblotting as described above.

8.18 Subcellular Fractionation Experiments
Subcellular fractionation of cultured primary neurons by glycerol velocity
gradient centrifugation was performed essentially as described (West et al.,
1997b). Rat cortico-hippocampal neurons (25 million cells) were nucleofected
with indicated M5 expression plasmids, plated in PLL-coated 100mm dishes, and
cultured as described above for 14 days. A 7-step 5-30% (v/v) gradient of
glycerol in SV buffer (10mM HEPES pH=7.4, 150mM NaCl, 1mM EGTA, 1mM
MgCl2) was prepared and allowed to diffuse at 24℃ for 2 hours during
membrane preparation. Cells were treated with 0.1mM CCh for 1 hour, washed
once in SV buffer, collected in SV buffer, and pelleted by centrifugation at 5500g
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for 5 minutes. Pellets were resuspended in ice-cold ddH20, homogenized with 12
strokes of a teflon-glass homogenizer at 500 rpm, adjusted to 1X SV buffer, and
centrifuged at 1000g for 5 minutes. The supernatant was collected,
supplemented with 1% (v/v) Protease Inhibitor Cocktail III (Calbiochem) and
0.5mM PMSF, loaded on top of the previously prepared glycerol gradient, and
was ultracentrifuged for 66 minutes at 48,000 rpm in a sw50.1 rotor (Beckman
Coulter). Fractions (8) were unloaded from the top of the gradient. For
immunoblot analysis, fraction volume was adjusted to 1.3ml with SV buffer,
fractions were ultracentrifuged for 2 hours at 150,000g, pellets were solubilized in
LDS sample buffer / 100mM DTT, and samples were processed as described
above. For analysis of M5 content by radioligand binding, fractions (250µl) were
diluted to a total volume of 500µl with SV buffer, and incubated with 1nM [3H]3quinuclidinyl benzilate (Perkin Elmer) for 1 hour at 37℃. Non-specific binding
was determined in the presence of 1µM atropine. Samples were collected by
vacuum filtration on GF/B glass fiber filters (Whatman) presoaked 1 hour in
0.05% (w/v) polyethylenimine. Filters were rapidly washed with 5ml ice-cold SV
buffer, dried, and bound radioactivity determined by liquid scintillation
spectrometry.
Analysis of M5 transport to lysosomes was performed by self-forming
Percoll density gradient centrifugation essentially as described (Schaub et al.,
2005). Rat cortico-hippocampal neurons (15 million cells) were nucleofected with
M5wt-GFP and M5∆-GFP and cultured for 19 days as described. Cells were
treated with 1mM CCh in the presence of the lysosomal protease inhibitor
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leupeptin (Sigma; 100µM) for 4.5 hours. Cells were collected in HB (250mM
sucrose, 1mM EDTA) and homogenized by 12 passes through a 1-ml syringe
attached to a 25-gauge needle. Homogenates were adjusted to 1.7ml with HB
and centrifuged for 10 minutes at 370g. The post-nuclear supernatant was
loaded on top of 8.5ml 17.5% (w/v) Percoll (sigma) / 1X HB, underlayered with
1.2ml 10X HB, and centrifuged for 30 minutes at 26,500g in an SS-34 rotor
(Sorvall / Thermo Scientific). Nine 1.2ml fractions were collected from the top of
the gradient, and fractions were ultracentrifuged at 200,000g for 30 minutes.
Membrane layers were collected, solubilized in 1X LDS/DTT, and analyzed by
immunoblotting as described above.
Fractionation of rat brain homogenate by density gradient using the isoosmotic centrifugation medium iodixanol was performed generally as described
(Lee et al., 2003). 1/2 of an adult female rat brain was homogenized in HM
(0.25M sucrose, 20mM tris, pH=7.4, 1mM EDTA, 1mM EGTA) with a tight-pestle
dounce homogenizer (20 strokes) followed by passage through 20- and 25gauge needles (20 and 10 times, respectively). Homogenates were centrifuged
for 10 minutes at 500g, and then the post-nuclear supernatant adjusted to 25%
(w/v) iodixanol (OptiPrep; Axis-Shield) / 1X HB and overlayered with an
iodixanol / 1X HB step gradient (20, 18.5, 16.5, 14.5, 12.5, 10.5, 8.5, 6.5, 5% (w/
v)). Gradients were centrifuged at 27,000 RPM for 20 hours at 4℃ in an SW41
rotor (Beckman Coulter), and 26 fractions collected from the top. Fractions were
solubilized in LDS sample buffer / DTT and analyzed by immunoblot as described
above.
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8.19 [N-methyl-3H]-Scopolamine Radioligand Binding Assay
For experiments in tissue culture cells, cells were plated in 12- or 24-well
dishes pre-coated with PLL. For transient plasmid transfection or siRNA
experiments, cells were transfected 24 hours after plating with expression
plasmids or siRNA duplexes as described above. Forty eight hours after
transfection, cells were treated as indicated, transferred to ice, and washed once
in ice-cold HEPES-HBSS (118 mM NaCl, 5mM KCl, 1mM CaCl2, 1mM MgCl2,
5mM Glucose, 15mM HEPES, pH=7.4). Cells were incubated for 3 hours at 4℃
in HHBS containing 1nM of the cell-impermeant MR antagonist [N-methyl-3H]scopolamine ([3H]NMS; Perkin Elmer). For heterologous competition binding
experiments, various concentrations of unlabeled drugs were added. Nonspecific binding was determined by addition of 10µM benztropine mesylate
(Sigma). Binding was terminated by aspiration and 3 rapid washes with ice-cold
HEPES-HBSS. Cells were solubilized overnight in 0.1% SDS, lysates were
removed to vials containing 5ml scintillation cocktail (Ready-Safe, Beckman
Coulter) and total radioactivity measured by liquid scintillation spectrometry.
Assays were performed in triplicate, with specific binding determined by
subtraction of NSB from all values. Non-linear regression analysis of competition
binding data was performed with curve-fitting software (GraphPad Prism). When
indicated, cell lysates were collected in RIPA buffer and stored at -20℃.
For radioligand binding experiments in primary cultured rat neurons,
mature cultures (DIV 12-13) were assayed essentially as described above.
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Neurons were nucleofected before plating with expression and/or shRNA
plasmids as indicated. Heterologous [3H]NMS competition binding pilot
experiments examining IC50 values of the muscarinic antagonist AF-DX 384
(Tocris) in control-, M5wt-, and M5∆- nucleofected cultures were performed as
described above. Thereafter, all M5 [3H]NMS binding experiments were
performed in the presence of 5µM AF-DX 384. M5-specific [3H]NMS binding was
defined by subtracting control (empty vector) values from those of M5wt- or M5∆nucleofected wells. All assays were performed in triplicate.

8.20 Muscarinic Receptor Internalization and Recycling Assays
For experiments in tissue culture cells, cells were pre-incubated 2 hours in
growth media containing 10µg/ml cycloheximide (CHX) in order to arrest
synthesis of receptor proteins. CHX was included in all washes and incubations
thereafter. To induce receptor endocytosis, the non-hydrolyzable acetylcholine
analogue carbachol (CCh) (100µM) was added, and cells were incubated for
various times. To measure recycling of internalized muscarinic receptors, CChtreated cells were rinsed 3 times in 37℃ Ca2+- and Mg2+- free HBSS, and then
incubated in CCh-free growth media for various times. At the end of the
treatment period, cells not subjected to recycling conditions were rinsed 3 times
in 37℃ HBSS, all wells were washed with ice-cold HEPES-HBSS, and cells were
assayed for surface muscarinic receptor binding with [3H]NMS as described
above.
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For experiments in primary cultured neurons, growth media was replaced
with HABG (pH=7.3) and cells were pre-incubated 1 hour at 37℃ in an ambientCO2 incubator. For Brefeldin-A (BFA) inhibition experiments, cells were preincubated 2 hours in HABG with (5µM) BFA or EtOH solvent only; BFA / EtOH
was also present in all subsequent washes and incubations. Internalization was
induced by incubation with 100µM CCh for 30 minutes. Recycling of internalized
receptors was induced by washing 3 times with with 37℃ MOPS rinse buffer
(10mM MOPS, pH=7.3, 90mM NaCl, 1.8 mM CaCl2, 5.4 mM KCl, 0.8mM MgCl2,
0.9mM NaHCO3, 0.9mM NaH2PO4, 25mM glucose) and incubation for 1 hour in
new HABG. Control- and non-recycled- wells were rinsed 3 times with MOPS
rinse buffer, all cells were washed with ice-cold HEPES-HBSS, and surface [3H]NMS binding was performed as described above. For K+ depolarization
treatments, cells were treated with depolarization buffer (10mM MOPS, pH=7.3,
45mM KCl, 50.4mM NaCl, 0.8mM MgCl2, 0.9mM NaHCO3, 0.9 mM NaH2PO4,
25mM glucose) for 1 or 5 minutes, with or without standard media washout as
indicated.

8.21 Mouse Cerebral Vasculature Isolation and Radioligand Binding
Microvessels from wild-type, M5∆/∆ and M5-/- mouse brains were isolated
according to a published protocol (Jung and Levy, 2005). Two mice from each
genotype were sacrificed by CO2 inhalation, and pooled brains were minced in
ice-cold DMEM / 20mM HEPES (pH=7.5). Tissue was collected by centrifugation
(5 minutes, 500g) and digested in 0.05% collagenase/dispase (Roche) in PBS for
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30 minutes at 37℃. The digestions were stopped by addition of 1mM EDTA, and
tissue was collected by centrifugation (10 minutes, 1000g) and resuspended in
DMEM / HEPES containing 17% dextran (molecular weight 60,000-90,000
daltons; Sigma). Tissue suspensions were centrifuged for 30 minutes at
10,000g, and blood vessel-containing pellets were collected, resuspended in 4℃
THM buffer (50mM Tris-HCl, pH=7.4, 2mM MgCl2) and re-centrifuged at 10,000g
for 15 minutes. Pellets were resuspended in 2.5ml THM, homogenized with a
Polytron device (Kinematica GmbH), and total protein measured by BCA assay.
Vessel homogenates were adjusted for equal protein content, and incubated in
triplicate with 1nM [3H]NMS at 4℃ for 3 hours. Non-specific binding was defined
by the addition of 10µM benztropine mesylate. Binding was terminated by
centrifugation at 10,000g for 5 minutes at 4℃. The supernatant was aspirated,
tubes rapidly washed with 1.5ml ice-cold THM buffer, and pellets incubated in
0.1% SDS overnight. [3H] content in solubilized pellets was measured by liquid
scintillation spectrometry, and specific [3H]NMS binding determined by
subtraction of non-specific DPM values from total binding.

8.22 MAP Kinase Activation Assay
HEK-293T cells transfected with MR-coding constructs were grown to
confluence in 24-well dishes and pretreated 30 minutes in serum-free Opti-Mem
(Invitrogen). Cells were treated with various concentrations of CCh for 10
minutes, rinsed once in ice-cold PBS, and lysed in phospho-triton buffer (PBS
pH=7.4, 0.5% Triton X-100, 2mM EDTA, 200µM Na3VO4, 50mM NaF, 5mM
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Na4P2O7, 1% (v/v) protease inhibitor cocktail III (Calbiochem), 0.5mM PMSF) at
4℃ for 1 hour. Lysates were cleared by centrifugation at 10,000g for 15 minutes
and processed for immunoblotting as described above. Total and
phosphorylated (pT202 / pY204) forms of p44/42 MAP kinase were detected by
Odyssey imaging (Li-Cor) with indicated antibodies.

8.23 Inositol Monophosphate Accumulation Assay
Activation of PLC-β by Gαq-coupled MRs was monitored via the
accumulation of the D-myo-inositol 1,4,5 triphosphate metabolite inositol
monophosphate (IP1) in the presence of the inositol monophosphatase inhibitor
LiCl (Trinquet et al., 2006). HEK-293T cells plated on poly-L-lysine -coated 24dishes were transfected with MR expression plasmids (0.25µg/well). Forty eight
hours later, growth media was replaced with IP-One stimulation buffer (10mM
HEPES , pH=7.4, 1mM CaCl2, 0.5mM MgCl2, 4.2mM KCl, 146 mM NaCl, 5.5
mM glucose, 50mM LiCl) containing various concentrations of carbachol. After 1
hour of incubation at 37℃, cells were lysed and assayed for IP1 content with the
IP-One ELISA kit (Cisbio) according to the manufacturerʼs protocol. Unknown
IP1 values were interpolated from a standard curve, and EC50 values for CCh
determined by curve-fitting to a dose-response model with nonlinear regression
software (GraphPad Prism).
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8.24 Fluo-3 Calcium Assays
Fluorometric measurement of intracellular Ca2+ concentration was
performed essentially as described (Cypess et al., 1999). CHO cells transfected
with MR expression plasmids 48 hours previously were harvested in PBS and
incubated at 37℃ for 1 hour. Cells were collected by centrifugation at 2000g for
2 minutes, and washed 3 times in EBSSH-P (26mM HEPES, pH=7.4, 125mM
NaCl, 5mM KCl, 1mM MgSO4, 1mM NaH2PO4, 5.6mM glucose, 2mM CaCl2,
0.1% (w/v) BSA, 2.5mM probenecid (Invitrogen)). Cells were resuspended in
EBSSH-P and loaded with 2µM of the cell-permeant fluorescent Ca2+ indicator
Fluo-3/AM (Invitrogen) for 1 hour at 24℃. Cells were washed once in EBSSH-P,
and pre-treated with 100µM CCh for 30 minutes when indicated. Cells were
washed twice more, resuspended in 1.5ml EBSSH-P, and Fluo-3 fluorescence
(excitation = 505nm, emission = 525nm) was monitored with a F-2000
fluorescence spectrophotometer (Hitachi) with constant stirring. MR stimulation
with 100µM CCh was performed after baseline fluorescence values had been
established (1 minute or greater). At the end of recordings, fluorescence maxima
and minima (Emax and Emin) were determined by cell lysis (.07% (v/v) Triton
X-100) and Ca2+ chelation (5mM EGTA, 37.5mM Tris, pH=8.7), respectively.
Fluorescence emission at each 0.1 second time point was normalized to Emax
and Emin and data were plotted as F/F0 ratios.
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8.25 In situ Hybridization
15µm thick coronal and sagittal sections of fresh-frozen C57Bl/6 wild-type
mouse brain were mounted on slides, fixed in 4% paraformaldehyde for 10
minutes, rinsed in PBS, acetylated with acetic anhydride in triethanolamine buffer
for 10 minutes, rinsed in PBS, dehydrated in ascending concentrations of EtOH,
and dried. A 772-bp region of the AGAP1 3ʼ UTR was amplified from a mouse
brain cDNA library by PCR (forward 5ʼ-AAG TTG CAA CCA CCA CGT GAG TCC
CTC AGT TCC CTC, reverse 5ʼ-CCA AGT AAG GGG ACT GAA GTC AAA TAA
TAC CCA GC) and cloned into pCRII. The plasmid was linearized and used as
template to prepare [33P]-labeled riboprobe using a Maxiscript kit (Ambion) and
either T7 (sense) or SP6 (antisense) RNA polymerase. Riboprobes were column
purified (NucAway, Ambion), and prepared slides were hybridized for 17 hours at
60℃ with 1x106 Ci of probe in hybridization buffer (50% (v/v) formamide, 0.6M
NaCl, 50µg/ml salmon sperm DNA, 1X Denhardtʼs solution (Invitrogen), 10%
(w/v) dextran sulfate, 250µg/ml tRNA, 100mM Tris-Cl pH=8, 2mM EDTA). Slides
were washed 3 times for 5 minutes with 2X SSC (30mM Na citrate, pH=7.0,
300mM NaCl) and treated for 1 hour at 37℃ with RNase A (2µg/ml). Slides were
rinsed twice in ddH2O, washed once in 2X SSC for 20 minutes, washed once
each in 0.5X and 0.2X SSC at 50℃ for 30 minutes, dehydrated in ascending
concentrations of EtOH, dried, and exposed to Kodak MR film at -80℃.
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8.26 Northern Blotting
For the mAGAP1 Northern blot, antisense [33P]-labeled riboprobe to the
AGAP1 3ʼ-UTR was synthesized and purified as described for in situ
hybridization. A mouse Multiple Tissue Northern blot (BD Biosciences) was prehybridized in Ultrahyb buffer (Ambion) for 30 minutes at 68℃, and then
hybridized with 8x106 Ci probe in 8ml Ultrahyb at 68℃ overnight. The blot was
washed twice for 5 minutes at 68℃ in 2X SSC / 0.1% (w/v) SDS, washed twice
for 15 minutes at 68℃ with 0.1X SSC / 0.1% SDS, and was then exposed to
Biomax XAR film (Kodak).

8.27 Phospholipid Binding Assay
The TNT T7 Quick coupled transcription/translation system (Promega)
was used to synthesize in vitro [35S]methionine-labeled full-length and truncated
AGAP1 proteins from AGAP1 cDNAs (full-length and 552-861 truncation mutant)
cloned in the T7 promoter-containing pcDNA3.1 vector. Reactions were
incubated at 30℃ for 2 hours, and product synthesis was confirmed by
autoradiography: One µl of reaction mixture was separated by SDS-PAGE as
described above, and the gel was fixed for 30 minutes in 40% MeOH / 10%
HOAc / 3% glycerol. The gel was dried and imaged by storage phosphor
autoradiography with a Storm scanner (GE Life Sciences) after overnight
exposure. Phospholipid dot-blot arrays (PIP strips; Echelon Biosciences) were
blocked 1 hour at 24℃ in PIP blocking buffer (TBS pH=8, 3% (w/v) fatty acid-free
BSA, 0.1% (v/v) Tween-20). Arrays were incubated with remaining
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[35S]methionine-labeled proteins in PIP blocking buffer for 3 hours, washed 6
times for 5 minutes in PIP blocking buffer, dried, and imaged by storage
phosphor autoradiography.

8.28 Superfused Mouse Striatal Synaptosome Neurotransmitter Release
Experiments measuring stimulated release of [3H]dopamine from striatal
synaptosomes were performed according to previously described protocols
(Yamada et al., 2001a; Westphalen and Hemmings, 2003; Martire et al., 2007) in
collaboration with Dr. Hugh Hemmings (Weill Cornell Medical School, New York
NY). Mice were sacrificed by cervical dislocation, and striata rapidly dissected on
ice. Striatal tissue was homogenized in 0.32M sucrose with a motor-driven
teflon-glass homogenizer (500rpm, 10 strokes, 4℃). The homogenate was
centrifuged at 4,000g for 2 minutes, the resulting supernatant layered on top of
0.8M sucrose, and was re-centrifuged at 36,000g for 30 minutes. The resulting
pellet, containing demyelinated nerve terminals (synaptosomes), was
resuspended in ice-cold 0.32M sucrose. Synaptosomes were suspended in
Krebs-HEPES buffer (20mM HEPES, pH=7.4, 140mM NaCl, 5mM KCl, 1mM
MgCl2, 1.2mM Na2HPO4, 5mM NaHCO3, 10mM glucose) containing 10µM
pargyline and 500nM desipramine, and were loaded with [14C]glutamate (Perkin
Elmer) for 45 minutes and with [3H]dopamine (Perkin Elmer) for 15 minutes at
35℃. [3H]/[14C]-Loaded synaptosomes were centrifuged at 20,000g for 10
minutes, resuspended in 0.32M sucrose, loaded into superfusion chambers
(Brandel) capped with GF/B glass fiber filters (Whatman), and superfused with
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superfusion buffer (Krebs-HEPES, 2mM CaCl2, 20µM pargyline) at 37℃ with a
modified Brandel SF12 superfusion apparatus (Westphalen and Hemmings,
2003) operating at a flow rate of 0.25ml/min and collecting fractions at 2-minute
intervals. After a 30-minute equilibration period, neurotransmitter release was
stimulated with a 2-minute pulse of superfusion buffer containing 15mM KCl.
After an additional 12 minute interval with standard (5mM KCl) superfusion
buffer, a second 2-minute pulse of superfusion buffer containing either 15mM KCl
or 15mM KCl + 100µM oxotremorine-M (Tocris) was applied. At the end of the
experiment, synaptosomes were lysed with 0.2M perchloric acid. [3H]Dopamine
and [14C]glutamate were quantified in collected fractions (including
synaptosomal lysate) added to Biosafe II scintillation cocktail (Research Products
International) using liquid scintillation spectrometry with dual isotope quench
correction.
Raw data were converted to fractional release values (CPM [3H]dopamine
or [14C]glutamate released as a % of total remaining labeled neurotransmitter at
the start of fraction collection) and plotted against fraction collection time. Basal
release curves were interpolated from pre-, inter-, and post K+ stimulation pulse
periods, and used to calculate the cumulative fractional release above baseline
after the 2 stimulation pulses.

8.29 Fast Scan Cyclic Voltammetry
Fast scan cyclic voltammetric measurement of dopamine release was
performed in the laboratory of Dr. David Sulzer (Columbia University, New York
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NY) according to previously published protocols (Zhang and Sulzer, 2003). For
the preparation of acute striatal slices, mice were sacrificed by cervical
dislocation, decapitated, and brains were washed in ice-cold oxygenated artificial
cerebrospinal fluid (aCSF in mM: 119 NaCl, 2.5 KCl, 23.8 NaHCO3, 2.4 CaCl2,
1.2 MgCl2, 1.2 NaH2PO4, 10 glucose, and saturated with 95% O2 / 5 % CO2).
Striatal brain slices were cut on a vibratome at 250µm thickness from the second
to fourth frontal slice of caudate–putamen (bregma, +1.54 mm to +0.62 mm)
(Franklin and Paxinos, 1997). Slices were allowed to recover for 1.5 hr in a
holding chamber in aCSF at room temperature.
For cyclic voltammetry recordings, striatal slices were placed in a
recording chamber and superfused (~1 ml/min) with aCSF at ~30 °C. Disk
carbon fiber electrodes of 5µm in diameter with a freshly cut surface were placed
close to corpus callosum in the dorsal striatum (laterodorsal to dorsal section).
Consistent insertion of the recording electrode into the tissue was achieved by
using geometrical feature of the stimulating electrode and changes in basal
currents associated to transition from solution to tissue. For cyclic voltammetry
(CV), triangular voltage waves (+450 to +800 mV at 294 V/s vs Ag/AgCl, every
100 ms) were generated using Igorʼs application (Data Acquisition) created by
Eugene V. Mosharov (Igor v5.0; WaveMetrics, Inc., www.wavemetrics.com),and
were applied to the recording electrode using an ITC-18 analog–digital interface
(HEKA Instruments Inc., Bellmore, NY)and the Axopatch 200B amplifier
(Molecular Devices, Burlingame, CA). Striatal slices were electrically stimulated
with a bipolar stimulating electrode using an Iso-Flex stimulus isolator triggered
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by a Master-8 pulse generator (A.M.P.I., Jerusalem, Israel). Currents were
recorded with an Axopatch 200B amplifier with a low-pass Bessel Filter setting at
10 kHz, digitized at 25 kHz, and acquired with the Igorʼs application. DA signals
were identified by background-subtracted cyclic voltammograms, and DA peak
currents were determined using an IGORʼs application (Quanta Analysis) created
by E. Mosharov (www.sulzerlab.org/download.html). Recording electrodes were
calibrated before and after each experiment to determine the concentration of
dopamine released by each stimulus. Eight prepulses were delivered every two
minutes before each experiment to achieve constant dopamine release. For
oxotremorine-M (Oxo-M) incubations, a single stimulus was applied every two
minutes. Four prepulses were used as preincubation controls. Oxo-M was either
applied for ten pulses (20 minutes), or for five pulses (10 minutes) followed by a
ten pulse (20 minute) washout with aCSF.
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Table 9.1 Immunocytochemistry antibody list
antigen (Ab name)
adaptin δ (SA4)
c-myc (ab9106)
c-myc (9E10)
EEA1 (610456)
GFP (ab6556)
GFP (ab13970)
HA (3F10)
HA (HA.11)
KIAA0701 (ab26176)
MAP-2 (AB5622)
rab5 (108011)
rab7 (ab50533)
synapsin I (ab8)
transferrin receptor
tyrosine hydroxylase
tyrosine hydroxylase

source
DSHB (A. Peden)
Abcam
Covance
BD Transduction Labs
Abcam
Abcam
Roche
Covance
Abcam
Chemicon
Synaptic Systems
Abcam
Abcam
Zymed
Abcam
Chemicon

host
mouse
rabbit
mouse
mouse
rabbit
chicken
rat
mouse
chicken
rabbit
mouse
mouse
rabbit
mouse
mouse
rabbit

dilution - IF
1:100
1:200
1:500
1:500
1:10000
1:2000
1:50
1:100
1:500
1:1000
1:150
1:150
1:500
1:500
1:250
1:1000

host
mouse
mouse
mouse
mouse
mouse
mouse
rabbit
mouse
mouse
mouse
mouse
rabbit
rat
mouse
chicken
rabbit
mouse
mouse
rabbit
mouse
mouse
mouse
mouse

dliution - IB
1:10000
1:1000
1:10000
1:5000
1:1000
1:250
1:1000
1:1000
1:2500
1:500
1:4000
1:5000
1:500
1:1000
1:2000
1:1000
1:500
1:500
1:1000
1:1000
1:250
1:250
1:20000

Table 9.2 Immunoblotting antibody list
antigen (antibody)
β-actin (AC-15)
adaptin α (610501)
adaptin β2 (610381)
adaptin γ (610385)
adaptin δ (SA4)
Adaptin σ3A (611272)
rAGAP1 (AS625)
c-myc (9E10)
EEA1 (610456)
GAL4 AD (345765)
GAL4 DNA-BD (5399)
GFP (ab6556)
HA (3F10)
HA (HA.11)
KIAA0701 (ab26176)
M3 pS577 (RU1653)
Na+, K+ ATPase β2 (610914)
β-NAP (610892)
p44/42 MAPK (9102)
Phospho-p44/42 MAPK (9106)
p47A (610890)
rab5 (610281)
synaptophysin (611880)

source
Abcam
BD Transduction Labs
BD Transduction Labs
BD Transduction Labs
DSHB (A. Peden)
BD Transduction Labs
S. Meurer
Covance
BD Transduction Labs
Calbiochem
Clontech
Abcam
Roche
Covance
Abcam
(affinity purified)
BD Transduction Labs
BD Transduction Labs
Cell Signalling
Cell Signalling
BD Transduction Labs
BD Transduction Labs
BD Transduction Labs

215

Table 9.3 RNA and DNA oligos used for siRNA transfection and
construction of shRNA plasmids
oligo
hAGAP1 1 +
hAGAP1 1 hAGAP1 2 +
hAGAP1 2hAGAP1 3 +
hAGAP1 3 shRNA ctl +
shRNA ctl rAP3b2 1374 +
rAP3b2 1374 rAP3b2 1611 +
rAP3b2 1611 rAP3b2 770 +
rAP3b2 770 rAGAP1 2680 +
rAGAP1 2680 rAGAP1 135 +
rAGAP1 135 rAGAP1 2059 +
rAGAP1 2059 rAp3d1 3582 +
rAp3d1 3582 rAp3d1 3288 +
rAp3d1 3288 rAp3d1 1169 +
rAp3d1 1169 -

sequence
CCGUGCACAUCAGCCAGACAAGUAA
UUACUUGUCUGGCUGAUGUGCACGG
GGUGGGAGUUUAAGCGACUAUUCCU
AGGAAUAGUCGCUUAAACUCCCACC
GCGUGCUGACCUAUCAUCCCAGUUU
AAACUGGGAUGAUAGGUCAGCACGC
GATCCCCGTTCCGAACACACGCACAATTCAAGAGATTGTG
CGTGTGTTCGGAACTTTTTC
TCGAGAAAAAGTTCCGAACACACGCACAATCTCTTGAATT
GTGCGTGTGTTCGGAACGGG
GATCCCCATTCCAGACCTACATTCGCTTCAAGAGAGCGAA
TGTAGGTCTGGAATTTTTTC
TCGAGAAAAAATTCCAGACCTACATTCGCTCTCTTGAAGC
GAATGTAGGTCTGGAATGGG
GATCCCCAGACAACATCCAGGTACCCTTCAAGAGAGGGTA
CCTGGATGTTGTCTTTTTTC
TCGAGAAAAAAGACAACATCCAGGTACCCTCTCTTGAAGG
GTACCTGGATGTTGTCTGGG
GATCCCCAACGCATCGACCTGATTCATTCAAGAGATGAATC
AGGTCGATGCGTTTTTTTC
TCGAGAAAAAAACGCATCGACCTGATTCATCTCTTGAATGA
ATCAGGTCGATGCGTTGGG
GATCCCCGACGCCATAAGTTCCACCATTCAAGAGATGGTG
GAACTTATGGCGTCTTTTTC
TCGAGAAAAAGACGCCATAAGTTCCACCATCTCTTGAATG
GTGGAACTTATGGCGTCGGG
GATCCCCCGTGAGTCTCTCAGTTCCCTTCAAGAGAGGGAA
CTGAGAGACTCACGTTTTTC
TCGAGAAAAACGTGAGTCTCTCAGTTCCCTCTCTTGAAGG
GAACTGAGAGACTCACGGGG
GATCCCCACCCTAGACGTGTCTCTCCTTCAAGAGAGGAGA
GACACGTCTAGGGTTTTTTC
TCGAGAAAAAACCCTAGACGTGTCTCTCCTCTCTTGAAGG
AGAGACACGTCTAGGGTGGG
GATCCCCCACCTATCGTGACGAGCTGTTCAAGAGACAGCT
CGTCACGATAGGTGTTTTTC
TCGAGAAAAACACCTATCGTGACGAGCTGTCTCTTGAACA
GCTCGTCACGATAGGTGGGG
GATCCCCTCGTACCTGATCACCACCCTTCAAGAGAGGGTG
GTGATCAGGTACGATTTTTC
TCGAGAAAAATCGTACCTGATCACCACCCTCTCTTGAAGG
GTGGTGATCAGGTACGAGGG
GATCCCCGAGGAAATGAAGACCACGCTTCAAGAGAGCGT
GGTCTTCATTTCCTCTTTTTC
TCGAGAAAAAGAGGAAATGAAGACCACGCTCTCTTGAAGC
GTGGTCTTCATTTCCTCGGG
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Table 9.4 PCR mutagenesis primers
primer
rAGAP1 S600A +
rAGAP1 S600A rAGAP1 S605A +
rAGAP1 S605A rAGAP1 T608A +
rAGAP1 T608A rAGAP1 S609A +
rAGAP1 S609A rM5 K371A S372A +
rM5 K371A S372A rM5 K374A C375A +
rM5 K374A C375A rM5 Y378A K379A F380A +
rM5 Y378A K379A F380A rM5 K371A K374A +
rM5 K371A K374A rM5 K379A K385A +
rM5 K379A K385A rM5 L382A V383A +
rM5 L382A V383A rM5 deletion mutant BbsI rM5 deletion mutant BbsI +
rM5 HA 1 HindIII +
rM5 HA 1 BbsI rM5 HA 2 BbsI +
rM5 HA 2 Xho rM5 e2 HA 1 EcoRI +
rM5 e2 HA 1 Bbs rM5 e2 HA 2 Bbs +
rM3 C-tail T549A +
rM3 C-tail T549A rM3 C-tail T552A +
rM3 C-tail T552A rM3 C-tail T553A +

sequence
CAGCCTGCAGTCCTGTGAGGCCAGCAAGAATAAGTCCCG
CGGGACTTATTCTTGCTGGCCTCACAGGACTGCAGGCTG
GAGAGCAGCAAGAATAAGGCCCGACTCACCAGCCAGAGC
GCTCTGGCTGGTGAGTCGGGCCTTATTCTTGCTGCTCTC
CAAGAATAAGTCCCGACTCGCCAGCCAGAGCGAAGCCATG
CATGGCTTCGCTCTGGCTGGCGAGTCGGGACTTATTCTTG
GAATAAGTCCCGACTCACCGCCCAGAGCGAAGCCATGGC
GCCATGGCTTCGCTCTGGGCGGTGAGTCGGGACTTATTC
GCTGCTCACAGACTCGCGGCTCAGAAGTGTGTTGCC
GGCAACACACTTCTGAGCCGCGAGTCTGTGAGCAGC
CTCACAGACTCAAGAGTCAGGCGGCTGTTGCCTATAAGTT
CCG
CGGAACTTATAGGCAACAGCCGCCTGACTCTTGAGTCTGT
GAG
CAGAAGTGTGTTGCCGCTGCGGCCCGATTGGTGGTAAAAG
CTTTTACCACCAATCGGGCCGCAGCGGCAACACACTTCTG
GCTGCTCACAGACTCGCGAGTCAGGCGTGTGTTGCCTATA
AG
CTTATAGGCAACACACGCCTGACTCGCGAGTCTGTGAGCA
GC
GAAGTGTGTTGCCTATGCGTTCCGATTGGTGGTAGCAGCC
GATGGGACCCAGG
CCTGGGTCCCATCGGCTGCTACCACCAATCGGAACGCATA
GGCAACACACTTC
GTTGCCTATAAGTTCCGAGCGGCGGTAAAAGCCGATGGGA
CC
GGTCCCATCGGCTTTTACCGCCGCTCGGAACTTATAGGCA
AC
ATATGAAGACCTGTGAGCAGCAGCTGGAGA
ATATGAAGACGCTCACGATGGGACCCAGGAGACTAACAAT
GGC
ATATAAGCTTACCACCATGGAAGGGGAGTCTTACAATGAA
ATATGAAGACTGGGACGTCATATGGATATCCATGGCGTTCC
AAAGCCTGGTGATTTAC
ATATGAAGACACGTCCCAGACTATGCCCTGTGGGAAGTCAT
TACTATTGCAGTTGTG
ATATCTCGAGTCAGGGTAGCTTGCTGTTTCCTTGCCAATAC
AA
ATATGAATTCACCACCATGGAAGGGGAGTCTTACA
ATATGAAGACTGGGACGTCATATGGATAGAGGAACTGGATC
TGGCACTCATCA
ATATGAAGACACGTCCCAGACTATGCCTCTGAACCCACCAT
CACTTTTGGGACTGCCATTGCT
CCCCGAATTCAACAAAGCATTCAGAACCACCTTC
GAAGGTGGTTCTGAATGCTTTGTTGAATTCGGGG
CAACAAAACATTCAGAGCCACCTTCAAGACGCTC
GAGCGTCTTGAAGGTGGCTCTGAATGTTTTGTTG
CAAAACATTCAGAACCGCCTTCAAGACGCTCCTC
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primer
rM3 C-tail T553A rM3 C-tail T556A +
rM3 C-tail T556A rM3 C-tail S577A +
rM3 C-tail S577A rM3 C-tail S577D +
rM3 C-tail S577D rM3 C-tail S577E +
rM3 C-tail S577E -

sequence
GAGGAGCGTCTTGAAGGCGGTTCTGAATGTTTTG
CAGAACCACCTTCAAGGCGCTCCTCTTGTGCCAG
CTGGCACAAGAGGAGCGCCTTGAAGGTGGTTCTG
GTACCAGCAGAGACAGGCGGTCATTTTTCACAAG
CTTGTGAAAAATGACCGCCTGTCTCTGCTGGTAC
GTACCAGCAGAGACAGGATGTCATTTTTCACAAG
CTTGTGAAAAATGACATCCTGTCTCTGCTGGTAC
GTACCAGCAGAGACAGGAGGTCATTTTTCACAAG
CTTGTGAAAAATGACCTCCTGTCTCTGCTGGTAC

Table 9.5 PCR Primers for cloning from cDNA libraries
primer
rM1 XhoI +
rM1 no stop HindIII rM1 FLAG HindIII +
rM1 XhoI rM2 outer +
rM2 outer rM2 + xhoI
rM2 Hind III- no stop
rM2 FLAG Hind III +
rM2 XhoI rM3 outer +
rM3 outer rM3 Asp718 I +
rM3 N-term HA EcoRI +
rM3 FLAG Asp718 +
rM3 PspOM I rM3 no stop PspOM I rM4 HindIII +
rM4 no stop EcoR I rM4 EcoRI rM4 FLAG HindIII +
rM4 EcoRI rM5 outer +

sequence
ATATCTCGAGGCCACCATGAACACCTCAGTGCCCCCTGCT
GTCAGTCCCAACAT
ATATAAGCTTCGCATTGGCGGGAGGGGGTGCGGTGCACAG
AGCCAG
ATATATAAGCTTATGGATTACAAGGATGACGACGATAAGAAC
ACCTCAGTGCCCCCTGC
ATATATCTCGAGTTAGCATTGGCGGGAGGGGGTGCGGTGC
AC
GGCCACTTGACTACTGAACACAAAA
TCACCGTGTAGCGCCTATGTTCTTG
ATATCTCGAGACCACCATGAATAACTCAACAAAC
TATAAAGCTTCCCGTGTAGCGCCTAT
ATATAAGCTTACCATGGATTACAAGGATGACGACGATAAGAA
TAACTCAACAAACTCC
ATATCTCGAGTCACCGTGTAGCGCCTATGTTCTTGTAATG
ATGACCTTGCACAGTAACAGTACAA
TCCTTGAAGGACAGAGGTAGAGTAG
ATATGGTACCGCCACCATGACCTTGCACAGTAACAGTACAA
CCTCGCCTTTGTT
ATATGAATTCGCCACCATGTATCCATATGACGTCCCAGACTA
TGCCACCTTGCACAGTAACAGTACAACC
ATATGGTACCATGGATTACAAGGATGACGACGATAAGACCT
TGCACAGTAACAGT
ATATGGGCCCCTACAAGGCCTGCTCCGGCACTCGCTTGTG
ATATGGGCCCATCAAGGCCTGCTCCGGCACTCGCTTGTGA
AAAATGA
ATATAAGCTTGCCACCATGGCCAACTTCACGCCTGTCAATG
GCAGCTCAGCCAA
ATATGAATTCTCCCTGGCTGTGCCGATGTTCCGATACTGGC
ACAGCA
ATATATGAATTCCTACCTGGCTGTGCCGATGTTCCGATACTG
ATATATAAGCTTATGGATTACAAGGATGACGACGATAAGGCC
AACTTCACGCCTGTCAA
ATATATGAATTCCTACCTGGCTGTGCCGATGTTCCGATACTG
ATGGAAGGGGAGTCTTACAATGAAAGC
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primer
rM5 outer rM5 XhoI +
rM5 HindIII - no stop
rM5 N-term HA EcoR I +
rM5 N-term HA Xho I rM5 FLAG HindIII +
rM5 XhoI rM1 c-tail EcoRI +
rM1 c-tail XhoI rM2 c-tail EcoRI linker +
rM2 c-tail XhoI linker rM3 c-tail EcoRI +
rM3 c-tail XhoI rM4 c-tail EcoRI linker +
rM4 c-tail XhoI linker rM5 c-tail EcoRI +
rM5 c-tail XhoI rNRBP2 5', Bgl II, pACT inframe
rNRBP2 3' Bgl II w/ stop
rNRBP2 5' w/UTR, HindIII
rNRBP2 internal EcoR I rAGAP1 + outer
rAGAP1 - outer
rAGAP1 + inner EcoRI
rAGAP1 - inner XhoI
rSNX20 outer +
rSNX20 outer rSNX20 inner EcoRI +
rSNX20 inner XhoI mAP3b2 outer +
mAP3b2 outer mAP3b2 inner XhoI +
mAP3b2 inner PspOMI mAP3b1 outer +
mAP3b1 outer -

sequence
GGGTAGCTTGCTGTTTCCTTGCCAA
ATATCTCGAGACCACCATGGAAGGGGAGTCTTACAATGA
ATATAAGCTTGGGGTAGCTTGCTGTTTCCTT
ATATGAATTCACCACCATGTATCCATATGACGTCCCAGACTA
TGCCGAAGGGGAGTCTTACAATGAAA
ATATCTCGAGTCAGGGTAGCTTGC
ATATAAGCTTACCATGGATTACAAGGATGACGACGATAAGGA
AGGGGAGTCTTACAAT
ATATCTCGAGTCAGGGTAGCTTGCTGTTTCCTTGCCAATA
ATATGAATTCAACAAAGCCTTCCGGGACACG
ATATCTCGAGTTAGCATTGGCGGGAGGGGG
AATTCAATGCCACCTTCAAAAAGACTTTTAAGCACCTCCTC
ATGTGTCATTACAAGAACATAGGCGCTACACGGTGAC
TCGAGTCACCGTGTAGCGCCTATGTTCTTGTAATGACACAT
GAGGAGGTGCTTAAAAGTCTTTTTGAAGGTGGCATTG
ATATGAATTCAACAAAACATTCAGAACCACCTTCAAGACG
ATATCTCGAGCTACAAGGCCTGCTCCGGCA
AATTCAATGCCACTTTCAAAAAGACCTTCCGGCACCTTTTG
CTGTGCCAGTATCGGAACATCGGCACAGCCAGGTAGC
TCGAGCTACCTGGCTGTGCCGATGTTCCGATACTGGCACA
GCAAAAGGTGCCGGAAGGTCTTTTTGAAAGTGGCATTG
ATATGAATTCAACAGAACTTTCAGGAAAACC
ATATCTCGAGTCAGGGTAGCTTGCTGTTTC
ATATATAGATCTTAGCGGCCCCGGAGCCGGCGCC
ATATATAGATCTCTACGCTTGTGTCCCACGGTACTTG
ATATATAAGCTTCGAGCCATGGCGGCCCCGGAGCCG
TTGTGGGCTGAGGGTCGGCGGGCAGGGTCC
TTTTTTTAGCGCCTCCTCGG
TTCCACCTGGAAGAGGGAGG
ATATATGAATTCTGCACCATGAACTACCAGCAGCAGCTGGC
CAACTCGGC
ATATATCTCGAGGATGACACTGGGCGCCCTCCCGCTACTGT
TGTTCCTGC
GCTGCATTTAGAAGGCACCC
ACTGTCTGCGCAGCCTGGAT
ATATATGAATTCGCCGCCATGGCAAGTCCACAGCATCCTGG
GGGCCCTGG
ATATATCTCGAGGGACAGATACTCCCGCACGGTGAGCTCCT
TCAGGGTGG
TTCCTCGACCAAAGCCCAACCCGGCCGCTCAGCCACCCC
TCAGCGCAGATCCATGT
GAGGCGAGGGGGAGAGATCTGTGAGCAGATGTCAC
ATATCTCGAGTTCGGCCGCTCCGGCCTACAGCGAAGACAA
GGG
ATATGGGCCCTCACTGGGTCAGAGCCTGAATCACATCCTT
TTGGTTCGGTGTCCTCCGAACGCCAGCCATCCGTAGA
GCCAGATTCTGAAGTCCAGATGTAAGCAGG
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primer

sequence
ATATGAATTCTTCTAGCAACAGTTTCGCCTACAACGAGCAG
mAP3b1 inner no start EcoRI +
TCGGGA
mAP3b1 inner PspOM I ATATGGGCCCTTACCCCTGGGACAGGACAGGCTTCAGCTC
rKIAA0701 outer +
AGTCTCTCCCGAGAGTGAGCTCTCCGGCGCCTCTCCT
rKIAA0701 outer GGTCTGGAACAGCCACACTTTACCACACGC
rKIAA0701 inner +
ATATGGTACCGGCACCATGGCTGGGATCATTAAGAAACAG
ATATGGGCCCCGGCCGCTGCAGCTGGCCCAGGGCCAGCC
rKIAA0701 inner no stop T
ATATGGGCCCATGGTGAGCAAGGGCGAGGAGGATAACATG
mCherry PspOMI +
GCCATC
ATATGCGGCCGCTGCTTGTACAGCTCGTCCATGCCGCCGG
mCherry NotI TGGAGTGGC

Table 9.6 PCR primers for cloning of Y2H constructs
primer
rM1 i3 loop BamHI +
rM1 i3 loop SalI rM2 i3 loop NcoI +
rM2 i3 loop BamHI rM3 i3 loop NcoI +
rM3 i3 loop BamHI rM4 i3 loop NcoI +
rM4 i3 loop BamHI rM5 i3 loop NcoI +
rM5 i3 loop SalI hM2 i3 loop NcoI +
hM2 i3 loop SalI hM3 i3 loop NcoI +
hM3 i3 loop BamHI hM5 i3 loop NcoI +
hM5 i3 loop BamHI rM5i3 (1) NcoI +
rM5i3 (91) BamHI rM5i3 (73) NcoI +
rM5i3 (162) BamHI rM5i3 (141) NcoI +
rM5i3 (229) SalI rM5i3 (18) NcoI +
rM5i3 (220) SalI rM5i3 (210) SalI rM5i3 (200) SalI rM5i3 (190) SalI rM5i3 (180) SalI rM5i3 (170) SalI rM5i3 (173) SalI rM5i3 (146) NcoI +
rM5i3 (151) NcoI +

sequence
ATATGGATCCTGCGCATCTACCGGGAGACAGAAA
ATATGTCGACTCAGGTCCGAGCTGCCTTCTTCTCC
ATATCCATGGCGCATATATCCCGGGCAAGCAAGA
ATATGGATCCTCATGTCCTGGTCACTTTCTTTTCC
ATATCCATGGCGAGGATCTATAAGGAAACTGAGA
ATATGGATCCTCACGTCTGGGCGGCCTTCTTCTCC
ATATCCATGGCGCACATCTCACTGGCCAGCCGCA
ATATGGATCCTCATGTCCGAGTCACTTTGCGCTCC
ATATCCATGGCGCGGATCTACCGGGAGACAGAGA
ATATGTCGACTCAGGTCTGAGCCGCTTTCCTCTCT
ATATCCATGGCGCACATATCCCGAGCCAGCAAGA
ATATGTCGACTCATGTCCTGGTGACTTTCTTTTCC
ATATCCATGGCGAGGATCTATAAGGAAACTGAAA
ATATGGATCCTCAGGTCTGGGCCGCTTTCTTCTCC
ATATCCATGGCGCGAATCTACCGGGAAACAGAGA
ATATGGATCCTCATGTCTGGGCTGCTTTCCTCTCT
ATATCCATGGGACGGATCTACCGGGAGACAGAGAAG
ATATGGATCCTCAGCTGCTACAGGTAGTAACCT
ATATCCATGGGAGCCACTGACCTAAGTGCTGA
ATATGGATCCTCAACACTTCTGACTCTTGAGTC
ATATCCATGGGAGACTATGACACTCCCAAATAC
ATATGTCGACTCAGGTCTGAGCCGCTTTCCTCT
ATATCCATGGGAGGTTCTGATTCTGTGGCAGA
ATATGTCGACTCACAGAACCATTCTCTTTCGTT
ATATGTCGACTCAATGACTGAGGTTGGGATCCG
ATATGTCGACTCATGAAGGGTCTTTGGACACTG
ATATGTCGACTCAGGGCATGATTTTCACCTTTC
ATATGTCGACTCAGTTAGTCTCCTGGGTCCCAT
ATATGTCGACTCACACCAATCGGAACTTATAGG
ATATGTCGACTCAGGCTTTTACCACCAATCGGA
ATATCCATGGGAAAATACTTTCTGTCTCCAGC
ATATCCATGGGACCAGCTGCTGCTCACAGACT
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primer
rM5i3 (156) NcoI +

sequence
ATATCCATGGGAAGACTCAAGAGTCAGAAGTG
CATGGGAAAGTGTGTTGCCTATAAGTTCCGATTGGTGGTAA
rM5i3 (161-180) NcoI + linker
AAGCCGATGGGACCCAGGAGACTAACTGAG
TCGACTCAGTTAGTCTCCTGGGTCCCATCGGCTTTTACCAC
rM5i3 (161-180) SalI - linker
CAATCGGAACTTATAGGCAACACACTTTCC
CATGGGAAAGTTCCGATTGGTGGTAAAAGCCGATGGGACC
rM5i3 (166-180) NcoI + linker
CAGGAGACTAACTGAG
TCGACTCAGTTAGTCTCCTGGGTCCCATCGGCTTTTACCAC
rM5i3 (166-180) SalI - linker
CAATCGGAACTTTCC
ATATGAATTCGCAAGCAAGAGTAGAATAAAGAAGGAAAAGA
rM2 i3 (5) EcoRI +
AGGAACCTGTGG
ATATGAATTCGGAAGAATTGTAAAGCCAAACAATAACAATAT
rM2 i3 (30) EcoRI +
GCCTGGTGGTGATGG
ATATGAATTCGACGGCGTGACTGAAAACTGTGTTCAGGGG
rM2 i3 (60) EcoRI +
GAGGAGAAAGA
ATATGAATTCGATGATGAGATAACCCAGGATGAAAACACAG
rM2 i3 (90) EcoRI +
TTTCCACTTCGCTG
ATATGAATTCGTCACCAAGGCCCAAAAGGGTGATGTGTGC
rM2 i3 (120) EcoRI +
ACCCCAACGAGTACC
ATATGAATTCCAGAACATTGTAGCCCGCAAAATCGTGAAGA
rM2 i3 (150) EcoRI +
TGACCAAG
rAGAP1 (520) BamHI +
ATATGGATCCAGCTCGACCCACCCC
rAGAP1 (591) XhoI ATATCTCGAGTCAGATCTGGCTCTCGAT
rAGAP1 (552) BamHI +
ATATGGATCCCTGAAGAGCAAGAAGA
rAGAP1 (645) XhoI ATATCTCGAGTCAGGCTCCCAAGTTCAA
rAGAP1 (592-611) BamHI +
GATCCTAGCCAGCCTGCAGTCCTGTGAGAGCAGCAAGAAT
linker
AAGTCCCGACTCACCAGCCAGAGCTGAC
TCGAGTCAGCTCTGGCTGGTGAGTCGGGACTTATTCTTGC
rAGAP1 (592-611) XhoI - linker
TGCTCTCACAGGACTGCAGGCTGGCTAG
rAGAP1 (602-621) BamHI +
GATCCTAAAGAATAAGTCCCGACTCACCAGCCAGAGCGAA
linker
GCCATGGCACTGCAGTCAATCCGTAACTGAC
rAGAP1 (602-621) XhoI TCGAGTCAGTTACGGATTGACTGCAGTGCCATGGCTTCGC
linker
TCTGGCTGGTGAGTCGGGACTTATTCTTTAG
rAGAP1 (612-631) BamHI +
GATCCTAGAAGCCATGGCACTGCAGTCAATCCGTAACATGA
linker
GAGGGAACTCGCACTGCGTGGACTGTTGAC
rAGAP1 (612-631) XhoI TCGAGTCAACAGTCCACGCAGTGCGAGTTCCCTCTCATGT
linker
TACGGATTGACTGCAGTGCCATGGCTTCTAG
rAGAP1 (622-641) BamHI +
GATCCTAAACATGAGAGGGAACTCGCACTGCGTGGACTGT
linker
GACACCCAGAACCCCAACTGGGCCAGTTGAC
rAGAP1 (622-641) XhoI TCGAGTCAACTGGCCCAGTTGGGGTTCTGGGTGTCACAG
linker
TCCACGCAGTGCGAGTTCCCTCTCATGTTTAG
rAGAP1 (552) BamHI +
ATATGGATCCCTGAAGAGCAAGAAGAAAACTTG
rAGAP1 (600) XhoI ATATCTCGAGTCAGCTCTCACAGGACTGCAGGC
rAGAP1 (596) BamHI +
ATATGGATCCAGTCCTGTGAGAGCAGCAAG
rAGAP1 (645) XhoI ATATCTCGAGTCAGGCTCCCAAGTTCAAACTGG
rAGAP1 (609)XhoI ATATCTCGAGTCAGCTGGTGAGTCGGGACTTAT
rAGAP1 (618) XhoI ATATCTCGAGTCATGACTGCAGTGCCATGGCTT
rAGAP1 (627) XhoI ATATCTCGAGTCAGTGCGAGTTCCCTCTCATGT
rAGAP1 (636) XhoI ATATCTCGAGTCAGGGGTTCTGGGTGTCACAGT
rAGAP1 (560) BamHI +
ATATGGATCCTGTTTATCATTGTGTCCCTCAC
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primer
rAGAP1 (568) BamHI +
rAGAP1 (576) BamHI +
rAGAP1 (584) BamHI +
rAGAP1 (614-861) Hind III +
rAGAP1 (1-613) XhoI rSNX20 (2) EcoRI +
rSNX20 (313) XhoI rSNX20 (2-156) XhoI rSNX20 (78) EcoRI +
rSNX20 (234) XhoIrSNX20 (157) EcoRI +
rSNX20 (87) EcoRI +
rSNX20 (97) EcoRI +
rSNX20 (107) EcoRI +
rSNX20 (117) EcoRI +
rSNX20 (127) EcoRI +
rSNX20 (137) EcoRI +
rSNX20 (147) EcoRI +
rNRBP2 (79) BamHI +
rNRBP2 (491) XhoI rNRBP2 (395) BamHI +
rNRBP2 (453) XhoI rNRBP2 (442) BamHI +
rKIAA0701 (1469) XhoI rKIAA0701 (1117) EcoRI +
rKIAA0701 (1188) EcoRI +
rKIAA0701 (1258) EcoRI +
rKIAA0701 (1328) EcoRI +
rKIAA0701 (1399) EcoRI +
rCentg1 (1095-1186) outer +
rCentg1 (1095-1186) outer rCentg1 (1095-1186) inner
BamHI +
rCentg1 (1095-1186) inner
XhoI rCentg3 (1299-1377) outer +
rCentg3 (1299-1377) outer -

sequence
ATATGGATCCTGCAGACGTGGCACTTTGAAGC
ATATGGATCCTGACATACGAGGAGCGAGACGC
ATATGGATCCTGGTCCAAGCCATCGAGAGCCA
ATATAAGCTTGCCACCATGGCACTGCAGTCAATCCGTAACA
TGAGAGGGAACTC
ATATCTCGAGGGCTTCGCTCTGGCTGGTGAGTCGGGACTT
ATATGAATTCTAGCAAGTCCACAGCATCCTGGGGGCCCTG
GCTGG
ATATCTCGAGTCAGGACAGATACTCCCGCACGGTGAGC
ATATCTCGAGTCACAGGCGCCGTTCGCAGATGGTCTCG
ATATGAATTCTAGCCTCAGCCAGAATCGAGGAGAGGAAAGT
CTC
ATATCTCGAGTCACAGGCACACGAGCATGGCGCAGAGA
ATATGAATTCTAGAGCTGCGCGAGTACCTGCGGCTGC
ATATGAATTCTAGTCTCCAAGTTTGTGATGTACCAGGTCGT
GGT
ATATGAATTCTAGTCATCCAGACTGGGAGCTTCGACAGC
ATATGAATTCTAAAGGCTGTGGTGGAGCGGCGCTACT
ATATGAATTCTATTCGAGAGGCTGCAGAGGGCCCTCC
ATATGAATTCTACGCTTCGGGCCGGAGCTGGAGGACG
ATATGAATTCTATTCCCGCGGAAGCGCCTGACCGGGA
ATATGAATTCTATCGGCCGAGACCATCTGCGAACGGC
ATATGGATCCTTGCGGCCCCGGAGCCGGCGCCGAGGAGA
G
ATATCTCGAGTCACGCTTGTGTCCC
ATATGGATCCTGTTGGCCCCACCCC
ATATCTCGAGTCAGGTCAGCTGCCGATG
ATATGGATCCTTTTGGTGCTTGAGG
ATATCTCGAGTCAGGGCCCCGGCCGCTGCAGCTGGCCCA
GGGC
ATATGAATTCTACTGGACAGCGTGGGATTCGAAGAGCAGCT
G
ATATGAATTCTAATGTCGGTCGTGGTGTTTAAAATCATTGGT
GTTAGTGG
ATATGAATTCTAGAAAGTGGGCCAGGTGCTGTCGTACACTC
T
ATATGAATTCTAGGTAGCACAGTGTCCCTCCAGCCAAGTCC
C
ATATGAATTCTAACGAGCCCAGAGGTTCCTTTGCCTTCACA
G
TTCTGCTGCTTCTGGCCCACGCGCGACATG
AATGGTCCACCCGGTGTAGTCGTGCCTGGCC
ATATGGATCCCTCGCCCACGTTGTTATTACACAGCTGCTG
ATATCTCGAGCTATACCAGCGCGATCGTGGTGTCCACGCG
GGGTCCAAGGAGGAGGTGAACGAGACCTACGGGGATGG
TTCATCCCTGCGCCCTCGTCACCCCTCTTCTCTGCACCCC
TGCT
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primer
rCentg3 (1299-1377) inner
BamHI +
rCentg3 (1299-1377) inner
XhoI hCtglf1 outer +
hCtglf1 outer hCtglf1 (379-437) BamHI +
hCtglf1 (379-437) XhoI rDynlt1 (2-113) BamHI +
rDynlt1 (2-113) XhoI -

sequence
ATATGGATCCGCCAACGTCGTTTTCACACAGCTGCTCATC
ATATCTCGAGTCATAGGATACTAGGGCTGCGGTGCAGTTC
ATGGGGAACATACTGACCTGTCGTGTGCAC
CAGATACTACACGCACTCGTCGGGGCAGCC
ATATGGATCCGACACCTAAAGAAGAAAAGCACCAACAACTT
TATGATTGTGTCTGCCACTGGC
ATATCTCGAGTCAGCTGGTCAGCTGGGACTTGCTTTTACTG
CTCTCGC
ATATGGATCCTAGAAGACTTCCAGGCCTCCGAGGAGACTG
CATTTGT
ATATCTCGAGTCAGATGGACAGTCCGAAGGCACTGACGAT
GCAGT

Table 9.7 Genotypes of yeast strains
strain

genotype

(Feilotter et al., 1994)

CG1945

MATa, ura3, his3, ade2,
lys2, trp1, leu2, 112,
gal4-542, gal80-538,
cyhr2, LYS::GAL1UASGAL1TATA-HIS3,
URA3::GAL417-mers(x3)CYC1TATA-lacZ

(Harper et al., 1993)

Y187

MATα, ura3, his3, ade2,
trp1, leu2, 112, gal4∆,
met-, gal80∆,
URA3::GAL1UASGAL1TATA-lacZ
MATa, trp1, leu2, his3,
LYS2::lexA-HIS3,
URA3::lexA-LacZ

(Vojtek et al., 1993)
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